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Abstract 
 
Black grass (Alopecurus myosuroides) is one of the most common weeds in Western Europe. 
With the increasing use of herbicides, in response to pressure to produce higher crop yields, 
incidences of multiple herbicide resistance have been widely reported. Previous work in this 
area has identified a phi class glutathione-s-transferase, AmGSTF1, as playing a causative role in 
this multiple herbicide resistance. Two classes of inhibitor have previously been identified: the 
first CNBF, a multi drug resistance drug; and the second a group of flavone compounds identified 
from ligand fishing experiments. These have been shown to have activity in vitro inhibiting the 
action of AmGSTF1 and in vivo against multiple herbicide resistant black grass. However, little 
was known about their mode of action. This work has focussed on investigating the interactions 
between these inhibitors and AmGSTF1 using crystallographic, biochemical and complementary 
biophysical techniques.  
Apo AmGSTF1 has successfully been crystallised, with the structure solved to 1.5 Å. In addition 
a structure has been solved to 2.0 Å with CNBF covalently modifying the Cys120 residue. For 
both these structures the crystal packing results in loops in the active site region being 
disordered as well as preventing small molecule binding within the active site. In order to 
determine the complete structure, a series of mutants were designed to alter crystal packing. 
The structure of these were determined, and they adopt a different packing arrangement which 
results in the previously disordered loops being ordered, as well as exposing the binding site. 
The structure of the F122T mutant was used for in silico modelling to determine the likely 
binding site for flavonoid ligands.  
The mutants were subsequently used for seeding and soaking experiments which allowed for a 
complete structure of wild type AmGSTF1 to be determined in complex with a glutathione 
conjugate of CNBF in the active site. This structure gives a significantly better understanding of 
the mode of action of these inhibitors, in addition to allowing for the possibility of future 
development of the inhibitors using structure based design.  
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1 Introduction 
 
1.1 Herbicides 
 
With the need to feed the growing population, and with the added pressure of decreasing land 
space, there has been a rising pressure to increase crop yields. This has led to the use of chemical 
control in the form of herbicides, fungicides and insecticides. Herbicides control weeds which 
compete with crops for light and nutrients. Their use has grown rapidly since the first herbicide, 
2,4-dichlorophenoxyacetic acid- originally a biological weapon, was used in 1945.1  
Herbicides can be either non-selective, where they kill all plants or selective, where they target 
the differences between monocots and dicots, killing weeds while sparing crops. It is possible to 
enhance selectivity using herbicide safeners which reduce herbicide toxicity to crops whilst 
maintaining activity against weeds.2 Herbicides can be applied either pre-emergence of weeds, 
where the herbicide works to stop weed germination, or post emergence where they act to kill 
existing weeds. 3  
Herbicides are further classified into groups based on their mode of action, they target only a 
few proteins and processes within the cell (Figure 1-1).   
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Figure 1-1: Schematic view of herbicide sites of action. Letters represent mode of action of herbicide 
according to Herbicide Resistance Action Committee classification.4 
 
Herbicide groups are assigned either a number (Weed Science Society of America (WSSA)), or a 
letter (Herbicide Resistance Action Committee (HRAC)) (Table 1-1) based on their mode of 
action. 
 
Table 1-1: Classification of herbicides according to their mode of action. Classification given according 
to WSSA classifications (numbers) or HRAC classification (capital letters in brackets)5 
Group Site of Action Examples Chemical Family 
1 (A) Acetyl CoA Carboxylase 
(ACCase) Inhibitor 
Pinoxaden Phenylpyrazoline (‘DEN’) 
Diclofop Aryloxyphenoxy-propionate (’FOPs’) 
2 (B) Acetolactate Synthase (ALS) 
Inhibitors 
Chlorsulfuron Sulfonylurea 
Flumetsulam Triazolopyrimidine 
3 (K1) Inhibitor of microtubule 
assembly 
Pendimethalin Dinitroanaline 
4 (O) Synthetic auxin 2,4-D Phenoxy-carboxylic acid 
5 (C1) Inhibitor of photosystem II site 
A 
Atrazine Triazine 
6 (C3) Inhibitor of photosystem II site 
B 
Bromoxynil Nitrile 
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1.2 Herbicide Metabolism 
 
The metabolism of herbicides in plants occurs in a process similar to that of xenobiotics in 
humans, in a three stage process: activation, conjugation and export (discussed further below) 
(Figure 1-2). The notable difference is that while in humans the process occurs in the liver and 
7 (C2) Inhibitor of photosystem II site 
A (Different behaviour from 
group 5) 
Chlortoluron Urea 
8 (N) Inhibitor of lipid synthesis; not 
ACCase inhibition 
Molinate Thiocarbamate 
9 (G) Inhibitor of 5-enolypyruvyl-
shikimate-3-phosphate 
synthase (EPSPS) 
Glyphosate Glycine 
10 (H) Inhibitor of glutamine 
synthetase 
Glufosinate Phosphinic acid 
11 (F3) Inhibitor of carotenoid 
biosynthesis (unknown target) 
Aclonifen Diphenylether 
12 (F1) Inhibitor of phytoene 
desaturase (PDS) 
Diflufenican Pyridinecarboxamide 
13 (F3) Inhibitor of 1-deoxy-D-xyulose 
5-phosphate synthatase (DOXP 
synthase) 
Clomazone Isoxazolidinone 
14 (E) Inhibitor of 
protoporphyrinogen oxidase 
(Protox, PPO) 
Aclifluorfen Diphenylether 
15 (K3) Mitosis Inhibitor Alachlor Chloroacetamide 
Flufenacet Oxyacetemide 
18 (I) Inhibitor of 7,8-dihydro-
preroate synthetase (DHP) 
Asulam Carbamate 
19 (P) Inhibitor of indoleacetic acid 
transport 
Naptalam Phthalamate Semicarbazone 
20 (L) Inhibitor of cell wall synthesis 
site A 
Dichlobenil Nitrile 
21 (L) Inhibitor of cell wall synthesis 
site B 
Isoxaben Benzamide 
22 (D) Photosystem I electron diverter Paraquat Bipyridylium 
23 (K2) Inhibitor of mitosis Carbetamide Carbamate 
24 (M) Membrane disruptor Dinoterb Dinitrophenol 
26 (Z) Unknown site of action Difenzoquat Pyrazolium 
27 (F2) Inhibitor of 4-hydroxyphenyl-
pyruvatedioxygenase (4-HPPD) 
Mesotrione Triketone 
28 (Z) Unknown site of action DMSA Organoarsenical 
29 (L) Inhibitor of cell wall synthesis 
site C 
Indaziflam - 
30 (R) Tyrosine aminotransferase Methiozalin  
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waste is excreted in urine there is no such excretory system in plants and as a result compounds 
undergo internal compartmentation in the vacuole (soluble conjugates) and cell wall (insoluble 
conjugates).6  
 
Figure 1-2: Metabolism of herbicides in plants. Showing enzymes used (blue), and locations of the 
plant where the differing phases occur (green).7 
 
In phase I metabolism, compounds are activated to allow for conjugation in phase II. This most 
commonly involves oxidation by cytochrome p450 monooxygenases (CYP450s). CYP450s are 
heme dependent proteins that typically use NADPH and/ or NADH to cleave atmospheric 
dioxygen and produce a functionalised organic substrate and a molecule of water.8 They are 
capable of carrying out a wide range of functionalisations most often producing hydroxylated 
derivatives but they are also capable of aromatic hydroxylation, epoxidation, N, S and O 
dealkylations, oxidative deamination, sulfoxide formation, N-oxidation, N-hydroxylation 
oxidative dehalogenation and reductive dehalogenation (Figure 1-3)9 Most CYP450s are 
anchored by a single N-terminal transmembrane helix in the endoplasmic reticulum (ER) with 
the remainder of the protein in the cytosol. They are localised alongside NADPH dependent P450 
reductases which transfer electrons from NADPH into the buried catalytic site of the CYP450.8 
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Figure 1-3: Reactions carried out by cytochrome P450 enzymes9 
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Phase II involves the conjugation of a small molecule to the compound. This acts to increase 
water solubility, as well as targeting the molecule for transport. It involves the use of either 
glutathione transferases (GST) or glycosyltransferases (GT).10 GTs catalyse the addition of a sugar 
molecule to a functional group, using uridine diphosphate glucose (UDP-Glc) as a sugar donor. 
O-GTs add to –OH or –COOH groups, while N-GTs add to NH2 groups.11 GSTs catalyse the addition 
of a glutathione (GSH) molecule to an electrophilic centre. Unlike glycosylation this does not 
always require initial functionalisation by a phase I enzyme as many herbicides contain an 
electrophilic centre.  
Phase II metabolism detoxifies compounds, but it is possible they may have another biological 
activity and therefore must be removed from the cytosol. For example, herbicide synergist 
tridiphane is converted to a GSH conjugate in phase II metabolism which is a powerful 
suppressant of GST-mediated atrazine metabolism.12 As a result metabolites are either 
deposited as bound residues in the extracellular matrix, or stored as water soluble metabolites 
in the vacuole.10 The uptake of GSH conjugates into the vacuole is ATP dependent, and uses 
specific ATP-binding casette (ABC) transporters.13 
1.3 Herbicide Resistance 
 
With increasing use of herbicides, resistance has become an increasing problem. Resistance has 
been reported across all modes of herbicide action, and across virtually every weed species. 
Since 1975 a rapid growth has been observed in the number of resistance cases that have been 
reported, with 495 unique cases being reported up to 2017, although an increase in surveillance 
and better reporting has probably partially factored in this rapid incline.14 
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Figure 1-4: The chronological increase in herbicide resistance cases observed globally since 1950 
reported in the international survey of herbicide resistant weeds.14 
 
Herbicide resistance can take two forms: target site and non-target site. Target site comes from 
mutations in the protein which the herbicide targets causing the herbicide to become less 
efficient while non-target site occurs from other complementary methods. 
Herbicide action is divided into 3 steps: penetration into the plant; translocation and 
accumulation at the target site; and binding to the biological target causing a phenotypic 
response and resulting in plant death. Resistance mechanisms can occur at each and every point 
of this pathway.4 
1.3.1 Target-site resistance 
 
Target site resistance occurs most commonly via a gene mutation conferring an amino acid 
change which prevents herbicide binding while allowing substrate binding. It can also occur by 
overexpression of the target enzyme.15 This can result in a fitness cost if the mutation impairs 
enzyme functionality or plant performance.16 This section will explore examples of target site 
resistance occurring against a range of herbicide mode of actions. 
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1.3.1.1 ALS Inhibiting Herbicides 
Acetolactate synthase (ALS) is the first enzyme in the biosynthetic pathway of branched amino 
acids (Val, Leu and Ile) (Figure 1-5). It is an essential protein, making it an excellent herbicide 
target. A huge number of resistance endowing mutations of ALS have been identified. By 2009 
22 had been observed across seven different amino acid sites. Most remarkably at Pro197 11 
different amino acid substitutions were observed which resulted in herbicide resistance.15 A 
Pro197Ser mutation is most common as this does not confer a fitness cost and requires only one 
nucleotide substitution. Crystal structures demonstrate that ALS inhibiting herbicides do not 
bind to the active site, instead binding across the channel that gives access to the active site for 
substrate binding.17 As a result resistance is common as different mutations are able to be made 
without affecting native substrate binding.18 
 
Figure 1-5: Synthesis of branched chain amino acids showing function of ALS and action of ALS 
inhibiting herbicides 
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1.3.1.2 ACCase Inhibiting Herbicides 
 
Acetyl CoA carboxylase (ACCase) is a key enzyme in lipid biosynthesis, responsible for catalysing 
the formation of malonyl CoA from the carboxylation of acetyl CoA (Figure 1-6). This blocks fatty 
acid biosynthesis altering membrane integrity, resulting in plant death.  
 
Figure 1-6: Lipid biosynthesis pathway showing enzymes in blue and action of ACCase inhibiting 
herbicides19 
48 species of grass weeds have been identified as having developed resistance (2018).14 The 
Leu1781Ile mutation is the most common resistance substitution but seven others have also 
been identified. Crystal structures have demonstrated that herbicides bind to a domain close to 
and partially overlapping the catalytic site.20 This means some amino acid substitutions can be 
made which prevent herbicide binding while not disrupting acetyl CoA binding, while others do 
disrupt acetyl CoA binding, resulting in a fitness cost.21 
1.3.1.3 Glyphosate resistance: EPSPS Inhibitors 
 
Glyphosate is the world’s most widely used herbicide, popular as it controls a very broad 
spectrum of weeds.15 Glyphosate is a potent inhibitor of EPSPS which catalyses the reaction of 
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shikimate-3-phosphate (S3P) and phosphoenolpyruvate (PEP) to form enolpyruvylshikimate-3-
phosphate (EPSP). Glyphosate inhibits this activity disrupting the shikimate pathway and 
inhibiting aromatic amino acid production.  
 
Figure 1-7: Synthesis pathway of aromatic amino acids showing inhibitory action of glyphosate22 
 
A single mutation has been observed conferring resistance where Pro106 is mutated to a 
number of different amino acids. While Pro106 is not involved in herbicide binding, mutating it 
results in a structural change in the active site reducing available space, evidenced by 
cyrstallography.23,24 No other resistance conferring mutations have been observed- it appears to 
be challenging to prevent herbicide binding while maintaining enzyme function.  
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Target site resistance has also been observed in glyphosate resistant crops where a large 
overexpression of EPSPS is observed. A 100 fold gene amplification resulting in a 40 fold 
overexpression of EPSPS has been observed in Amaranthus palmeri.25 
1.3.2 Non-target site resistance 
 
Non-target site resistance can occur via a number of different mechanisms. Weeds have been 
observed which show reduced penetration to herbicides, as well as those with altered 
translocation of herbicides. For example, plants have developed resistance to glyphosate by 
reducing its translocation through the plant and to its roots.26 Reduced translocation has also 
been observed in response to paraquat, a herbicide that targets the electron transfer chain. 
Reduced translocation inherits as a single nuclear semi-dominant gene meaning it is easily 
spread to future populations.27 
Perhaps the most common methods of non-target site resistance involve the metabolic enzymes 
CYP450s and GSTs. CYP450s are known to be involved in herbicide resistance although this is 
poorly understood. Non-target site resistance occurs when CYP450s are upregulated. Crops are 
able to CYP450 metabolise many herbicides so their use on weeds acts as a strong selection 
pressure for weeds with the same ability. It is a very threatening form of resistance as it is able 
to confer resistance to many different types of herbicides (Cross resistance discussed in more 
detail in 1.3.3.1).15 
GSTs are also known to be involved in resistance to herbicides. Maize is able to detoxify triazine 
herbicides because of GST activity. A mutation has been reported in A. theophrasti which leads 
to an improved catalytic activity of a GST resulting in atrazine resistance.28 The role of GSTs in 
resistance will be discussed in more detail later as part of their role in multiple herbicide 
resistance (MHR). (See section 1.3.3.1.2) 
1.3.3 Cross Resistance and Multiple Resistance 
 
Cross resistance and multiple resistance are both methods by which weeds can become resistant 
to a number of different herbicides. In cross resistance plants have a single mechanism which 
gives resistance to two or more chemical families targeting one site of action. In multiple 
resistance plants possess multiple target site resistance traits that give resistance to several 
different sites of action.29 
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1.3.3.1 Cross resistance 
 
Cross resistance is a genetically endowed mechanism conferring the ability to withstand 
herbicides from different chemical classes. It can occur as a result of either target site or non-
target site methods.29 
1.3.3.1.1 Target site cross resistance 
 
Target site cross resistance occurs where a change at the biochemical site of action of a herbicide 
confers resistance to herbicides from different chemical classes that inhibit the same site of 
action. It does not necessarily give resistance to all herbicide classes with similar mode of action 
or even all herbicides within a chemical class.29 For example, cross resistance is observed in 
response to ALS inhibiting herbicides. The Asp376Glu mutant is resistant to imidazolinone, 
pyrimidinylthiobenzoate, sulfonylaminocarbonyltriazoline, sulfonylurea and triazolopyrimidine 
herbicides.30 Increased amplification of a target gene and overexpression of a protein will also 
result in resistance to all chemical classes targeting a particular mode of action.25 
1.3.3.1.2 Non-target site cross resistance 
 
Non target site resistance weeds often have a central defence mechanism which gives resistance 
to many different sites of action. The most studied form of these is multiple herbicide resistance. 
This is seen in P450s, GSTs, GTs and ABC transporters.4  
CYP450 activity has been seen to correlate with herbicide resistance in weeds. CYP450 
involvement in black grass resistance to chlortoluron was identified through exogenous 
application of a P450 enzyme inhibitor and by analysing metabolites that accumulated after 
herbicide treatment.31  
GSTs were first implicated in herbicide resistance in 1970s with their involvement in atrazine 
resistance in grasses. It has been seen to occur both as a result of increased activity of GSTs32 
and in “Peldon” populations of black grass in response to an increase in gene expression.33,34 
This role in peldon populations will be discussed further with regards to the role of AmGSTF1 in 
multiple herbicide resistance in black grass (see section 2.2).  
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1.3.3.2 Multiple resistance 
 
Multiple resistance occurs when a weed develops resistance to multiple different sites of action 
through a number of different genetic changes. Resistance is able to spread and accumulate 
quickly particularly with cross pollination.15 Some weed populations have been seen to show 
resistance to up to seven different modes of action (Figure 1-8).14 
 
Figure 1-8: Weed populations resistant to herbicides of different sites of action. Showing the number 
of individual weed populations which have been identified as showing resistance to multiple sites of 
action and the number of sites of action and the number of weed populations identified in each case. 
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1.4 Glutathione-S-Transferases 
 
GSTs are a class of enzyme primarily associated with their role in catalysing the nucleophilic 
addition of reduced glutathione (GSH) to electrophilic centres in compounds to produce a less 
reactive compound and increase solubility.35 
They are divided into a number of classes based on sequence similarity of which six classes are 
present in plants (Table 1-2). Phi, tau, lambda and dihydroascorbate reductase (DHAR) are plant 
specific while theta and zeta classes are also found in mammals. They are ubiquitous, with 53 
members encoded for in the Arabidopsis genome.36 They are soluble proteins,37 with phi and 
tau classes most represented.38 
Table 1-2: Classes of plant GST and their single letter codes 
 
GST Class Single Letter Code Kingdom 
Phi F Plant 
Tau U Plant 
Theta T Plant and Mammal 
Zeta Z Plant and Mammal 
Dihydroascorbate DHAR Plant 
Lambda L Plant 
 
There is specific nomenclature used to describe and identify these GSTs, eg. AmGSTF1-1. The 
italicised letters denote a two letter code for the organism where the GST is found, usually based 
on binomial nomenclature, in this case Alopecurus myosuroides. The letter following the GST 
represents the class, in this case phi. This is then followed by a number which represents the 
dimer subunits. In this case F1-1 represents a homodimer of the F1 subunit. 
1.4.1 The multiple roles of GSTs 
 
While GSTs are most commonly associated with, and were initially discovered for their ability to 
detoxify metabolites, they have also been found to participate in a number of other cellular 
activities. These roles will be discussed in this section.  
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1.4.1.1 Glutathione conjugation  
GSTs are able to catalyse the quantitative conjugation of GSH, which is the major phase II 
metabolism reaction in many species. GSTs catalyse nucleophilic aromatic substitutions, Michael 
additions to α,β unsaturated ketones and epoxide ring-opening reactions, all of which result in 
the formation of GSH conjugates.39 
 
Figure 1-9: Examples of reactions carried out by Glutathione Transferases.39 GS- represents a 
glutathione anion.  
1. Nucleophilic Aromatic Substitution 
2. Michael Addition to α, β-unsaturated ketones 
3. Epoxide ring opening reactions 
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1.4.1.2 Other Catalytic Activity 
A number of plant GSTs have been identified as showing glutathione peroxidase activities, 
including proteins present in Arabidopsis,40,41 wheat42 and black grass.33 
Some GSTs have been identified as having isomerase activity. They use GSH in a catalytic role, 
with the end product not including a GSH conjugate. For example, the zeta class GST in 
Arabidopsis adds GSH across a cis-double bond in maleylacetoacetate, allowing bond rotation 
followed by elimination of GSH to yield fumarylacetoacetate.43 
1.4.1.3 Targeting transmembrane transport 
Secondary metabolites are often toxic, and require glutathione conjugation to mark them for 
transport to the vacuole. For example, in anthocyanin biosynthesis if the pigment is retained in 
the  cytoplasm it prevents pigment production and is toxic to cells.44 
1.4.1.4 Protection from oxidative damage 
Oxidative damage caused by hydroxyl radicals is cytotoxic. GSTs are able to conjugate GSH with 
endogenously produced electrophiles to detoxify them.40 
During pathogen attack, some plants protect themselves using a process called systemic 
acquired resistance.45,46 This process involves production of salicylic acid, which prevents 
catalase activity, stopping breakdown of H2O2. This pathway leads to GST genes being induced 
to protect the plant from the damaging effect of the reactive oxygen species.47 
1.4.1.5 Ligandins: Non-enzymatic binding and intracellular transport 
In addition to their catalytic function, GSTs are able to function as carrier proteins. In mammals 
they have been identified to be involved in transport of steroids, heme, bilirubin, bile salts, 
carcinogens and some drugs.48 
In plants some GSTs serve as carriers of natural auxins,49 while others have been identified to 
bind flavonoids in their non-catalytic L-site.50 
1.4.1.6 Other functions in Mammals 
GSTs have been studied more extensively in mammals than plants, and a number of other 
function identified. GSTs are responsible for catalysing the penultimate step in the catabolism 
of Phe and Tyr amino acids.51 They are also involved in steroid synthesis of testosterone and 
progesterone.52 They contribute to the biosynthesis of pharmacologically important metabolites 
of arachidonic acid.53 Finally GSTs are involved in modulating the signalling pathways of 
cyclopentenone prostaglandins.54,55  
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1.4.2 Structure of GSTs 
 
GST structure in plants is well understood thanks to crystal structures being available for all 
cytosolic classes except the theta class for which mammalian structures are available (Table 1-3). 
Sequence similarity is low and substrate specificity varies, however 3D structure is highly 
conserved, especially within the glutathione binding site.35 
Table 1-3: Representative crystal structures of plant GSTs available in the Protein Data Bank (PDB). For 
Theta class no plant structure is available however the human structure is well characterised. Rmsd 
values are given for each structure compared to the Phi class Maize structure (1axd), and are 
calculated using Pymol.  
GST 
Class 
Organism GST 
code 
PDB 
Code 
Ligand Reference rmsd/ 
Å 
Phi Arabidopsis 
thaliana 
AtGSTF2 5a4w Quercetrin 50 0.92 
Zea mays ZmGSTF1 1axd Lactoylglutathione 56 - 
Tau Mangifera 
indica 
MiGSTU1 5kej S-hexyl 
glutathione 
57 3.223 
Arabidopsis 
thaliana 
AtGSTU23 6ep6 - 58 3.17 
Theta Homo 
sapiens 
HsGSTT1 2c3t - 59 2.72 
Zeta Arabidopsis 
thaliana 
AtGSTZ1 1e6b - 43 6.36 
DHAR Oryza sativa OsDHAR1 5d9v - 60 3.95 
Arabidopsis 
thaliana 
AtDHAR2 5lol Glutathione 61 3.79 
Lambda Populus 
trichocarpa 
PtGSTL1 4pqh Glutathione 62 2.52 
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Phi (1axd)56 Theta (2c3t)59 
 
 
Tau (6ep6)58 Zeta (1e6b)43 
  
Lambda (4pqh)62 DHAR (5lol)61 
Figure 1-10: Representative structures for each of the classes of plant GST. PDB codes are given in 
brackets. Structures are all orientated in the same manner with domain I on the left and domain II on 
the right. N and C termini are marked for each structure. Figures produced in pymol. 
N 
C 
N 
C 
N 
C 
N 
C 
N 
C 
N 
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Most classes have a dimeric composition (except DHAR and lambda classes) with the enzyme 
active as a homo or heterodimer of subunits from the same gene class of about 25 kDa in size. 
Each subunit is composed of a catalytic site with two components (domain I and domain II) 
joined by a short linker region (Figure 1-11).  
 
Figure 1-11 A: Structure of a Phi Class GST (PDB:1AXD) showing location of domain I and II, position of 
G and H sites are circled, and location of N and C terminus marked. Domain I is coloured in blue, with 
domian II in cyan, and the linker region is coloured in grey. The protein is orientated with the dimer 
interface facing out. B: Dimer form of a Phi Class GST (PDB 1AXD) with the monomer form in the same 
orientation as for figure A (left) and rotated by 90° (right). Each half of the dimer is coloured either 
cyan or blue.  Figure produced in pymol. 
G-Site 
H-Site A 
B 
N Terminus 
C Terminus 
90° 
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Domain I is composed of residues from the C-terminus and provides the residues for GSH binding 
and catalytic activity.63 It contains an α/β core structure composed of a four stranded β-sheet 
(β1-4) flanked by two α-helices (α1 and 3) (Figure 1-12). It resembles the thioredoxin fold 
observed in crystal structures for E. coli thioredoxin,64 bacteriophage T4 glutaredoxin,65 and 
glutathione peroxidase.66 
Domain II is an all α structure composed of 5 α helices (α4-8).63 It provides the residues for 
hydrophobic substrate binding (H-site) and as a result shows greater sequence diversity than 
domain I to provide substrate specificity.35 
β4 
β3 β1 
β2 
α1 
α2 
α3 
α6 
α4 
α8 
α5 
α7 
Figure 1-12: Structure of a Phi Class GST (PDB 1AXD) showing conventions for numbering secondary 
structure elements. Labels for secondary structure elements are shown in the same colour as the 
secondary structure element. Figure produced in Pymol. 
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Dimers are stable with no spontaneous exchange of subunits occurring. Class specific 
heterodimers are seen, but dimers cannot include monomers from differing classes. 
Dimerisation contacts are primarily hydrophobic and occur between domain I of one subunit 
and domain II of the neighbouring subunit.63 While dimerisation is essential for activity, and it is 
essential to form a full G-site, it is unclear why it is essential for GSTs to form dimers. Positive 
cooperativity has never been demonstrated,38 however in Pi class GSTs it has been 
demonstrated that dimerisation stabilises the tertiary structure of the subunit.67 
In plants Phi, Tau, Theta and Zeta classes have an active site serine residue (tyrosine in mammals) 
which stabilises the formation of a thiolate anion of GSH, enabling glutathionylation of 
substrates in the H-site. This residue has been shown to be catalytically essential via site directed 
mutagenesis across a range of organisms.43,59,63,68 While the serine residue in plants is not 
located at the equivalent amino acid position to the tyrosine, Ser is at the N-terminus of α1 while 
Tyr is at the C-terminus of β1, their hydroxyl groups are positioned such that they occupy a 
similar location in the active site. By contrast Lambda and DHAR have a cysteine in their active 
sites. They do not catalyse the S-glutathionylation of substrates present in the H-site and instead 
are more likely to catalyse redox reactions.69 
The G-site is made of a network of specific polar interactions between the glutathione tripeptide 
and protein moieties in domain I, and one interaction with a residue in domain II of the other 
subunit of the dimer. Glutathione binds in an extended conformation at one end of the four 
strand β-sheet in domain I.70 The orientation is important to catalysis, and is governed by the 
selectivity of the binding site.71 Surprisingly, given the number of interactions formed, and the 
specificity observed for glutathione the residues are predominantly conservatively replaced 
between classes and members of classes rather than conserved.63 Glutathione binding occurs 
via an induced fit mechanism with the loop over the G-site displaying a large conformational 
change on binding.56 
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Figure 1-13: Structures demonstrating the induced fit mechanism of loop over the G-site. GSH bound 
(PDB: 1AXD; green) and apo (PDB: 1AW9; cyan). On GSH binding the loop is seen to adopt an 
alternative structure, allowing it to form additional interactions with the GSH molecule. Figure 
produced in Pymol.  
 
The molecular details of the H-site differ more than the G-site both within and between classes. 
It is composed of clusters of hydrophobic amino acid side chains which provides a highly 
hydrophobic surface. Structural elements arise from both domains I and II including the active 
site loop between β1 and α1, the C-terminal region of α4 and the C-terminal segment of the 
polypeptide chain. The variation observed in H-site residues explains the variation observed in 
xenobiotic specificities by GSTs.63 
In a number of GSTs a third non-catalytic binding site has been identified. The L-site is found in 
the dimer interface (Figure 1-14), and is involved predominantly in transport.50,72 
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Figure 1-14: GST from squid showing location of L-site.72 Each half of the dimer is shown in a different 
colour, with the drug Praziquantel (shown in green) bound in the L-site. Figure produced in Pymol. 
 
1.4.3 Mechanism of GSTs 
 
In plants nucleophilic substitution is most common. This forms a conjugate that is less reactive 
than the parent and increases solubility. During the reaction a Meisenheimer complex is formed, 
and this has been seen in an enzyme bound GSH anion with 1,3,5-trinitrobenzene.73 The catalytic 
mechanism lowers the pKa of the GSH thiol group from around 9 in aqueous conditions to 
between 6 and 7 when bound to the protein. Kinetics suggests this would occur via a random 
sequential two substrate, two product reaction. However, in cellular conditions GSH addition 
occurs first because GSH concentration is 1-10 mM (about 3 orders of magnitude higher than 
the GSH dissociation constant from the enzyme).35,74  
In an in vitro system, it appears that σ complex formation is rate limiting. If the Cl group is 
substituted for a more electrophilic group the rate constant increases approximately 50 fold. If 
σ complex decomposition was rate limiting we would expect the opposite. However, viscosity 
experiments suggest that in vivo there is most likely a non-chemical rate limiting step, and that 
Kcat is limited by product release which is limited by a diffusional barrier.75 
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1.5 Summary 
 
This chapter has discussed herbicides and the mechanisms of resistance that have developed in 
response to their use. It has also looked at glutathione-s-transferases and their role in herbicide 
metabolism. The next chapter will focus on previous work which has been done on this project 
investigating multiple herbicide resistance in black grass, and the role GSTs play. 
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2 Previous Work and Aims 
 
2.1 Black Grass 
Black grass (Alopecurus myosuroides) is an annual rye grass that is found on cultivated land, and 
is a major weed of cereal crops. It produces a large quantity of seeds, and occurs at very high 
densities competing with the crop and resulting in major yield losses.76 Whilst wild type black 
grass can be well controlled through herbicide application, incidences of herbicide resistance 
have led to a loss of control. A recent survey determined that 80% of black grass collected from 
132 fields was highly resistant to all herbicides that can be used for selective black grass control 
in a wheat crop.77 
 
Figure 2-1: Black Grass78 
MHR was first reported in the UK in Peldon in 1982. It has now been reported in independent 
outbreaks all over the UK. MHR has been linked to an increase in metabolic enzymes and occurs 
through resistance to several herbicides.56 The work in this project has focussed on MHR 
observed in this Peldon population.  
 
2.2 Identification of AmGSTF1 
 
GSTs are known to play a large role in non-target resistance. In velvetleaf (Abutilon theophrasti), 
a resistant maize weed, GSTs have been implicated in atrazine resistance,79 and GSTs have also 
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been identified as responsible for herbicide detoxification in maize crops. Work in the Edwards 
group has focussed on identifying the role of GST activity in herbicide resistance in black 
grass.33,34,42 Work has focussed on a population from Peldon, identified to be particularly 
herbicide resistance, and has also used a herbicide susceptible population from Rothamsted. 
The Peldon population is seen to have higher GST activity (1.9 ×) than the herbicide susceptible 
Rothamsted population.42 Using anti-wheat GST sera for western blotting, it was possible to 
identify three populations of GST that were up-regulated in the herbicide resistant populations 
(25, 27 and 28 kDa). In order to allow for detailed characterisation, cDNAs encoding the different 
types of GST subunits in black grass were cloned from Peldon seedlings and the recombinant 
proteins overexpressed.33  It was concluded that the 25 kDa protein observed in western blots 
was AmGSTU1. However, exhaustive screening was unable to identify peptides of 27 and 28 kDa, 
instead identifying AmGSTF1a and AmGSTF1c of nearly identical mass (24.8-24.9 kDa). When 
these peptides were analysed with western blotting they were seen to migrate with the 28 kDa 
polypeptide. The 27 kDa polypeptide was determined to be a partial degradation product, with 
an increase observed after prolonged dialysis. Both AmGSTF1 and AmGSTU1 were identified to 
be active as their respective homodimers by gel filtration chromatography.33  
RNA transcripts were analysed from susceptible Rothamsted and resistant Peldon populations. 
For both AmGSTF1 and AmGSTU1 it was clear that the enhancement of GSTs observed in 
resistant black grass was due to increased gene expression.33  
 
2.3 Role of AmGSTF1 in Multiple Herbicide Resistance 
 
Activity assays were undertaken to identify the possible roles of the GSTs.33 AmGSTU1 was seen 
to be highly active in conjugating the herbicides fluorodifen and fenoxaprop-ethyl. Significantly 
however, AmGSTF1 was seen to have low activity towards these herbicides, suggesting the 
protective role played by these proteins was unlikely to be as a result of accelerating herbicide 
metabolism. The proteins were then assayed for glutathione peroxidase (GPOX) activity. While 
AmGSTU1 had no activity as a GPOX, AmGSTF1 was seen to be very active catalysing the 
reduction of both cumene hydroperoxide and linoleic acid hydroperoxide. This suggests that 
AmGSTF1 may be functioning to protect the black grass from toxic organic hydroperoxides 
formed as a result of herbicide injury.  
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Further work was undertaken to investigate the role that AmGSTF1 plays in multiple herbicide 
resistant black grass using transgenic Arabidopsis.34 Arabidopsis plants expressing either high or 
low levels of AmGSTF1 were shown to have increased resistance to a range of herbicides, 
chlortoluron, alachlor and atrazine, in both spray and germination trials (Figure 2-2). Both 
transgenic lines showed an enhancement in GPOX and CDNB conjugating activities in line with 
the activity profile of the enzyme. Interestingly, the transgenic plants also showed increased 
conjugative activity towards atrazine, which is not a substrate of AmGSTF1. These activity 
increases are therefore likely to arise as a result of increased expression of endogenous 
Arabidopsis enzymes.34 Furthermore, an enhancement in unrelated glycosylating activities 
towards the xenobiotic 2,4,5-trichlorophenol were also observed. Thus, two independent routes 
of bioconjugation of atrazine were both enhanced in the transgenic plants.  
 
Figure 2-2: Transgenic Arabidopsis expressing AmGSTF1 in intermediate (line 8) and high (line 12) 
amounts. Plants were grown on agar containing herbicide (A) or sprayed after germination (B).34 
Plants expressing AmGSTF1 are observed to show resistance to the herbicides. 
 
In addition, the transgenic plants were analysed using liquid chromatography-mass 
spectrometry (LC-MS), and a number of metabolites were identified which accumulated at 
higher levels in these plants than the vector only controls. The compounds were identified as 
conjugates of the flavonoid kaempferol and the anthocyanin cyanidin. The transcriptome of the 
transgenics was compared with wild type plants, and no consistent changes in gene expression 
were determined. This suggests that the changes in biochemistry observed were not regulated 
at the level of transcription.34 
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2.4 Chemical Inhibition of AmGSTF1  
 
Having determined using transgenic Arabidopsis that AmGSTF1 played a causative role in MHR, 
a chemical strategy was sought which would restore herbicide activity. Multi-drug resistance 
(MDR) in humans shows parallels to MHR, as it involves a drug detoxifying GST, HsGSTP1. 
HsGSTP1 has been a successful target for inhibitors in medicinal chemistry programs.80 These 
inhibitors can be subdivided into GSH conjugates and peptidomimetics which bind the G-site 
and compounds which act on the larger H-site.81 These simpler H-site compounds were tested 
for their ability to inhibit AmGSTF1 and restore herbicide efficacy. Four compounds were tested: 
4-chloro-7-nitrobenzofurazan (CNBF), ethacrynic acid, cyanuric acid and bromoenol lactone 
(Figure 2-3a). Ethacrynic acid and cyanuric acid were found to be phytotoxic, and bromoenol 
lactone showed no ability to enhance herbicide activity so these were discontinued from further 
exploration. However, CNBF was seen both to inhibit AmGSTF1 in vitro and to enhance the 
herbicidal activity of chlortoluron, fenoxaprop-p-ethyl and clodinafop-propargyl when pre-
applied to Peldon plants (Figure 2-3).  
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CNBF Ethacrynic Acid 
  
Cyanuric Chloride Bromoenol Lactone 
Work was carried out to identify the mechanism by which CNBF was having an inhibitory effect 
on AmGSTF1. In HsGSTP1 CNBF forms a covalent interaction with Cys47.82 Cys47 is thought to 
play a regulatory role, modulating activity with a c-Jun N-terminal kinase (JNK1), which is 
involved in the apoptotic pathway.83,84 Mass spectrometry was used to confirm that in AmGSTF1 
CNBF was also forming a covalent interaction, with it being found to modify the Cys120 
residue.34  
2.5 Identification of novel inhibitors 
 
Attempts to modify the CNBF inhibitor with groups similar to those used in human MDR drugs 
proved ineffective. While several maintained activity in vitro against AmGSTF1 no activity was 
seen against MHR plants, probably due to problems in uptake by the leaves.34 As a result work 
focused on identifying a novel class of inhibitors.  
a 
b c 
Figure 2-3: (a)GST Inhibitors tested for activity against MHR black grass (b and c) effect of CNBF 
(written as NBD-Cl) against WT and MHR black grass using Chlortoluron (CHL) as a herbicide. 
While CNBF alone is seen to have no toxic effect on plants, in combination with Chlortoluron 
this is seen to lead to plant death.   
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A ligand fishing experiment was used to identify possible compounds that bind to AmGSTF1.85 
Strep tagged AmGSTF1 was immobilised on a streptactin column, and a cocktail of compounds 
washed over it. Liquid Chromatography-Mass Spectrometry (LC-MS) was then used to identify 
which compounds had bound to the AmGSTF1 (Figure 2-4). 
 
Figure 2-4: Shematic showing ligand fishing method used to identify new inhibitors. E. coli expressed 
strep-tagged AmGSTF1 enzyme is immobilised on a strep column. A cocktail of inhibitors are passed 
over the column and those that bind identified by HPLC. 
 
This experiment identified three main compounds that bound to AmGSTF1: the 4-Glutathione 
conjugate of CNBF; a purine-CNBF hybrid and apigenin. The most significant binding was 
observed with apigenin. A subsequent ligand fishing experiment with a selection of commercial 
flavonoids identified that AmGSTF1 was capable of binding to a range of flavonoids. These 
commercial flavonoids along with a selection from the Syngenta compound library were tested 
for their ability to inhibit AmGSTF1 activity in the CDNB assay. This identified compound SYG8, 
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which gave 100% inhibition at 10 µM, as a new lead compound. In vivo tests demonstrated that 
it was also capable of acting as a synergist, restoring the activity of pinoxaden against MHR black 
grass. 
 
 
Figure 2-5: Initial lead compound identified from screening of Syngenta library 
 
2.6 Flavone Inhibitors 
  
Recent efforts in the Steel group have focussed on the synthesis of derivatives of this lead 
compound SYG8.85,86 Work to improve activity afforded compound MS-1-134 with a structure 
very similar to SYG8 and a similar level of inhibition (71% at 1 µM). The structure activity 
relationships (SAR) observed from these compounds will be discussed in more detail in (Section 
4.3.1.2). 
 
 
Figure 2-6: Lead compound obtained from initial SAR studies 
 
Further work focussed on increasing the solubility of compound MS-1-134.86 While the long alkyl 
chain significantly increases activity it also results in the compound being highly insoluble, which 
SYG8 
MS-1-134 
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was thought to be limiting activity in planta as a synergist. The effects of adding different groups 
on solubility and activity were investigated and the results shown in Table 2-1. 
Table 2-1: Compounds designed to increase solubility, giving aqueous solubility measured at Syngenta 
Jealott's Hill, and inhibition against AmGSTF1 measured in the CDNB assay 
 
Compound Aqueous 
solubility/ ppm 
Inhibition at 
10 µM 
 
25.0 20% 
 
70.1 8% 
 
88.3 11% 
 
15.9 13% 
 
467.7 23% 
 
16.7 6% 
 
16.9 9% 
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21.4 19% 
 
148.6 8% 
 
N.D. 95% 
 
A thiazole group was observed to significantly increase solubility, whilst maintaining activity, 
resulting in this group being incorporated into compounds with the long chain to give 
compound MS-4-48 as a more soluble lead compound (Figure 2-7). This compound was 
observed to show activity both in vitro against AmGSTF1 and in vivo acting as a synergist to 
restore pinoxaden sensitivity in MHR black grass.86 
 
  MS-4-48 
Figure 2-7: Lead compound produced from work  to increase solubility 
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2.7 Project Aims 
 
The principal aim of this project was to gain a molecular understanding of the interactions and 
mechanisms of inhibitors for AmGSTF1. Work would primarily focus on the flavonoid inhibitors 
synthesised in the Steel group, with the aim of using this information to guide synthesis 
decisions. However, CNBF was also investigated to try to understand the mode of action of this 
inhibitor.  
Previously, an apo crystal structure of AmGSTF1 had been solved at a resolution of 1.95 Å,87 
although this was incomplete, and with two disordered loops including one in the active site 
area. This work aimed to increase the resolution and completeness of this structure. In addition, 
it was aimed to crystallise protein-ligand complexes to identify ligand binding sites and allow for 
rational inhibitor design. An in silico approach would also be used to identify and evaluate 
possible binding sites for the inhibitors. Furthermore, thermal shift assays would be used to 
assess the binding of compounds to AmGSTF1 and to act as a complementary method for 
assessing them alongside the previously used CDNB activity assays.  
Biophysical methods would be used to improve understanding of the mode of action of 
inhibitors, and the mechanisms by which they are able to restore herbicide sensitivity to MHR 
black grass.  
Finally, it was aimed to correlate the results of spray tests, biochemical and structural studies, 
in order to better understand the inhibition of MHR in black grass. 
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3 Materials and Methods 
 
3.1 Materials 
 
All chemicals were purchased from Sigma-Aldrich unless otherwise specified.  
All protein concentrations were calculated using A280 on the DeNovix DS-11+ 
spectrophotometer, using extinction coefficients calculated using ExPASy ProtParam.88 
Sonication was carried out using the Bandelin Sonopuls HD2200 sonicator.  
 
3.2 Protein Expression and Purification 
3.2.1 Transformation of E. coli 
 
Plasmid (2 μL) was added to competent E. coli cells (New England Biolabs, 50 μL, see 3.2.3 and 
3.2.4) and incubated on ice for 30 minutes. Bacteria were heated at 42 °C for 45 secs and 
immediately incubated on ice for 2 min. SOC medium pre warmed to 37 °C was added and the 
cells incubated with shaking (1h, 37 °C). 100 μL of culture was spread onto a lysogeny broth (LB) 
agar plate (inoculated with appropriate antibiotics), the remaining cells spun down and 
resuspended in LB (1mL) and 100 μL spread on an LB agar plate (with appropriate antibiotics). 
Plates were grown overnight at 37 °C.  One culture was taken from the plate and grown 
overnight in LB (with appropriate antibiotics). 500 μL of culture was combined with 500 μL 50% 
glycerol to make glycerol stocks which were stored at -80 °C until needed. 
3.2.2 Plasmid Purification 
 
A colony from an LB agar bacterial plate was added to LB inoculated with appropriate antibiotics 
(see 3.2.3 and 3.2.4). The culture was incubated overnight with agitation at 37 °C. The plasmid 
was purified from the overnight culture using GeneJet Plasmid Miniprep Kit (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 
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3.2.3 Strep tagged AmGSTF1 and Strep tagged AtGSTF8 
 
Strep tagged proteins were in pETStrpIII plasmids,89 with resistance to kanamycin (Kan), and 
were expressed in E. coli Rosetta II cells. For all steps requiring antibiotics, Kan was used at a 
concentration of 50 μg/ mL and Chloramphenicol (Chlor) at a concentration of 34 μg/ mL. 
3.2.3.1 Expression of Strep tagged protein 
 
Buffer A: HEPES free acid (20 mM), NaCl (150 mM) pH 7.6 
LB (15 mL, Kan/Chlor) was inoculated with cells from a glycerol stock. The culture was grown 
overnight (37 °C, 200 rpm). The overnight culture was added to 1 L LB (Kan/ Chlor) and grown 
at 37 °C with shaking at 200rpm until OD600= 0.6. Cultures were induced with Isopropyl β-D-1-
thiogalactopyranoside (IPTG; 100 μM) and incubated at 37 °C with shaking at 200 rpm for 16 h. 
Cells were collected by centrifugation (4000 g, 30 min), the media decanted off, and pellets 
resusupended in Buffer A (10 mL/ L E. coli expression) with cOmplete ULTRA Tablets, Mini, EDTA 
free (1 per 15 mL), and dithiothreitol (DTT, 1 mM). Pellets were frozen at -20 °C until needed.  
3.2.3.2 Purification of Strep tagged protein 
 
Pellets were removed from the freezer defrosted on ice, and lysed by sonication (3 × 30 sec, 
30%) and centrifuged (20,000 rpm, 50 min). Purification was carried out using a 5 mL 
Strep-tactin sepharose high performance column (GE Healthcare) attached to a peristaltic 
pump. The column was pre-equilibrated with buffer A. The cell lysate was filtered through a 
0.2 μm filter and loaded onto the column at a rate of 1 mL/min. Unbound protein was washed 
off the column using buffer A. Once all unbound protein was removed from the column 
according to the A280 reading the protein was eluted using desthiobiotin (5 mL, 2.5 mM in buffer 
A). Protein was dialysed against buffer A overnight, and stored at -80 °C until needed when it 
was defrosted on ice.  
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3.2.3.3 AtGSTF8 Protein 
Strep tagged AtGSTF8 was expressed in E. coli, from a plasmid provided by Prof. Robert Edwards 
(Newcastle) and purified using streptactin resin (Section 3.2.3). This produced pure protein 
(Figure 3-1), with no subsequent purification step required, however it was seen to express at 
significantly lower levels than AmGSTF1, with around 2 mg of purified protein per litre of 
recombinant E. coli. As only small amounts were required for assays to investigate selectivity no 
attempts were made to optimise this procedure.  
 
3.2.4 Untagged AmGSTF1 and mutants 
 
Genes encoding untagged proteins were in a construct in pET24a plasmid with Kan resistance, 
and were expressed in BL21 (DE3) cells. Kan was used at a concentration of 50 μg/ mL.  
3.2.4.1 Expression of untagged proteins  
 
LB (Kan) was inoculated with cells from a glycerol stock. The culture was grown overnight (37 °C, 
200 rpm). The overnight culture was added to 1 L LB (Kan) and grown at 37 °C with shaking at 
200rpm until OD600= 0.7. Cultures were induced with IPTG (100 μM) and incubated at 37 °C with 
shaking at 200rpm for 16 h. Cells were collected by centrifugation (4000g, 30 min), the media 
decanted off, and pellets resusupended in Buffer A with cOmplete™ ULTRA Tablets, Mini, EDTA 
free (1 per 15 mL), and DTT (1 mM). Pellets were frozen at -20 °C until needed.  
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Figure 3-1: SDS-PAGE gel to show the purity of AtGSTF8. Lane A- 
Molecular weight marker, B-Strep tagged AtGSTF8. Expected 
molecular weight for monomer= 25941 Da 
A B 
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3.2.4.2 Purification of untagged proteins 
 
Buffer A: 20 mM HEPES free acid, 150 mM NaCl pH 7.6 
Buffer B: 200 mM KCl, 20 mM TRIS, 1 mM DTT, pH 7.5 
Buffer C: 5 mM GSH, 20 mM TRIS, 1mM DTT pH 7.5 
Buffer D: 20 mM TRIS, 1 mM DTT, pH 7.5  
Buffer E: 20 mM TRIS, 1 mM DTT, 500 mM NaCl, pH 7.5 
Cell pellets suspended in Buffer A were lysed by sonication (3 × 30 sec, 30 % power) and re-
pelleted by centrifugation (20,000 rpm, 50 min). Cell lysate was incubated (1 h) with free 
glutathione agarose beads (3 mL) with agitation. Using a gravity column, Buffer B was run until 
protein concentration was less than 0.1 mg/mL. Protein was eluted using 10 mL of buffer C, 
purity of fractions was confirmed by SDS-PAGE before they were pooled and dialysed against 
buffer D overnight. Using an Akta Explorer FPLC the protein was purified using a MonoQ column. 
The column was equilibrated with buffer E followed by buffer D. The sample was loaded onto 
the column and a gradient of 1-100 % buffer E run over 30 mins. The protein was collected in 1 
mL fractions.  
3.3 Cloning of mutants  
 
Mutants (Y118S, F122T and Y118S F122T) were created from the wild type construct using PCR 
and the Q5® Site-Directed Mutagenesis Kit (New England BioLabs), using primers in Table 3-1 
and the appropriate annealing temperatures (Ta). The Y118S F122T double mutant was created 
from the F122T mutant using the Y118S primers. 
Table 3-1: Primers used for cloning of mutant AmGSTF1 
Mutant Forward Primer Reverse Primer Ta/ °C 
Y118S CCGATCGTGTCTCAGTGTCTG GCTCAGTGCCGGATTATAG 62 
F122T TCAGTGTCTGACCAACCCGATGATGC TACACGATCGGGCTCAGT 64 
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3.4 Labelling of AmGSTF1 with CNBF 
 
DTT (5 mM) was added to AmGSTF1 (1 mg/mL), incubated on ice for 30 min, and desalted using 
a PD10 column (GE Healthcare). To 100 μL aliquots was added 11 μL of 1 mM CNBF in DMSO 
(100 μM final concentration). Reaction mixtures were incubated at room temperature (rt) for 
20 min prior to a second desalting step (as above). Protein samples were analysed using Quad 
time of flight electrospray ionization mass spectrometry (QToF ESI-MS), for further details see 
section 3.9.  
3.5 Thermal Shift Assays 
3.5.1 Solvent Screens 
 
To protein (0.5 mg/mL in 20mM HEPES, 150 mM NaCl pH 7.6) was added 20 × SYPRO orange® 
(4 μL/ mL protein). 10 μL of protein with dye was added to each well of a 96 well polymerase 
chain reaction (PCR) plate. 10 μL of solvent at varying concentrations was also added to the well. 
The plate was sealed with a PCR seal and centrifuged (1000 rpm, 2 min). Experiments were 
performed as described in 3.5.3.  
3.5.2 Ligand binding 
 
To protein (0.5 mg/mL) was added 20 × SYPRO orange (4 μL/ mL protein). 10 μL of protein (in 
20mM HEPES, 150 mM NaCl pH 7.6) was added to each well of a 96 well PCR plate. 10 μL of 
ligand at varying concentrations (in 20 mM HEPES, 150 mM NaCl, pH 7.6 and 2% DMSO) was also 
added to the well. The plate was sealed with a PCR seal and centrifuged (1000 rpm, 2 min). 
Experiments were perfomed as described in 3.5.3. 
3.5.3 Performing Thermal Shift Assays 
 
Experiments were performed using the Applied Biosystems 7500 Fast Real-Time PCR (RT-PCR) 
system using Filter C with an excitation of 470 nm and an emission of 569 nm. Samples were run 
from 24-96 °C with a temperature increase of 1 °C/ min. Once samples had been run results 
were analysed using NAMI software.90  
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3.6 CDNB Activity Assay 
3.6.1.1 CDNB Activity Assay 
 
It is possible to investigate the conjugative activity of GSTs using the 1-chloro-2,4-dinitrobenzene 
(CDNB) assay. This is a colorimetric assay that follows the formation of dinitrophenyl thioether 
(GS-DNB) at 340 nm, as GS-DNB absorbs at this wavelength while CDNB does not.91,92  
 
Figure 3-2: CDNB activity assay 
 
0.1M potassium phosphate buffer (pH 6.5, 890 μL) was pre-incubated at 30 °C. 25 μL AmGSTF1 
(1 mg/mL in HEPES buffer) was added followed by CDNB (25 μL, 40 mM in ethanol) and inhibitor 
(10 µL in DMSO) and a blank recorded. 50 μL GSH (100 mM in water) was added and the change 
in absorbance at 340 nm monitored over 30 s using a Beckman Coulter DU-530 
spectrophotometer.  
 
3.7 Protein Gels 
3.7.1 SDS-PAGE gels 
 
Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) gels were run using the 
Bio-Rad Mini-PROTEAN® Tetra Cell system. Gels were prepared using 12% resolving gel solution 
and 8% stacking gel solution. Samples were prepared by the addition of 2 × loading buffer to 
10 μL of sample and heating to 95°C for 5 minutes.  The gel was loaded with 10µL of SpectraTM 
Multicolor Broad Range Protein Ladder (Thermo Scientific) into a well and 10µL of sample into 
the remaining wells. The gel was run at 200V until the lowest molecular weight marker of the 
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ladder was 1cm from the end of the gel. The gel was removed and incubated overnight with 
agitation in a tray with Quick Coomassie staining solution (Generon).  
3.7.2 Native PAGE gels 
 
Mini-Protean TGX Precast Gels with 4-20% resolving gel (Bio-Rad) were run using the Bio-Rad 
system. Samples were made up with protein (5 μL, 1 mg/ mL), Buffer A (see 3.2.4.2, 4.5 μL) and 
inhibitor/DMSO (0.5 μL) and 10 μL native sample buffer (Bio-Rad). 10 μL of sample was added 
to each well. NativeMark™ (Thermo Fisher Scientific) was used as a molecular weight ladder. 
Gels were run at 200 V for 35 min. Gels were removed and stained with Quick Coomassie 
staining solution (Generon). 
3.8 Fluorescence Anisotropy 
3.8.1 Labelling of AmGSTF1 with HiLyte Fluor™ 488 
  
AmGSTF1 (1 mg/mL in PBS buffer) was reduced with a 10-fold molar excess of tris(2-
carboxyethyl)phosphine (TCEP) and incubated at rt for 2 h with 400 μM HiLyte Fluor™ 488 C2 
Maleimide (AnaSpec). Unreacted dye was separated by passing through two PD10 columns (GE 
healthcare). Fractions containing labelled protein were analysed by absorbance at 280 nm. The 
contribution of HiLyte Fluor™ 488 to the absorption was estimated by the absorption value at 
507 nm multiplied by 0.2 subtracted from the total absorbance at 280 nm, and protein 
concentration calculated using the extinction coefficient of the protein (42525 M-1 cm-1).  
 
3.8.2 Fluorescence anisotropy measurements 
 
100 μL of the HiLyte Fluor™ 488 labelled protein in PBS buffer was placed in a standard black 96 
well plate. 100 μL of inhibitor at various concentrations (in PBS buffer +4% DMSO) was added to 
each well. Fluorescence anisotropy measurements were performed on a BioTek Synergy™ H4 
Hybrid Microplate Reader. Fluorescence anisotropy was measured at λex=485 nm ± 20 nm and 
λem= 528 nm ± 20 nm.  
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3.9 Mass Spectrometry 
 
For mass spectrometry, protein samples were buffer exchanged into water. Mass spectrometry 
was carried out on a QtoF Premier mass spectrometer with Acquity UPLC (Waters Ltd, UK).  
3.10 Crystallisation and structure determination 
3.10.1 Crystal structure analysis 
 
Unless specified otherwise, all figures were created using PyMol.  
All root-mean-square-deviation (rmsd) values were calculated using RAPIDO.93,94 
3.10.2 Crystallisation and structure determination of wild type AmGSTF1 (hexagonal and 
CNBF labelled) 
 
Untagged wild type AmGSTF1 was used for crystallographic studies. For the CNBF structure 
AmGSTF1 (37 µM) was labelled as previously described (3.4). Crystals were obtained across a 
range of conditions containing sodium citrate, Na/K tartrate and ammonium sulfate (Table 3-2). 
Crystals were cryoprotected in 25% glycerol and frozen in liquid nitrogen. Data was collected on 
beamline Diamond light source (DLS i04-1). Data was processed using Xia295 and scaled using 
AIMLESS/POINTLESS.96,97 The structure was solved using Phaser98 by molecular replacement 
against a lower resolution AmGSTF1 structure for the wild type, and against the higher 
resolution structure for the CNBF labelled form. Models were built in CCP499 using Coot100, and 
refined using Refmac.101 Ligand restraints were generated using JLigand.102 Further experimental 
detail is summarised in Appendix B.  
Table 3-2: Crystallisation conditions used for crystallisation of hexagonal wild type and CNBF labelled 
AmGSTF1 
Well Number pH of 0.1 M Sodium 
Citrate buffer 
Concentration of K/ Na 
Tartrate/ M 
Concentration of 
Ammonium sulfate/ M 
1 5.0 0.3 2.0 
2 5.5 0.3 2.0 
3 6.0 0.3 2.0 
4 4.5 0.2 2.0 
5 5.0 0.2 2.0 
6 5.5 0.2 2.0 
7 6.0 0.2 2.0 
8 3.5 0.1 2.0 
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Well Number pH of 0.1 M Sodium 
Citrate buffer 
Concentration of K/ Na 
Tartrate/ M 
Concentration of 
Ammonium sulfate/ M 
9 4.0 0.1 2.0 
10 4.5 0.1 2.0 
11 5.0 0.1 2.0 
12 5.5 0.1 2.0 
13 6.0 0.1 2.0 
14 3.5 0 2.0 
15 4.0 0 2.0 
16 4.5 0 2.0 
17 5.0 0 2.0 
18 5.5 0 2.0 
19 6.0 0 2.0 
20 5.0 0.3 1.0 
21 5.5 0.3 1.0 
22 6.0 0.3 1.0 
23 4.5 0.2 1.0 
24 5.0 0.2 1.0 
 
 
3.10.3 Crystallisation and structure determination of F122T AmGSTF1 
 
Protein was crystallised using the sitting drop method in the Morpheus screen (Molecular 
Dimensions),103 with crystals produced in a number of wells. Crystals were cryoprotected in 25% 
glycerol and frozen in liquid nitrogen. Data was collected at Diamond Light source on beamline 
i24. Crystals were screened and full datasets collected for those showing best diffraction. The 
data was processed using Xia2, and the structure solved using molecular replacement using the 
wild type (hexagonal) structure, and the previously disordered loops built using Buccaneer.104 
Models were built in CCP4 using Coot and refined using Refmac. Ligand restraints were 
generated using AceDRG.105 Further experimental detail is summarised in Appendix B. 
3.10.4 Crystallisation and structure determination of Y118S AmGSTF1 
 
Protein was crystallised using the sitting drop method in the Morpheus screen,103 with crystals 
produced in a number of wells. Crystals were cryoprotected in 25% glycerol and frozen in liquid 
nitrogen. Data was collected at Diamond Light source on beamline i04-1. The data was 
processed using Xia2, and the structure solved using molecular replacement using the F122T 
structure. Models were built in CCP4 using Coot and refined using Refmac. Ligand restraints 
were generated using AceDRG.105 Further experimental detail is summarised in Appendix B. 
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3.10.5 Crystallisation and structure determination of wild type AmGSTF1 (tetragonal) and 
NBF-GS structure 
 
Protein was crystallised using the sitting drop method in the Morpheus screen, using seeds of 
F122T protein. Seeds were created using a Hampton Seed Bead™ (Hampton Research) and 
associated protocol for matrix microseeding. For ligand bound structures solid NBF-GS was 
added directly to drops and left for 24 hours. Crystals were cryoprotected in 25% glycerol and 
frozen in liquid nitrogen. Data was collected at Diamond Light source on beamline i04-1. The 
data was processed using Xia2, and the structure solved using molecular replacement using the 
F122T structure. Models were built in CCP4 using Coot and refined using Refmac. Ligand 
restraints were generated using AceDRG.105 Further experimental detail is summarised in 
Appendix B. 
 
3.11 Molecular modelling 
3.11.1 Using Chimeric GSTs (Homology models) 
 
Models were made using Modweb from MODELLER,106 based on 1AXD56 and 1AW9.56 For the 
1AXD based homology model residues 30-55 and 119-139 were inserted into the black grass 
structure. For the 1AW9 based homology model residues 34-53 and 121-141 were inserted into 
the black grass structure. Geometry minimisation was carried out using Phenix. The models were 
used with H-atoms added, and with no waters in the binding site. Molecular modelling was 
carried out using GOLD107 with ChemPLP as a fitness function. A search space of 10 Å around 
Ser12 was defined. 10 runs were carried out for each ligand, with an early termination setting 
of 3 ligands within an rmsd of 1.5 Å used. 
3.11.2 Using F122T structure 
 
The structure of the F122T mutant was used with the threonine mutant at the 122 position 
replaced with a phenylalanine, using Coot, to create a model of the native enzyme. The model 
was used with H-atoms added, and with no waters in the binding site. Molecular modelling was 
carried out using GOLD with ChemPLP as a fitness function. A search space of 10 Å around 
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Phe122 was defined. 10 runs were carried out for each ligand, with an early termination setting 
of 3 ligands within an rmsd of 1.5 Å used. 
 
3.12 Synthesis of NBF-GS 
 
 
 
 
CNBF (0.5 mmol), GSH (0.5 mmol) and K2CO3 (0.5 mmol) were suspended in H2O. Acetonitrile 
(MeCN) was slowly added, with stirring initially until all compounds were dissolved, and then in 
excess until a green precipitate was formed. The precipitate was separated by filtration and 
confirmed as NBF-GS by ESI LCMS m/z 472.2 at 97% purity.  
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4 Biophysical Investigations of 
AmGSTF1 with Inhibitors 
 
In order to better understand the mode of action of both the flavonoid inhibitors identified in 
ligand fishing experiments, and CNBF inhibitors, a series of biophysical investigations were 
carried out. For the flavonoid compounds their structure-activity relationship (SAR) was 
investigated using binding assays, and further experiments were carried out to identify the 
selectivity and potential mode of action of these inhibitors.  
4.1 AmGSTF1 Strep Production 
 
For biophysical studies, a strep tagged construct of AmGSTF1 was used. The protein was 
over-expressed in E. coli and purified using a Streptactin column to produce protein of sufficient 
purity (Figure 4-1).89 Using this method it was possible to produce around 20-25 mg or pure 
protein per litre of recombinant E. coli. Protein activity was confirmed using the CDNB assay. 
Freezing the protein at -80 °C did not significantly affect the activity, and as a result protein that 
had been frozen and then thawed was used for convenience for all assays.  
Figure 4-1: SDS-PAGE to demonstrate purity of strep tagged AmGSTF1. Lane A- Molecular weight 
marker, B- Strep tagged AmGSTF1. Expected molecular weight of monomer=26665 Da. 
 
 
 
100 
10 
15 
25 
kDa 
35 
55 
70 
A B 
Biophysical Investigations of AmGSTF1 with Inhibitors 
 
47 
 
4.2 Introduction to Thermal Shift Assays 
 
Thermal shift assays (TSA) were used to investigate compound binding. TSA uses a fluorescent 
dye, in this case SYPRO orange®, to determine the folding state of the protein. In aqueous 
solutions the fluorescence signal is quenched, however the molecule is highly fluorescent in a 
non-polar environment, in this case the hydrophobic sites exposed in unfolded proteins.108 As 
temperature is increased, a protein will denature exposing its hydrophobic sites. The SYPRO 
orange® dye will bind to these sites and result in an increase in fluorescence. The unfolding of 
the protein can thus be followed using an RT-PCR machine (Error! Reference source not found.).  
 
 
This method can be used to determine the effect of various factors on the thermal stability of a 
protein.90 These can be either changes in buffer composition, where interactions are non-
specific, or ligands which bind at a specific site. In the event that a ligand binds this will normally 
lead to a stabilisation of the folded state and an increase in melting temperature (Tm). However, 
occasionally destabilisation of the protein has been observed, and an associated decrease in Tm. 
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Figure 4-2: Schematic to show fluorescent probe binding in thermal shift assays, and associated 
curve generated. Yellow dots represent fluorescent dye binding to hydrophobic regions of the 
protein.  
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(Error! Reference source not found.) For the case of specifically binding ligands the extent of 
stabilisation by a ligand has been shown to correlate to the binding affinity of ligands to the 
protein.109–111  
 
 
TSA allows for easy screening of proteins in a high throughput manner, as small amounts of 
material are needed in low concentration, and experiments can be carried out using a 96 well 
plate, allowing large numbers of inhibitors to be investigated in parallel. As a result this method 
was selected for screening of flavonoid inhibitors to identify those with highest affinity. 
4.3 Flavonoid Inhibitors 
 
4.3.1 Thermal Shift Assays 
 
As discussed in section 2.5 a series of flavonoids had been identified as modulators of the MHR 
response. In studies to date the SAR of the compounds had been investigated using the CDNB 
assay.85,86 As the conjugative activity of AmGSTF1 is low, it was a concern that this assay, which 
measures the inhibition of GST catalysis of GSH conjugation  might not be the best way to assess 
compound binding. As a consequence it was decided to use thermal shift assays to directly 
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Figure 4-3: Schematic to show the effect of ligand binding on a thermal shift assay, showing a 
typical melting curve for protein in the absence of ligand (blue) and protein with a ligand that 
binds (red) 
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investigate the relative binding affinities of the flavonoids and to determine if these correlated 
with inhibition results from the CDNB assay.  
4.3.1.1 Solvent screens 
 
As the flavonoid inhibitors show limited aqueous solubility, it was necessary for them to be 
dissolved in an organic solvent for use in the assays. As a result, the stability of AmGSTF1 in a 
range of different solvents was investigated. Four water miscible organic solvents, acetonitrile, 
DMSO, methanol and ethanol were selected for screening. Solvents were tested at a range of 
final concentrations from 0.05% to 50% with the remainder of the sample composed of protein 
in buffer (Figure 4-4).  
 
Figure 4-4: Temperature change observed on addition of various concentrations of solvent to 
AmGSTF1 in a thermal shift assay. For both DMSO and ethanol a value at 50% solvent concentration is 
excluded as the protein was seen to be denatured at room temperature. Results are the average of 
three technical replicates.  
 
AmGSTF1 was seen to be most stable in acetonitrile, where only a small change in stability was 
detected at 25%. For the remaining solvents, protein stability was seen to decrease significantly 
with increasing concentration of solvent, with the greatest loss of stability observed with DMSO. 
However, all the solvents proved to be viable at low concentrations. Solvent selection is a 
compromise between protein stability and compound solubility. Although acetonitrile gave the 
highest degree of protein stability, the solubility of the flavonoids in this solvent proved to be an 
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insurmountable problem. Ultimately, as the difference in stability effect between DMSO and 
ethanol or methanol was minimal, and the inhibitors proved to be significantly more soluble in 
DMSO, this was selected for use in assays. DMSO was used at a final concentration of 1% to 
provide a balance between inhibitor solubility and protein stability.  
4.3.1.2 Structure-activity relationship investigations 
 
Synthetic work has focussed on modifying the core flavonoid inhibitor from an initial hit pulled 
from the Syngenta library by modification in a range of positions on the structure. Work focussed 
predominantly on investigating the effect of groups at the C5 and C7 positions, and altering the 
B ring (Figure 4-5).85,86  
With thermal shift assay conditions established each flavonoid inhibitor synthesised was probed 
to determine relative binding affinities to AmGSTF1. Results from thermal shift assays were then 
compared with data obtained from inhibition assays from the CDNB assay, performed by Maria 
Schwarz, to investigate SAR.86 In general, the results from the CDNB assays and thermal shift 
assays were seen to agree, with those compounds found to inhibit the enzyme most effectively 
also seen to show the greatest stabilisation on binding. For weaker binders, the CDNB assay was 
able to provide more sensitivity. While no significant change in stability could be observed using 
thermal shift due to the resolution of the technique, it was possible to identify a significant 
difference using CDNB. As the effect of a number of modifications were investigated on only a 
core compound, lacking an α-alkoxy carboxylate at the 5 position, this allowed these 
modifications to be investigated more thoroughly. For each substitution results to demonstrate 
the trends are shown in the section. A full table of results for all flavonoid compounds generated 
is available in Appendix A.  
 
 
Figure 4-5: General structure of Flavonoid Inhibitors showing ring numbering and naming conventions 
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Substitution at the C5 Position 
Table 4-1: Biophysical results obtained for a selection of flavonoid compounds. Selected to 
demonstrate the trends observed for substitution at the C5 position. 
Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-123 
 
0.2 0 0.2 N.D. 25 98 
MS-3-13 
 
0.2 0.2 1.1 N.D. 14 N.D. 
MS-3-21 
 
0.2 0.4 2.3 4 69 N.D. 
MS-1-134 
 
0.2 0.5 1.2 71 99 N.D. 
MS-5-34 
 
1.2 1.3 2.1 N.D. 13 93 
MS-1-139 
 
0.1 0.3 1.1 6 39 N.D. 
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It was observed that the addition of an α-alkoxy carboxylate group at the C5 position resulted in 
a large increase in activity. This effect was increased with the addition of a long alkyl chain in 
place of the R group, with activity increasing with increased chain length up to 10 carbons where 
the effect was seen to plateau.  
Compounds were synthesised where this alkyl group was replaced with a polyethyleneglycol 
(PEG) chain, or an amide bond inserted, to increase solubility, however these resulted in a 
significant loss of activity, suggesting that this tail is situated in a hydrophobic region of the 
protein.   
The effect of stereochemistry on the α-alkoxy carboxylate group was investigated. While both 
isomers were seen to be active, the S-isomer was seen to bind less well and show marginally 
lower activity than the racemic mixture, in compounds MS3-13 and MS3-12. For compound 
MS1-134 one isomer is also seen to have higher activity, indicating a possible slight preference 
for one isomer in the binding site. 
  
MS-3-12 
 
0.3 0.2 0.5 N.D. 5 N.D. 
MS-3-13 
 
0.2 0.2 1.1 N.D. 14 N.D. 
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Substitution at the C7 Position 
Table 4-2: Biophysical results obtained for a selection of flavonoid compounds. Selected to 
demonstrate the trends observed for substitution at the C7 position. 
 
The majority of compounds were synthesised with either a hydroxyl group, or a methoxy group 
at the C7 position. Those with a hydroxyl group were observed to show better binding and better 
inhibition, however the methoxy variants were still seen to have good activity. Addition of a long 
PEG chain at this position was also observed to result in only a small loss of activity, suggesting 
that there is room for this group to extend into a large binding site. Previous work carried out 
by Hannah Straker demonstrates that the absence of an oxygen group at this position reduces 
activity,85 suggesting that these groups may be involved in hydrogen bonding. Methoxy and PEG 
groups are able to act exclusively as hydrogen bond acceptors,112 and in this case it would be 
expected that the methoxy group would be a stronger acceptor than the hydroxyl group as a 
result of the electron donating methyl group. It is possible that steric interactions may result in 
the methoxy group showing lower activity than the hydroxyl group in spite of this theoretically 
stronger hydrogen bond.   
Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-4-30-2 
 
0.4 0.4 0.1 N.D. 23 61 
MS-4-50 
 
0.3 0.4 0.9 N.D. 26 89 
MS-5-6 
 
0.7 1.6 3.8 67 98 N.D. 
MS-5-7 
 
1.3 1.7 4.2 72 100 N.D. 
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B Ring 
Table 4-3: Biophysical results obtained for a selection of flavonoid compounds. Selected to 
demonstrate the trends observed for substitution of the B Ring. 
 
The effect of placing different functional groups on the B-ring was investigated. A range of 
different groups were used, with a range of properties. Hydroxyl and sulfonyl groups were added 
to investigate the effect of addition of hydrogen bonding groups, with no major effect to binding 
being observed in any case. Interestingly, addition of a large cyclic group as a substituent at the 
Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-51 
 
 
 
0.2 0.3 0.3 N.D. 20 70 
MS-1-53-6 
 
0.1 0.1 -0.1 N.D. 12 87 
MS-1-66-D 
 
0.3 0.3 0.3 N.D. 20 58 
MS-1-19 
 
0.2 0.1 0.3 N.D. 12 67 
MS-3-132A 
 
-0.1 -0.1 0 N.D. 6 59 
MS-3-140 
 
-0.1 -0.2 -0.2 N.D. 11 64 
MS-4-30-1 
 
-0.4 -0.5 -0.5 N.D. 23 83 
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4’ position, while slightly reducing activity, did not result in total loss of activity, suggesting that 
the B-ring sits in a large cavity or towards the edge of the protein, allowing space for larger 
groups.   
Secondly, in an attempt to increase solubility a number of different heterocycles were inserted 
in place of the B-ring. It was observed that, in all cases, insertion of a non-aromatic ring into the 
B-ring position resulted in a major loss of activity and binding, suggesting that this group may be 
involved in π-π interactions. Replacement of the B-ring with a non-cyclic functional group such 
as a sulfonyl or chloride group was also observed to result in loss of activity.  
A range of aromatic heterocycles were added, with the thiazole showing marginally the best 
activity over the other rings used (oxadiazole, oxazole, tetrazole, pyrazole, methylpyrazole and 
methylpyridazine). As the thiazole ring also resulted in the largest increase in compound 
solubility, this ring was used in place of the phenyl B-ring for a further series of inhibitors.  
4.3.2 Selectivity against AtGSTF8 
 
Ultimately it was aimed that flavonoid inhibitors would be used alongside herbicides for 
treatment of crops, therefore it was of interest to determine whether the compounds were 
acting as general or selective GST inhibitors.  To determine this, their binding and inhibition 
effects were measured against another GST. AtGSTF8, a protein from Arabidopsis thaliana, was 
selected as another GST which was known to bind flavonoids, and had good activity in the CDNB 
assay. 
4.3.2.1 Selectivity results 
 
Using a range of flavonoid inhibitors selectivity was initially assessed using the thermal shift 
assay to investigate binding. Each compound was observed to bind to, and inhibit both AmGSTF1 
and AtGSTF8 (Figure 4-6). 
In general, the flavonoid compounds were seen to stabilise AtGSTF8 to a much larger extent 
than AmGSTF1. This can be attributed to the lower Tm for AtGSTF8 compared to AmGSTF1 
(36.2 °C as opposed to 62.8 °C).  
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Figure 4-6: (a) Compounds used for selectivity studies. (b) Change in melting temperature observed 
for various compounds at 1, 10 and 100 µM using the thermal shift assay with AmGSTF1 and AtGSTF8, 
to investigate selectivity. Results are the average of three technical replicates. 
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The largest differences were observed in the nature of the C5-alkylcarboxylate chain. Whilst 
short alkyl chains were seen to stabilise AtGSTF8 well, and gave good inhibition, it was observed 
that longer alkyl chains showed a reduced effect, with MS-1-134 seen to have very minimal 
binding. In contrast, although showing lower changes in Tm this compound retained significant 
binding efficacy to AmGSTF1.  Again, good correlation with results from the CDNB assay was 
obtained.86 This further highlights the importance of this long chain, and identifies it as an area 
that could be further targeted for increased selectivity.  
4.3.3 Investigation of Dimer Dissociation 
 
As the long alkyl chain on the flavonoid inhibitors had been identified to have a significant effect, 
both in terms of binding and inhibition of enzymatic activity, and also for giving selectivity, it was 
of interest to identify what possible role this may be playing. AmGSTF1 has a large, hydrophobic 
dimer interface. It has a surface area of 1390.1 Å, and ePISA predicts a negative ΔiG of -
19.4 kcal/ mol indicating a highly hydrophobic surface.113 It was hypothesised that the long alkyl 
chain could be binding here and disrupting dimer formation. As GSTs have been seen to be active 
only in their dimeric form,38,63 this would then result in loss of activity, and it was considered 
possible that this was the mechanism by which these inhibitors were having an effect. This 
possible dimer dissociation was investigated using Native-PAGE and fluorescence anisotropy. 
4.3.3.1 Native-PAGE gel 
 
The simplest way to identify whether proteins exist in monomeric or dimeric form is using gel 
electrophoresis. As a result this was initially used to investigate whether the long chain flavonoid 
was causing dissociation of the AmGSTF1 dimer. In AmGSTF1 the dimer interface is formed by a 
network of hydrogen bonds and hydrophobic interfaces therefore it was not possible to use SDS-
PAGE. While SDS-PAGE can be used to separate dimers held together by disulphide bridges, by 
using non-reducing conditions, for dimers such as that in AmGSTF1 the heat denaturation alone 
would disrupt the dimer. Unlike SDS-PAGE which uses SDS, heat and reducing agents to denature 
and reduce proteins, native PAGE allows for analysis in their folded, oligomeric states.  
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AmGSTF1 and AmGSTF1 incubated with MS-1-134 were run on a native gel in non-denaturing 
conditions. Preliminary experiments used a single percentage gel, however, it was not possible 
to get separation of low weight molecular weight markers, and as a result gradient gels were 
used as these achieved good separation (Error! Reference source not found.). AmGSTF1 in the 
absence of inhibitor was seen to run as a single band. Based on the molecular weight markers, 
this appeared to be higher than the expected weight of 52 kDa. In native PAGE, the isoelectric 
point of the protein and pH of the sample have a major effect on the separation of proteins in 
addition to molecular weight. Consequently, the differences observed were not a cause for 
concern. For protein incubated with low concentrations of MS-1-134, no difference in molecular 
weights could be seen. However, for AmGSTF1 incubated with 500 µM of MS-1-134, the protein 
was seen to run lower on the gel. This suggested that it was possible the protein had dissociated 
into its monomeric form. As it was possible that the compound may have affected the pH and 
therefore migration of the sample, and as no concentration dependent effect could be observed 
with differing inhibitor concentrations, results were not conclusive. Consequently, further 
investigations were carried out with complementary methods.  
4.3.3.2 Fluorescence Anisotropy 
 
To confirm the results from native PAGE, fluorescence anisotropy was used to identify if 
flavonoid inhibitors with long alkyl chains were resulting in dimer dissociation. Fluorescence 
anisotropy has previously been used to investigate the monomer-dimer equilibrium of 
Figure 4-7: Native PAGE for AmGSTF1 incubated with MS-1-134 in various concentrations. Lane 0- 
Molecular weight marker, 1-AmGSTF1, 2-AmGSTF1+ 10% DMSO, 3- AmGSTF1 + 500 µM MS-1-134, 4- 
AmGSTF1 + 10 µM MS-1-134. Expected molecular weights 26665 Da (monomer), 53330 Da (dimer). 
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HsGSTP1,114 and the investigation was based on this work. A fluorescent dye, HiLyte Fluor 488 
was used, which contained a reactive maleimide group, known to efficiently label cysteine 
residues within the protein.115  
Fluorescence anisotropy uses polarised light to investigate the rotational diffusion of a 
macromolecule. Upon excitation with fluorescent light, a fluorophore will also be polarised. 
Anisotropy describes the extent of this polarisation, and the angular displacement that occurs 
between absorption and emission, caused by rotational diffusion.116 For a small molecule, for 
example an unbound fluorophore, with a high tumbling state, the rotational diffusion is very 
high, giving an anisotropy of near zero. The maximum anisotropy that could theoretically be 
achieved is 0.4, which would be observed where no depolarisation occurs. As the extent of 
anisotropy is relative to size of molecule, it would be expected that the anisotropy of the 
monomer would be lower than that of the dimer. Fluorescence anisotropy was measured for 
two concentrations of protein (20 and 100 nM) and four different inhibitor concentrations (1, 
10, 100 and 200 μM).  
 
Figure 4-8: Steady state anisotropy for Hi-Lyte Fluor 488 labelled AmGSTF1 incubated with various 
concentrations of inhibitor. Controls were carried out using buffer only and buffer and DMSO, and 
each value is the result of eight technical replicate measurements. Error bars represent one standard 
deviation. 
In the event that the inhibitor disrupted dimer formation a decrease in anisotropy would be 
observed. This is not seen suggesting that dimer disruption does not occur (Figure 4-8). 
Interestingly, at high inhibitor concentrations, an increase in anisotropy is observed, indicative 
of a possible increase in complex weight. Initially, it was suspected that at high concentrations 
the inhibitor might be causing protein aggregation. However, work on HsGSTp1 has suggested 
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that MDR inhibitors may function to stabilise the dimer form, preventing protein-protein 
interactions and the MDR phenotype.117 The results observed would be consistent with an 
increase in the quantity of dimeric protein compared to monomeric protein. Consequently, 
further experiments should be carried out to confirm if this may also be the case for inhibitors 
of AmGSTF1 and MHR.  
4.4 Conclusions 
 
Thermal shift assays have been used to investigate the SAR of flavonoid inhibitors. These have 
giving useful complementary information to that previously gained from CDNB activity assays. 
The results from thermal shift assays support the results from CDNB assays and demonstrate 
that in spite of the low conjugative activity of AmGSTF1 CDNB assays do represent a useful tool 
for testing compounds in vitro. From SAR data several functional groups on flavonoid inhibitors 
were identified as important to activity. It was found to be essential that the B-ring was aromatic, 
suggesting that this group is involved in π-interactions in the binding site. A hydroxyl group at 
the C7 position was found to increase activity. This activity increase was also seen if this is 
replaced with a methyl or PEG group suggesting that this is acting as a hydrogen bond acceptor. 
Interestingly, activity is slightly lower for either of these, in spite of their electron donating alkyl 
groups, suggesting that sterics may play a part at this site.  In addition, the presence of an α-
alkoxy carboxylate group, with a long chain alkyl group was found to dramatically increase 
inhibition.  Introduction of hydrophilic substituents along this chain reduced activity, suggesting 
that it binds to a highly hydrophobic area of the protein.  
Assays to investigate selectivity of the compounds were also carried out. These investigated the 
relative binding of compounds to AmGSTF1 and another flavonoid binding protein AtGSTF8. 
These identified that increasing the length of the alkyl chain to C10 reduced activity in AtGSTF8 
whilst maintaining inhibition in AmGSTF1. This suggests that this alkyl chain may be an area to 
focus on for increasing selectivity in future.   
Further preliminary investigations were also carried out to investigate the potential mode of 
action of the flavonoid inhibitors. Experiments investigating whether flavonoid inhibitors might 
be resulting in the dissociation of the dimer suggested that this was unlikely to be the case.  
Instead these demonstrate that flavonoids may be functioning to stabilise this dimer, 
functioning in a manner similar to MDR inhibitors.  
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5 Crystallography of Wild Type 
AmGSTF1 
 
In order to unravel the molecular basis of the interactions of inhibitors with AmGSTF1, and their 
mode of action, crystal structures of the protein in complex with ligands were sought. While 
structures had previously been obtained by the group for Apo AmGSTF1 at 1.95 Å and AmGSTF1 
with CNBF at 2.8 Å,87 this work aimed to produce higher resolution structures, particularly of the 
CNBF structure. In addition to this, it was aimed to crystallise AmGSTF1 in the presence of a 
variety of the flavonoid series of inhibitors.  
5.1 Production and Purification of Untagged AmGSTF1 
Initial work in the group had found crystallisation using strep tagged AmGSTF1 to be 
unsuccessful, possibly due to the flexible tag used for purification, and as a result untagged 
protein was used for all crystallographic studies. Protein was expressed in E. coli and purified 
using glutathione agarose affinity chromatography in a method optimised from 
Cummins.85,118,119 By streamlining the purification protocol from a four column process 
(Hydrophobic interactions, GSH agarose affinity, desalting and anion exchange) down to only 
two columns (GSH agarose affinity and anion exchange) it was possible to increase production 
of pure AmGSTF1 protein from around 2 mg/ L of recombinant E. coli culture to higher yields of 
around 10-12 mg/ L of recombinant E. coli. Protein purity was confirmed by SDS-PAGE as 
sufficient for crystallisation experiments (Figure 5-1).  
Figure 5-1: SDS-PAGE gel to show the purity of untagged AmGSTF1 protein used for 
crystallography. Lane A- molecular weight ladder, B-untagged AmGSTF1. Expected 
molecular weight of monomer= 24931 Da. 
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5.2 Crystal Structure Determination of Apo AmGSTF1 
 
Crystals were obtained in a bipyramidal hexagonal prism morphology (Figure 5-2), which 
diffracted to 1.5 Å at the Diamond Light Source. Detailed information about data collection and 
processing are given in section 3.10.2 and Appendix B. A hexagonal modification was obtained, 
in space group P 63 2 2, with one protein chain in the asymmetric unit.  
 
Figure 5-2: Morphology of Apo AmGSTF1 crystals 
 
The structure displayed the classical GST fold, with two domains forming the two active site 
binding pockets. The N-terminal domain forms the G-site, lower portion of the H-site and 
contains the catalytic residue (Ser12). It was composed of four anti-parallel β-sheets and two α-
helices (Figure 5-3a). The loop region associated with the G-site (residues 38-48) showed no 
electron density and as a result was not included in the model.  The C-terminal domain consisted 
of six α-helices, the first of which (α-4) forms the upper portion of the H-site binding.120  No 
density was observed for an associated loop region (residues 125-137). Based on the derived 
symmetry related structure (Figure 5-3b), the four residues preceding this disordered loop 
(Cys120-Leu121-Phe122-Asn123) were found to project into the other monomer subunit, 
blocking the active sites.  
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a 
b 
Figure 5-3: (a) Structure of AmGSTF1. (b) Crystal packing of AmGSTF1.  
Α-helices are shown in cyan, β-sheets in cyan and for (b) the symmetry mate in pale cyan. Dashed 
lines show the location of loops for which no density is observed. The Ser12 catalytic residue is shown 
as sticks. Figure produced in Pymol. 
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Table 5-1: Details of crystallographic and active dimer inetrfaces observed in WT AmGSTF1 structure. 
Values obtained from analysis using PISA113 
Dimer 
Surface 
Area/ 
Å 
ΔiG/ 
kcal mol-1 
P-value 
Active 1390 -19.4 0.198 
Crystallographic 1364.8 -25.1 0.048 
 
While only one monomer is seen in each asymmetric unit, AmGSTF1 is active as a dimer. The 
interfaces for this crystal form were analysed using PISA (Table 5-1).113 Two interfaces are 
observed as significant in the structure. The first (Figure 5-4) has a large area of 1390 Å2, and is 
composed of mainly hydrophobic interactions in addition to 8 hydrogen bonds and 16 salt 
bridges. These occur between α-4 and α-5 of one monomer and the N-terminal domain of the 
other.121 PISA calculates a negative ΔiG for interface formation of -19.4 kcal/ mol, which is 
indicative of a hydrophobic interface. A P-value of 0.198 is indicative of a highly hydrophobic 
surface, very likely to be interaction specific. The second (Figure 5-3B) is also seen to have a large 
area of 1364.8 Å2 and to be formed largely of hydrophobic interactions in addition to 14 
hydrogen bonds. It has a more negative ΔiG of -25.1 kcal/ mol, and a P-value of 0.048, indicative 
of a highly specific interface. In spite of the larger ΔiG and smaller P-value observed for the 
second interface, in this case the first interface is expected to be the biological form observed 
in solution for two main reasons. Firstly, GSTs have been well characterised and in all cases of 
dimeric GSTs it is this form which has been observed. Secondly, the second interface occurs in 
the active site, which would prevent the protein carrying out its catalytic activity. 
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Figure 5-4: Structure of active dimer of AmGSTF1, across a crystallographic 2-fold axis. The two 
monomers are shown in different colours (cyan and grey). Figure produced in Pymol. 
 
5.2.1 Comparison with lower resolution structure 
 
As expected, the structure was found to be similar to the 1.95 Å resolution structure previously 
obtained with an RMSD of 0.21 for 189 equivalent Cα atoms.87 The main differences occur in the 
regions surrounding the disordered loops. In the higher resolution structure it was possible to 
model more residues surrounding each of these disordered loops. For the loop over the G site 
(residues 38-48) one additional residue could be modelled at either end of the loop in the higher 
resolution structure, and for the loop in the C-terminal domain it was possible to model one 
additional residue at the end of the α-4 helix.  
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A number of changes are observed between the active sites of the two structures. Most 
noticeably, the side chain of the catalytic Ser12 is seen to adopt a different conformation with 
the oxygen pointing at almost 180° to the direction in the lower resolution structure (Figure 
5-5a) Some small changes are also observed in some of the residues which form part of the H-
site. Phe36, one of the final visible residues before the disordered loop, sits near to where we 
would expect a GSH molecule to bind and as a result could form part of the H-site.56 In the higher 
resolution structure this adopts a pose 1.1 Å closer to α-4, which would have the effect of closing 
up the binding site slightly (Figure 5-5b). In addition, in the higher resolution structure it has 
been possible to model a side chain for Tyr118 and Gln119, located on α-4 which form part of 
the upper H-site.120  
5.2.2 Comparison with ZmGSTF1 structure 
 
To gain additional insight into AmGSTF1 we compared it with ZmGSTF1 from maize. This was of 
interest for two main reasons. Firstly, it is the protein with a structure in the PDB which has the 
highest sequence similarity to AmGSTF1 (63%), and secondly it is known to be involved in 
herbicide tolerance in maize.56,120,122  Two different structures of ZmGSTF1 are available in the 
PDB, 1AXD, a structure in complex with lactoylglutathione56 and 1BYE, a structure in complex 
with an atrazine-GSH conjugate.120 As 1AXD is the higher resolution of the two structures this 
comparison will focus primarily on it, however we will also look at the H-site of 1BYE, in particular 
the residues involved in herbicide binding.  
Figure 5-5: Differences between active site residues between high resolution (cyan) and low 
resolution (grey) structures of AmGSTF1. (a): Ser12 and (b): Phe36 
b a 
Ser12 
Phe36 
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Figure 5-6: Superposition of AmGSTF1 (cyan and magenta) with ZmGSTF1 (green) PDB code 1AXD. 
Figure produced using Pymol. 
 
Despite having a sequence similarity of only 63%, the overall folds of AmGSTF1 and ZmGSTF1 
are very similar, with an rmsd of 1.27 Å across 182 equivalent Cα atoms (Figure 5-6). ZmGSTF1, 
like AmGSTF1, is composed of two domains, with the N-terminal domain being composed of 
four antiparallel β-sheets flanked by two α-helices, and the C terminal domain composed of six 
α-helices. Unlike AmGSTF1 it contains a short helical section in the linker between the two 
domains. 
The largest differences between the two structures are seen to be surrounding the two loops 
which are disordered in the AmGSTF1 structure. The residues from Asp35 in the AmGSTF1 which 
are situated in the run up to the disordered loop over the G-site have a different conformation 
to that of the ZmGSTF1 structure. In ZmGSTF1 this loop is known to undergo a conformational 
change on GSH binding, resulting in an induced fit to the substrate. It is likely that this difference 
is due primarily to the fact that the AmGSTF1 structure is apo, while the ZmGSTF1 has a 
lactoylglutathione molecule bound. It would be expected that in a structure with GSH bound the 
loop in AmGSTF1 would adopt a very similar conformation to that seen in ZmGSTF1.  
A difference is also observed in the structures in the upper portion of the α-4 helix which forms 
part of the H-site. In the AmGSTF1 structure this is seen to be bent away slightly from the active 
site above Asn110 compared to α-4 in the ZmGSTF1 structure. The degree of flexibility observed 
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in this area is known to be involved in determining substrate specificity of the H-site120, and the 
difference observed between these two enzymes indicates that they are likely to have different 
substrates. Alternatively, it is possible that the crystal packing, where the upper portion of α-4 
and α-5 of the crystal mate are sitting in the active site, is resulting in a slight distortion in this 
area.  
The G-site is seen to be very well conserved between the two proteins (Figure 5-7). In 1AXD nine 
residues are associated with lactoylglutathione binding, which would mimic the position of a 
GSH molecule in the active site. Of these nine residues, eight are conserved between ZmGSTF1 
and AmGSTF1 and one is a conservative substitution from Val54 in ZmGSTF1 to Ile55 in 
AmGSTF1. Unsurprisingly, the structure of this G-site is also very well conserved. Due to the 
disordered loop present in AmGSTF1 it is not possible to see the location of His41 or Lys42 in 
the AmGSTF1 structure, and only one sizeable difference is observed between the two 
structures. Phe36 in AmGSTF1 is seen to lie in a different orientation to Phe35 in ZmGSTF1. This 
residue is situated at the start of the disordered loop present in AmGSTF1. It is likely that on GSH 
binding this residue would move to adopt the position observed in ZmGSTF1. In light of the 
similarities between the G-sites of the two proteins it seems reasonable to expect that GSH 
would adopt a very similar binding pose in AmGSTF1 to that observed in ZmGSTF1.  
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Figure 5-7: Superposition of the residues in the G-site of AmGSTF1 (cyan) and ZmGSTF1 (grey) PDB 
code 1AXD. Residues with differences between the structures are labelled. These refer to AmGSTF1 
residues (black labelling) or ZmGSTF1 residues (red labelling). Produced using Pymol. 
Ile55 
Phe36 
Lys42 
His41 
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Next we examined the H-site from 1BYE120, a structure of ZmGSTF1 in complex with a GSH-
atrazine conjugate (Figure 5-8). In addition to the residues previously observed as binding GSH 
in the G-site, four main residues are involved in atrazine binding, with atrazine lying in a cleft 
between Met10, Phe35, and Trp12 and Ile118. Met10 and Phe35 are conserved within 
AmGSTF1, although as discussed earlier the Phe36 in AmGSTF1 lies in a different location in our 
structure. However Trp12 and Ile118 are non-conservatively substituted as Thr13 and Phe122 
resulting in a very differently shaped H-site. Preliminary experiments (Appendix F) show that 
AmGSTF1 does not bind herbicides, most likely due to these inherent differences between the 
H-sites. This further enforces the hypothesis that AmGSTF1 does not cause MHR by a direct 
involvement in herbicide detoxification.34  
 
  
Phe36 
Phe35 
Met11 
Thr13 
Phe122 
Ile118 
Met10 
Trp12 
Figure 5-8: Superposition of the H-site of ZmGSTF1 (PDB: 1BYE; grey; red residue labels) with a bound 
atrazine GSH conjugate (marine) and AmGSTF1 (cyan; black residue labels). Produced using Pymol 
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5.3 Crystal Structure Determination of AmGSTF1 with CNBF 
 
 
Figure 5-9: Morphology of CNBF treated AmGSTF1 crystals 
 
Protein was alkylated with CNBF, and this was confirmed using mass spectrometry. It was 
observed that modification had not occurred with 100% efficiency (Figure 5-10). Trays were set 
up using the same conditions as for the apo protein. Crystals were obtained in the same 
hexagonal bipyramidal morphology as for the apo protein, however they were visibly yellow in 
colour (Figure 5-9). The crystals diffracted to 2.0 Å in the same hexagonal space group as for the 
wild type. Additional information on data processing and collection is available in Section 3.10.2 
and Appendix B. 
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The structure obtained for the CNBF bound structure is very similar to that of the apo protein, 
with an rmsd of only 0.19 Å for 188 equivalent Cα-atoms. The NBF-adduct was seen to couple 
to Cys120, as had been expected from previous mass spectrometric results (Figure 5-11a).34 This 
residue is one of the last visible residues before the disordered loop that points into the active 
site of the neighbouring subunit (Figure 5-11b).  
 
 
 
AmGSTF1 
AmGSTF1+CNBF 
Figure 5-10: ESI Mass spectrum to confirm CNBF modification of AmGSTF1 
Crystallography of Wild Type AmGSTF1 
 
73 
 
 
Figure 5-11: (a) Location of CNBF covalent modification on AmGSTF1. (b) Crystal packing of AmGSTF1 
showing location of CNBF modification in active site of symmetry mate. Produced using Pymol. 
a 
b 
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The density for the CNBF indicated that the modification was only partially occupied (modelled 
at 0.7 occupancy) in the crystal (Figure 5-12). Mass spectrometry analysis of the sample used for 
crystallography confirms this, showing that only partial modification has occurred. 
 
Figure 5-12: Density observed for CNBF molecule covalently linked at Cys120. 2Fo-FC map shown, 
contoured at 0.5σ. Figure created using CCP4mg. 
 
It had been expected that CNBF modification at Cys120 might result in a structural change which 
would result in the observed inhibition. Surprisingly, with the exception of the covalent 
modification observed at Cys120, the crystal structure of the NBF-adduct does not show any 
major structural changes compared to the apo structure (Figure 5-13A). This could be for a 
number of different reasons. It is possible that CNBF is resulting in a change of structure of one 
of the loops that are disordered in our structure. Alternatively, it is possible that the crystal 
packing arrangement of the structure may be preventing us from seeing the minimum energy 
conformation of that loop in solution. It is possible that the CNBF binding may cause the α-4 
helix to adopt a different conformation, but that the strong crystal packing interactions observed 
between the α-4 helices of the two crystal packing monomers prevent us from observing this 
effect.  
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Figure 5-13A:Superposition of CNBF bound AmGSTF1 (cyan and pink) with Apo AmGSTF1 (blue). B: 
Superposition of AmGSTF1 (cyan and magenta) and HsGSTP1 (slate, PDB code 3GSS) showing locations 
of Cys47 (HsGSTP1) and Cys120 (AmGSTF1). Figure produced using Pymol. 
 
Finally, it is possible that the CNBF is acting to either stabilise or destabilise the G or H sites in a 
way that cannot be seen from this single crystal form. This could result either in compounds no 
longer binding to the active site or being stabilised in the active site. It is known that for HsGSTP1, 
the presence of GSH reduces its interaction with JNK1, reducing its ability to cause multi-drug 
Cys120 
Cys47 
A 
B 
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resistance.83 It is thought that inhibitory drugs for HsGSTP1 function by stabilising this GSH 
bound form. Interestingly, while CNBF also inhibits HsGSTP1 via covalent modification of a 
cysteine (Cys47), this cysteine is located in a different area of the protein. In the HsGSTP1 the 
Cys47 is located in the region of the loop over the G-site while in AmGSTF1 the cysteine is located 
on α4 helix in the region of the H-site (Figure 5-13). Although initial work to identify protein 
binding partners of AmGSTF1 has proved unsuccessful this has not been ruled out as a 
possibility. It is possible that the covalently bound CNBF is acting to stabilise the GSH form, or 
that it is stabilising a glutathione conjugate of CNBF (NBF-GS). We would expect NBF-GS to form 
spontaneously on addition of CNBF to protein in vivo and for it to be bound in the active site, 
however this cannot be seen in this structure, most likely due to the crystal packing observed.  
 
5.3.1 Effect of CNBF modification on compound binding 
 
Preliminary experiments were carried out to further investigate the effect that CNBF binding at 
Cys120 might be having on compound binding in the active site. Thermal shift assays were 
carried out to investigate the binding of a range of compounds to modified and unmodified 
protein. Compounds were selected which were predicted to bind to the active site (Figure 5-14). 
This comprised two flavonoid inhibitors: baicalein and MS 5-7 one of the synthesised flavonoid 
inhibitors with a C5 long alkyl chain and a C2 thiazole group. Ethacrynic acid, an MDR drug known 
to bind to the active site of HsGSTP1 was also selected.123 In addition NBF-GS was synthesised, 
to investigate if the alkylation had an effect on the binding of its conjugate.  
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Figure 5-14: (a)Compounds used for binding assays with apo and CNBF modified protein (b)Changes of 
melting temperature observed with addition of various ligands to AmGSTF1 (blue) and CNBF modified 
AmGSTF1 (purple). Results are the average of three technical replicates. 
 
It is clear that the CNBF modification does not prevent the binding of flavones to the protein, in 
both cases these are seen to stabilise the protein, increasing the Tm in a concentration 
dependent manner consistent with binding. CNBF modified protein was observed to have a 
lower Tm than for the unmodified protein, 60.7 °C as opposed to 63.6 °C, and as a result the slight 
differences observed in magnitudes of ΔTm could not be used to indicate any difference in the 
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strength of binding. For both modified and unmodified protein, ethacrynic acid is observed to 
bind, but to destabilise the protein. The NBF-GS conjugate is seen to bind to and destabilise the 
apo protein. By contrast, it is seen to weakly stabilise the CNBF modified AmGSTF1, suggesting 
that it is possible the modification affects the binding of this conjugate. As it is not possible to 
determine the relative binding affinities from thermal shift assay data this result is inconclusive, 
and further work will need to be carried out to determine if this modification is affecting the 
binding affinity for the NBF-GS conjugate. 
 
5.4 Crystal Structure Determination of AmGSTF1 with Flavonoid Ligands 
 
In order to unravel the molecular basis of flavonoid inhibition, co-crystallisation experiments 
were carried it. Whilst initial docking studies (discussed in detail in Chapter 7) suggested that 
the ligands most likely bound into the active site, it was not possible to completely rule out an 
alternative binding position in the dimer interface of the protein, where flavonoids have been 
identified to bind in AtGSTF2.50 Co-crystal structures would then enable targeted inhibitor 
design.  
5.4.1 Selection of ligands and initial trials 
 
Based on the results of biophysical investigations, a selection of inhibitors was selected for 
crystallisation trials (Figure 5-15). As initial trials with SYG8 had resulted in precipitation of the 
compound,85 solubility was also considered closely when selecting compounds. Compounds 
with a thiazole group in place of the B ring had proved to be significantly more soluble than any 
others synthesised, while maintaining strong binding, and as a result the majority of ligands 
selected contained this group.  Compounds with a long C10 carbon chain had proved to be highly 
active both in vivo and in vitro, and as a result it was desirable to identify what role this long 
chain might be playing. MS4-48 was selected as it contained this long C10 chain, in addition to 
the thiazole ring which increased its solubility. As the long chain dramatically decreased 
solubility, MS4-33 was selected as this contained a shorter C1 chain which would help to identify 
the location this chain might be binding to. MS4-31-2 was selected as it was a smaller ligand, 
which showed good binding and solubility. Baicalein was also selected as this was the 
commercial flavonoid which had performed best in the biophysical binding tests, it could be 
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bought in large quantities, and used in testing to reduce the concern about a limited supply of 
the synthesised flavonoid inhibitors.  
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Figure 5-15: Structures of small molecule compounds selected for  crystallography trials 
 
Because of the low solubility of many of the ligands, it was necessary to dissolve the compounds 
in DMSO. As a result, tests were carried out to determine the maximum amount of DMSO that 
would be tolerated by the protein and it still crystallise. The same conditions were used as for 
crystallising the apo protein, and DMSO was introduced with end concentrations of 0.5%, 1.25%, 
2.5%, 5% and 10%. While crystals were visibly much smaller and grew much more slowly with 
increasing DMSO concentration, crystals still grew at up to 2.5% DMSO concentration in the 
same morphology as for the wild type. However, for 5% and 10% DMSO concentration the 
protein was seen to precipitate and no crystals were formed. As a result an end DMSO 
concentration of 2.5% DMSO was used within crystal conditions to help solubilise the 
compounds.  
Initially, compounds dissolved in DMSO and protein buffer were added directly to drops at a 
concentration 5× that of the protein. However, compounds were seen to precipitate within 20 
mins using this method. As a result, proteins were pre-incubated with compound for either 4 h 
or overnight, and centrifuged to remove undissolved compound before trays were set up. This 
strategy proved to be much more successful, and whilst in some wells, low levels of compound 
precipitation was seen, this was not sufficient to prevent crystallisation, or prevent crystals being 
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collected for analysis.  As a result of this low compound solubility soaking trials were not 
attempted. 
Crystals were selected from a range of conditions, containing a variety of ligands and different 
incubation times with the protein. All crystals were seen to adopt the same morphology 
observed for the apo and CNBF structures. 9 datasets were collected ranging from 1.52-2.4 Å. 
Full details are available in Appendix G. Structures were solved using molecular replacement 
against the apo protein and data was refined to obtain a difference map of sufficient quality to 
identify if ligand density was present. In each case it was determined that no ligand was bound. 
The lack of ligand binding observed was thought to be as a result of the crystal packing which 
prevented small molecule binding in the active site. The crystal packing observed in other areas 
of the protein was as would be biologically expected, and the other contacts observed are 
consistent with the structure of the active dimer. Therefore this should not prevent observation 
of density for ligands binding in other areas. As a result it seems likely that the flavonoid ligands 
are binding in the G or H-site, and a binding pose in the L-site or an alternative allosteric site can 
most likely be ruled out.  
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5.4.2 Crystal packing analysis 
 
The majority of crystals were obtained in a P63 2 2 space group. A crystal mate is observed, with 
the α4 and α5 helices of another monomer situated in the active site of the first monomer 
occupying both the G and H sites (Figure 5-16a). As can be seen from the surface plot this forms 
a tight interaction which would prevent small molecule binding (Figure 5-16b). 
  
Figure 5-16: (a) Superposition of AmGSTF1 and symmetry mate (cyan and light cyan) with 
ZmGSTF1 (grey) and its bound ligand, highlighting location of active site. (b) Surface representation 
of AmGSTF1 and symmetry mate (cyan and blue) 
a b 
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While an alternative space group of R3 2 was also observed for some datasets this posed the 
same problem. The interactions observed in the hexagonal datasets were highly conserved, 
and the crystal mate was in an almost identical position, with an rmsd of only 0.31 Å, again 
completely blocking the active sites (Figure 5-17).  
 
Figure 5-17: Superposition of hexagonal (cyan and light cyan) and rhomboedric (grey) crystal forms 
 
5.4.3 Experiments to identify a new crystal packing form for AmGSTF1 
 
As attempts to co-crystallise AmGSTF1 with compounds in the active site in the current crystal 
form had proved unsuccessful, it was attempted to identify crystals with a different crystal 
packing form. A variety of 96 well high throughput crystallography screens were set up using 
either protein alone or protein pre-incubated with one of the four ligands used for previous co-
crystallography experiments, in an attempt to encourage the formation of crystals with ligands 
bound.  
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Whilst there were no conditions in which crystals were produced in trays with ligand but not 
apo trays, there were a series of promising hits where the crystals looked visibly very different 
to the previous hexagonal ones obtained. Of these, four different forms were of sufficient size 
to take for testing on i03 beamline at Diamond Light Source (Figure 5-18). Two of the four tested 
crystals diffracted in a pattern that was visibly different to the hexagonal form, whilst the 
remaining two did not diffract. Unfortunately, in both the cases where diffraction did occur, 
none was seen above approximately 7 Å. Attempts to optimise these crystals also proved 
unsuccessful, with no better crystals being observed in optimisation plates set up around each 
of the conditions.  
 
  
Figure 5-18: Morphologies of AmGSTF1 crystals observed 
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5.5 Conclusions 
  
It has been possible to obtain a higher resolution structure of wild type AmGSTF1, with the 
structure being determined to 1.5 Å. This has demonstrated that it has a structure that is highly 
conserved with that of other phi class GSTs.50,56,124 As expected, it has a highly conserved G-site, 
but significant differences exist in the H-sites. Notably, this structure still has two disordered 
loops, one of which is in the region of the G-site, preventing a full model of the structure from 
being determined.  
Higher resolution data has also been obtained for AmGSTF1 modified with CNBF, with the 
structure being determined to 2.0 Å. From this structure it has been possible to demonstrate 
the covalent modification of Cys120 by CNBF.  No other major structural changes are observed 
in the structure compared to the apo structure. Using thermal shift assays it has been possible 
to rule out that CNBF modification is preventing compound binding in the active site, however 
it is possible that it may be affecting the binding of an NBF-GS conjugate. As no other structural 
changes have been observed from the apo structure, it has not been possible to determine the 
method by which the covalent modification could be having an inhibitory effect. It is possible 
that changes could be occurring in disordered loops in the region of both the CNBF molecule 
and active site, which are obscured as a result of crystal packing.  
Thus far, it has not been possible to solve co-crystal structures of AmGSTF1 in complex with 
flavonoid ligands. It has been determined that this is most likely the result of the crystal packing 
observed for wild type AmGSTF1. A crystal packing mate forms a tight interaction in the active 
site preventing the binding of small molecules. As no density was observed for flavonoid ligands 
in other locations this has identified the G or H-sites as the most probable locations for flavonoid 
inhibitor binding. 
Work to disrupt the crystal packing of wild type AmGSTF1 has proven unsuccessful, possibly as 
a result of the size and predicted strength of the crystal packing interface. In any cases where 
crystals of different morphologies have been produced it has not been possible to optimise 
these sufficiently to collect data that would enable the structure to be solved. As a result it has 
not yet been possible to solve a complete structure of AmGSTF1 including loops or to study 
binding in the active site. The next chapter of this thesis will focus on the design of mutants to 
specifically disrupt the crystal packing observed.
 85 
 
6 Crystallography of Mutant AmGSTF1 
 
As discussed in chapter 5, previous models of AmGSTF1 were incomplete, displaying two 
disordered loops, and with the crystal packing form thought to be preventing small molecule 
binding in the active site.  Work attempting to identify an alternative crystal packing form of wild 
type (WT) AmGSTF1 had proved to be unsuccessful. As a result, it was decided to use a protein 
engineering approach to attempt to disrupt this crystal packing form. 
To modify the protein as little as possible it was decided to design single site mutants to disrupt 
the contacts observed between crystal mates. A similar approach has previously been used 
successfully to crystallise a fluorescein-scFv complex.125 The native antibody was found to 
crystallise in a form where a loop occluded its binding site. By mutation of an exposed 
tryptophan which was involved in crystal packing it was possible to crystallise the protein in a 
different form with the binding site exposed. A similar method was used, using single site 
mutations to disrupt contacts, promote an alternative crystal form and expose the binding site.  
6.1 Design and production of mutants 
 
Detailed analysis of the crystal packing from the wild type AmGSTF1 structure identified contacts 
that occurred between a monomer and a symmetry mate that was not the functional dimer 
(Figure 6-1a).  
The main contacts were formed between aromatic residues in the α4 helix interacting with the 
same helix in another monomer. Interactions were seen to occur predominantly between 
Tyr118 and Phe122 of opposite monomers (Figure 6-1b) with the rings lying 3.5 Å apart allowing 
them to form π interactions. 
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Figure 6-1: (a) Crystal packing interactions observed in AmGSTF1. AmGSTF1 is shown in cyan with its 
symmetry mate in grey. (b) Tyr118 and Phe122 are shown to show the π-interactions formed between 
monomers. (b) shows a zoomed in view of the area shown in the blue box from (a). Figure produced 
using Pymol. 
 
Two single site mutants were constructed which replaced one of the residues, and one double 
site mutant which replaced both residues. In order to disrupt the π interactions observed the 
residues were mutated to non-aromatic ones. Phe122 was mutated to a threonine, as this 
enabled the formation of hydrogen bonds with a carbonyl on the backbone of the protein which 
might stabilise the α-helix and prevent loss of secondary structure. As no hydrogen bonds could 
be formed with the backbone at the Tyr118 position, this residue was mutated to a serine to 
maintain the hydrophilic nature.  
Site directed mutants were generated using PCR, expressed in E. coli, and purified using GSH 
agarose affinity chromatography (see sections 3.2.4 and 3.3). In each case proteins bound to the 
GSH agarose column. This purification method relies on the protein’s inherent ability to bind 
GSH. The fact that the mutants bind the column indicates they are correctly folded and have a 
correctly folded G-site. However in each case less protein was purified than for the wild type 
protein, with the mutants binding less efficiently to the column, and more protein passing 
through the column in the flow through. This suggests that their binding to the column may have 
been slightly impaired. This was particularly noticeable in the Y118S mutant where purification 
provided only around 3 mg of pure protein per litre of recombinant E. coli, compared to around 
a b 
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10-12 mg of wild type AmGSTF1. Protein purity was confirmed as sufficient for crystallisation 
experiments using SDS-PAGE gel (Figure 6-2).  
 
6.1.1 Characterisation of mutants 
 
In order for the mutant proteins to be used for further biophysical and crystallisation 
experiments it was important that they were correctly folded, with a particular focus on a 
correctly folded active site. As purification of the mutants was performed using GSH agarose 
affinity this required the protein to have a correctly formed G-site in order to bind to the column. 
Further characterisation was also carried out to confirm this.  
Circular dichroism was used to confirm that the tertiary structure of the protein was similar to 
that of the wild type and that the protein had a fully folded conformation.126 Each mutant gave 
spectra clearly indicative of a folded protein and which closely matches the spectra of the wild 
type protein in each case (Figure 6-3). The spectra produced are typical of proteins which are 
predominantly α-helical in nature.127 
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Figure 6-2: SDS-PAGE to demonstrate purity of mutants of AmGSTF1. Expected 
molecular weights: Y118S=25029 Da, F122T=25059 Da, Y118S F122T= 29483 
Da. 
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The conjugative activity of each protein was then tested using the CDNB assay (Figure 6-4). In 
each case the mutants were found to show activity, albeit reduced compared to that of the 
wild type protein. As the Y118S mutant had been seen to less efficiently bind to the GSH 
agarose column it had been expected that this mutant would have the most reduced activity of 
the mutants, however this was not the case. While the Y118S mutant had lower activity than 
the wild type protein, probably due to this weaker binding to GSH, it had a markedly higher 
activity than the F122T or double mutant.  
 
The results from protein purification, circular dichroism and activity assays suggested that the 
mutations were unlikely to have affected the overall fold of the protein, nor their ability to 
function as GSTs. As a result it was decided to continue with these designed mutants for 
crystallographic studies.  
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6.2 Crystal structure determination of mutants 
 
Having determined that the mutant AmGSTF1 proteins were correctly folded and partially 
functional, attempts were then made to crystallise them.  
 
6.2.1 Crystal structure determination of F122T AmGSTF1 
Initially trials were carried out with the F122T mutant as it was possible to purify this in higher 
quantities. The F122T mutant of AmGSTF1 was found to crystallise well in high-throughput 
screens, across a range of conditions, with the Morpheus screen proving most successful.103 
Crystals were produced in two morphologies: rods, and smaller prismatic crystals (Figure 6-5). 
Notably, crystals were not found to grow in the condition in which the original hexagonal wild 
type crystals had grown reliably, suggesting that the mutation had successfully disrupted the 
packing interactions found in the wild type structure. The crystals with the rod morphology were 
found to diffract best (to 2.8 Å).  Detailed information about data collection and processing are 
available in section 3.10.3 and Appendix B. Crystals were obtained in a tetragonal modification, 
in space group I 41 2 2, with one protein chain in the asymmetric unit. As with the original wild 
type structure, the functional dimer can be generated from a two-fold crystallographic axis. 
Figure 6-5: Crystal morphologies observed for F122T mutant of AmGSTF1- prismatic (left) 
and rods (right) 
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The structure was found to display a fold very similar to that of the wild type, however, there 
was clear density to build in both loops which had previously been disordered, giving a complete 
structure (Figure 6-6). Density was observed for 214 residues (from Ala2 to Ala215), and 6 water 
molecules. The model has an R factor of 0.18, an Rfree of 0.24 and 4 Ramachadran outliers were 
observed. One of these was the Glu67 observed in the wild type structures, in addition to Asp60 
which is observed as an outlier in all ligand bound structures and two further residues in poorly 
defined areas. 
Density was also seen within the G-site for a GSH molecule. The presence of this GSH molecule 
confirmed that the absence of small molecules in the previous wild type structure was due to 
the crystal packing. GSH was not added to crystal conditions and therefore must have remained 
from expression and purification.  
 
Figure 6-6: Structure of F122T mutant of AmGSTF1 showing structure of ordered loops and GSH 
molecule in the G-site, shown in green in a stick representation. Figure produced using Pymol. 
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6.2.1.1 Comparison with wild type and maize structures 
Unsurprisingly, the F122T AmGSTF1 is seen to have a structure very similar to that of the wild 
type, with an rmsd of 1.12 Å for the 186 equivalent Cα atoms that make up the structure without 
the loops (Figure 6-7). The main visible differences between the structures are in the areas 
around the now ordered loop regions. In the area surrounding the loop in the area of the G-site 
the structure is seen to diverge significantly from Asn33 until Asn37 where the wild type loop 
became disordered. It is also seen to differ from Ala49, the first visible amino acid after the 
disordered loop to Ala57. Differences are also seen in the upper part of the α4 helix. In the WT 
structure, this is seen to bend further away from the H-site than in the F122T structure. In 
addition the C terminus of the F122T mutant is disordered within our structure, with the last 
visible residue being Ala215 compared to the full length protein observed in the wild type (to 
Ala219). As this C terminus is not thought to be related to ligand binding the fact that this area 
is disordered does not pose a problem.   
Figure 6-7: Superposition of structure of F122T mutant of AmGSTF1 (slate and green) with WT 
structure (cyan). Areas showing divergence between the structures are highlighted. Figure 
produced using Pymol.  
Asn33 
Ala57 
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The structure is found to closely resemble that of ZmGSTF1,56 with the structures having an 
overall rmsd of 0.97 Å for 208 equivalent Cα-atoms, including both the core structure and loops 
(Figure 6-8).123 Two insertions are seen in the AmGSTF1 structure compared to the ZmGSTF1 
structure, explaining the structural differences in these areas.  
The loop surrounding the G-site is found to closely resemble the loop seen in this structure of 
ligand bound ZmGSTF1. This is also the case for the upper part of the α4 helix.  This difference 
between the wild type and F122T structures could be for one of two reasons. Either as a result 
of the crystal packing in the wild type, or as a result of the amino acid substitution in the mutant. 
The mutant shows the same positioning of this helix as both ZmGSTF1 and also Arabidopsis 
AtGSTF2.50 This suggests that this is the more likely positioning of this helix in AmGSTF1 and that 
Figure 6-8: Superposition of F122T AmGSTF1 (slate and green) with ZmGSTF1 maize (marine; PDB 
code: 1AXD). Areas with amino acid insertions are marked with black rings. Figure produced using 
Pymol. 
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the difference in the wild type is caused as a result of crystal packing. The fact the change occurs 
lower down the helix than the mutation further supports this, making the difference in the F122T 
less likely to be as a result of the single site mutation.   
We observe small structural differences between the AmGSTF1 and ZmGSTF1 structures as a 
result of two short insertions in the AmGSTF1 sequence. The first, a 3 residue insertion in the 
linker region, and the second, occurring in the loop region in domain II between the α4 and α5 
helices.  
The fact that the F122T mutant has a structure very similar to both the wild type and maize 
structures, and that a GSH is bound in the active site suggests that the reduced activity observed 
in the CDNB assay should not be of concern. A crystal structure of cGSTA1-1 in complex with a 
GSH-CDNB conjugate provides a possible explanation for this lack of activity (PDB code 1VF3).128 
The CDNB is seen to form a π-π interaction with Phe111 which is equivalent to Phe122 in 
AmGSTF1. Substituting this residue for a non-aromatic one would be likely to have a dramatic 
effect on the binding of CDNB in the active site. As a result it is most likely that the considerably 
lower activity of the F122T mutant and Y118S F122T double mutant was due to a reduced 
binding affinity of CDNB rather than an inability to function as a GST. 
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6.2.1.2 Analysis of the GSH binding site 
 
In the unbiased density there is clear density observed in the G-site for a GSH molecule (Figure 
6-9). The GSH molecule is seen to form a number of hydrogen bond interactions with the loop 
over the G-site, as well as with the two α-helices which surround it. It is seen to form an extensive 
network of hydrogen bonds with hydrogen bonding side chains and the protein backbone, as 
well as hydrophobic interactions with three further residues (Figure 6-10). 
 
Figure 6-9: Omit map for the GSH molecule in the G-site of the F122T mutant. 2Fo-Fc (blue) 
contoured at σ=1 and Fo-FC (red and green) at σ=3. Figure produced using CCP4mg. 
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Figure 6-10: A) G-site of F122T mutant of AmGSTF1 (slate) with residues involved in binding of GSH 
(green)  shown in  stick representation. Figure produced using Pymol. B) LigPlot to show 
interactions of GSH with the active site of the F122T mutant of AmGSTF1. Hydrogen bonds are 
shown as green dashed lines and hydrophobic interactions as red combs. 
a 
b 
Gln54 
His41 
Lys42 Glu67 
Ser68 
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As has previously been discussed, the G-site is highly conserved between AmGSTF1 and 
ZmGSTF1 and, the GSH molecule is seen to form very similar interactions. The main difference 
occurs in the location of the sulphur atom of the GSH or conjugated GSH molecule. In ZmGSTF1 
this is observed to lie close to and form interactions with the catalytic Ser12 residue while in 
AmGSTF1 it does not. It is plausible that this difference is as a result of the fact that the ZmGSTF1 
structure is of a conjugated GSH-atrazine molecule. It seems likely that during a conjugation 
reaction we could expect the carbon-sulphur bond of the GSH in AmGSTF1 to rotate to allow the 
sulphur to form an interaction with the Ser12 residue. The loop over the binding site is also seen 
to adopt a very similar structure. In ZmGSTF1 this is seen to have an induced fit on GSH binding, 
and it is likely the same would occur in AmGSTF1. 
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6.2.2 Crystal structure determination of Y118S AmGSTF1 
 
Having identified the conditions where the F122T mutant would crystallise, crystallisation trials 
were then set up for the Y118S mutant using the conditions which had proven most effective 
for F122T crystallisation. As the majority of crystals of F122T AmGSTF1 were observed using the 
Morpheus screen, and due to a limited supply of Y118S protein, this mutant was exclusively 
screened using these conditions. Crystals of the Y118S mutant were observed in a number of 
wells, most of which also produced crystals of the F122T mutant, although notably under far 
fewer conditions than had been observed for the F122T mutant. Crystals had the same 
morphologies as for the F122T mutant (Figure 6-11). Crystals in the prismatic morphology 
diffracted best to 2.6 Å. Crystals were obtained in a tetragonal modification with space group 
I 41 2 2. Both the space group and unit cell observed are identical to that for the F122T mutant.  
 
 
 
Figure 6-11: Crystal morphologies observed for Y118S mutant of AmGSTF1- 
prismatic (left) and rods (right) 
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The structure is of excellent quality, 2 Ramachadran outliers are observed: Glu67, Asp60 both 
seen as features. The protein adopts the typical GST fold (Figure 6-12), and again density was 
observed for the loop over the G site. Density was also observed again for a GSH molecule in the 
binding site, although this was refined at only 0.7 occupancy (Figure 6-13). Interestingly, the 
Y118S mutation appears to have resulted in the top of the α4 helix becoming disordered, with 
no density is observed for residues from Phe122 to Thr131. This suggests that interactions 
formed by this Tyr118 residue are essential to the structure of this helix. 
Figure 6-12: Structure of Y118S mutant of AmGSTF1 (purple) with a GSH molecule bound in the G-
site shown in green in stick form. Figure produced using Pymol. 
Crystallography of Mutant AmGSTF1 
 
99 
 
 
Figure 6-13: Omit map for GSH molecule bound in the G-site of the Y118S mutant of AmGSTF1. 2Fo-Fc 
(blue) contoured at σ=1 and Fo-FC (green) at σ=3. Figure produced using CCP4mg.  
 
With the exception of this area of disorder the structure is virtually identical to that of the F122T 
mutant, and they superimpose with an rmsd of 0.31 Å across 207 Cα atoms (Figure 6-14). There 
are no apparent differences in the location of any of the residues involved in GSH binding, except 
Phe36 which is rotated slightly between the structures (Figure 6-15). This is of particular interest 
as evidence suggests that the Y118S mutant binds GSH less efficiently than the wild type protein 
or other mutants. The Y118S mutant bound to the GSH agarose column less efficiently and the 
GSH molecule observed in the active site is only partially occupied, with weaker unbiased density 
than was observed for the F122T mutant. This suggests that it is possible that the structure of 
the α4 helix may be able to play a part in binding in the G-site, in a way that cannot be seen via 
crystallographic methods which capture only one conformation of the protein. This is 
particularly relevant in relation to a possible mechanism for CNBF inhibition, which binds to this 
helix (see section 5.3).  
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Figure 6-14: Superposition of structures of Y118S mutant (purple) and F122T mutant (slate) of 
AmGSTF1 including the GSH molecule from the Y118S structure (green) 
 
Figure 6-15: Superposition of the G-sites from the AmGSTF1 Y118S mutant (purple) and F122T mutant 
(slate) with the GSH molecule from the Y118S structure (green). Residues involved in binding are 
shown in stick form. Figure produced using Pymol. 
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6.3 Ligand binding assays with mutants 
 
In order to use co-crystal structure determination to investigate ligand binding at the molecular 
level it was necessary to identify if the mutants bound the ligands. The ligand binding properties 
of the mutants were investigated using thermal shift assays. Due to the disorder observed at the 
top of the α4 helix, the F122T mutant was selected for these experiments over the Y118S mutant 
in order to ensure the protein structure was as close as possible to what would be expected for 
the wild type.  
A selection of inhibitors was chosen for testing, incorporating predominantly flavonoid based 
inhibitors but also a NBF-GS conjugate, in order to evaluate compounds with potentially 
different binding poses within the H-site. The flavonoid ligands selected all contain the thiazole 
group, as these were most soluble (Figure 6-16). Ligands were selected which had shown varying 
levels of binding to the wild type protein to identify if the mutant responded in a similar manner 
to the wild type to the variously positioned functional groups.  
 
Figure 6-16: Inhibitors selected for testing in thermal shift assay with mutant AmGSTF1 
 
For the F122T mutant, no thermal stabilisation is observed for any of the flavonoid inhibitors 
(Figure 6-17a), indicating that no binding occurs, suggesting that Phe122 was essential for 
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binding. This will be discussed further in Chapter 7. However, for the GSH-CNBF conjugate, a 
change in thermal stability was still observed (Figure 6-17b), with the F122T mutant binding in a 
destabilising manner. 
 
 
As the flavonoid inhibitors had not been seen to bind to the F122T mutant they were also tested 
with the Y118S mutant, again no thermal stabilisation was seen suggesting the molecules did 
not bind (Figure 6-18). This was most likely as a result of the disorder in the upper portion of the 
α4 helix resulting in a change in binding. 
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Figure 6-17: Change in melting temperature observed for F122T mutants using thermal shift assays with 
A) Flavonoid compounds and B) NBF-GS at a range of concentrations 
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Figure 6-18: Change in melting temperature observed for Y118S mutants using thermal shift assays 
with flavonoid compounds 
6.4 Cross-seeding with mutants 
 
As the mutants were seen not to bind to the flavonoid inhibitors, it was necessary to resume 
working with the wild type protein, in order to identify whether this was due to an overall 
structural change between the mutants and wild type or as a result of the substituted amino 
acid. In some cases, groups have had success using homologous proteins for cross-seeding to 
encourage the crystallisation of proteins. This is particularly the case where sequence identity is 
high, however studies investigating metallo-β-lactamases have had successes with sequence 
similarity as low as 24%.129 Seeding removes the need for spontaneous nucleation to occur, and 
as a result can lead to crystals forming in conditions in which they otherwise would not. By 
seeding with the mutant crystals, wild type protein would be more likely to form crystals in the 
modification of the mutant protein.  As the F122T mutant had a fully ordered core structure it 
was selected for use for micro-cross-seeding matrix screening. This method uses micro-seeds to 
screen for crystallisation forms, across varied crystallisation conditions, using high throughput 
screens.130–132  
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6.4.1 Structure of wild type AmGSTF1 
 
From high throughput screen conditions containing seeds of F122T mutant, crystals of wild type 
AmGSTF1 were produced. Crystals were produced in the same rod morphology as the F122T 
protein used to seed, as well as the prismatic morphology also seen for the F122T and Y118S 
crystals (Figure 6-19). As with the F122T mutant crystals of the rod morphology diffracted best, 
to 2.25 Å. Crystals were obtained in a tetragonal modification with a space group of I 41 2 2, the 
same as observed for the mutant structures. Prismatic crystals were also seen to be in a 
tetragonal modification with space group I 41 2 2, but these diffracted less well (to 2.8 Å). This 
may be as a result of a marginally larger unit cell C axis (104 Å as opposed to 99 Å).   
Density is seen for 214 residues (from Ala2 to Ala215), 24 water molecules and a GSH molecule. 
The model has an R factor of 0.23, an Rfree of 0.28, and 4 Ramachadran outliers: Glu67 and Asp60 
and two residues in the loop between α4 and α5. Unsurprisingly there is virtually no structural 
difference observed between the wild type structure and the F122T mutant, with an rmsd of 
0.32 Å across 214 Cα atoms (Figure 6-20).  
It is notable that the α4 helix adopts the same conformation as observed in the F122T mutant 
as opposed to the hexagonal form wild type crystal. This confirms that the conformation of this 
α-helix in the hexagonal wild type crystal, where this bends away from the H-site, is most likely 
as a result of the crystal packing observed. The other monomer packed in the active site probably 
results in the hexagonal form wild type structure adopting this conformation.   
Figure 6-19: Crystal morphologies observed for WT AmGSTF1 after seeding 
with F122T protein-prismatic (left) and rods (right) 
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The location and orientation of the GSH molecule is seen to mirror that observed in the F122T 
mutant. It is seen to form the same interactions as in the mutant structure, and additional 
hydrogen bonding interactions are observed, mediated by two water molecules (Figure 6-21). 
The G-site is also found to be mostly unchanged from the hexagonal form wild type structure. 
The only major variations are that the Phe36 residue immediately before the loop over the G-
site adopts an alternative conformation, and that the loop over the region is now visible.   
Figure 6-20: Superposition of structures of WT (light teal) and F122T mutant of AmGSTF1 with the 
GSH from WT (green). Figure produced using Pymol. 
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Figure 6-21: LigPlot to show the interactions observed between GSH and the active site of wild type 
AmGSTF1. Hydrogen bonds are represented as green dashed lines and hydrophobic interactions as red 
combs 
The fact that the structure of this wild type AmGSTF1 is virtually identical to that of the F122T 
mutant also points towards a possible binding site for the flavonoid inhibitors. The only major 
difference is the presence of a Phe122 in the wild type as opposed to a Thr122 in the mutant. 
The fact that the F122T mutant is seen not to bind the flavonoid inhibitors suggests that this 
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aromatic Phe122 residue may be essential for forming π-π interactions with the aromatic rings 
in the flavonoid inhibitor.  
 
6.4.2 Crystal structure determination of wild type AmGSTF1 with inhibitors 
 
Having determined a complete structure of wild type AmGSTF1, it was desirable to use this to 
determine the structure of AmGSTF1 in complex with inhibitors. Soaking experiments were 
carried out using the tetragonal form crystals produced in seeding experiments. Experiments 
were carried out using both the flavonoid based ligands, in addition to a CNBF-GSH conjugate, 
to try to determine further the mode of action of both of these inhibitor types.  
Flavonoid ligands were available as DMSO stocks and these were added to crystal conditions to 
give a compound concentration 5× that of the protein, and a final DMSO concentration of 5%. 
Unfortunately on addition of these stocks crystals were observed to crack and then dissolve. 
Controls were carried out using just DMSO to determine if this was as a result of the DMSO or 
whether the compounds binding to the protein was resulting in the crystal form becoming 
unstable. DMSO was added to drops at a variety of concentrations decreasing to 0.5% final 
concentration, and in each case crystals were seen to crack and dissolve. This suggests that these 
crystals are particularly sensitive to DMSO. As flavonoid ligands were only available as DMSO 
stocks, it was not possible to use them for further soaking experiments. In addition, their low 
solubility would make it difficult to use them for soaking in the absence of any DMSO, were solid 
forms available. This suggests that co-crystallisation may prove to be a better option for 
structure determination of AmGSTF1 in combination with a flavonoid ligand, as additional 
screening and optimisation would need to be carried out to identify crystals which are less 
DMSO sensitive. 
The NBF-GS conjugate was available as a solid and as the conjugated GSH molecule means it is 
highly soluble this was suitable for use in soaking experiments. A small amount of solid was 
added directly to drops using a needle, drops were seen to rapidly turn yellow, and crystals were 
also seen to adopt a bright yellow colour.  
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6.4.2.1 Crystal structure of wild type AmGSTF1 in complex with NBF-GS 
 
Following soaking in NBF-GS, a dataset was collected, and crystals were found to diffract to 
2.30 Å. As with the GSH bound structure, crystals were in a tetragonal modification, with a space 
group of I 41 2 2. Further details on data processing are available in section 3.10.5 and Appendix 
B. 
 
Figure 6-22: Structure of WT AmGSTF1 in complex with NBF-GS. Figure produced using Pymol. 
 
Density was seen for 214 residues (from Ala2 to Ala215), and 8 water molecules (Figure 6-22). 
The model had an R factor of 0.21, an Rfree of 0.25, and 4 Ramachadran outliers. The structure 
was found to be virtually identical to the GSH bound structure, with an rmsd of 0.23 across 214 
equivalent Cα atoms. Following initial molecular replacement unbiased density for the NBF-GS 
molecule could clearly be seen in the active site (Figure 6-23).  
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Figure 6-23: Omit map for NBF-GS ligand in AmGSTF1 structure. 2Fo-Fc (blue) contoured at σ=1 and Fo-
FC (red and green) at σ=3. Figure produced using CCP4mg. 
 
The NBF-GS molecule was seen to bind across both the G and H sites. The GSH portion of the 
molecule adopts the same conformation as the unconjugated GSH molecule seen in previous 
structures. The CNBF portion of the molecule is then seen to extend into the upper portion of 
the H-site (Figure 6-24). The aromatic portion of the molecule is seen to form a strong π-stacking 
interaction with Phe36, and the Phe36 is seen to rotate from its location in the structure with 
only GSH to allow this to occur (Figure 6-25). Whilst density for the Phe122 residue cannot be 
seen, it is probable that this would form an edge on face interaction, with a likely orientation for 
Phe122 lying within range for this interaction to occur. Additionally, hydrophobic interactions 
are seen to occur with Met126, Pro9 and the CNBF portion of the molecule (Figure 6-26).  
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Figure 6-24: Interactions observed for NBF-GS (shown in yellow in stick form) binding in the active site 
of WT AmGSTF1 (shown in teal). Figure produced using Pymol. 
 
Figure 6-25: Movement of Phe36 observed in WT AmGSTF1 with (light teal) and without (grey) NBF-GS 
bound. Figure produced using Pymol. 
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Figure 6-26: LigPlot to show interactions formed between the NBF-GS conjugate and the active site of 
AmGSTF1. Hydrogen bonds are shown as green dotted lines, and hydrophobic interactions as red 
combs  
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6.4.2.1.1 Comparison with HsGSTP1 structure  
The structure was then compared with structures of HsGSTP1. As CNBF was originally identified 
as an inhibitor for this protein and MDR, it was of interest to determine whether it might be 
functioning in AmGSTF1 in the same manner. Interestingly this NBF-GS conjugate is seen to 
occupy a similar position to that observed of inhibitors in the active site of HsGSTP1. Notably 
NBDHEX,133 a derivative of CNBF, and the GSH conjugate of ethacrynic acid123 occupy a similar 
location within the active site (Figure 6-27). In both these cases and the AmGSTF1 structure the 
ligands are seen to form interactions both with residues in the α4 helix and the loop over the G-
site.  
a 
b 
Figure 6-27: Comparison between binding site of NBF-GS (shown as yellow sticks) in  AmGSTF1 
(light teal)  and HsGSTP1 (grey) binding site of (a)- NBDHex (PDB code:3GUS; dark grey sticks)13 and 
(b) Ethacrynic acid-GSH conjugate (PDB code: 3GSS; dark grey sticks).7 Figure produced using 
Pymol. 
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In HsGSTP1 these compounds are thought to stabilise GSH binding in the active site by 
preventing its conjugation with natural substrate molecules and subsequent dissociation. This 
GSH bound form is thought to show a lower affinity to JNK1. Consequently stabilising the GSH 
bound form prevents HsGSTP1 binding to JNK1 and in turn apoptosis.83 That this CNBF conjugate 
binds in a similar location supports the hypothesis that this may also be functioning to block the 
active site and stabilise GSH binding. It is probable that this CNBF-GSH conjugate would work in 
conjunction with the covalent CNBF modification observed in the wild type protein following 
alkylation to achieve this.  
6.5 Conclusions 
 
In order to disrupt a crystal packing arrangement where the active site was blocked, preventing 
small molecule binding, a protein engineering approach was used. Two single site mutants, and 
one double mutant were designed to disrupt the interactions that held together this crystal 
packing arrangement. The two single site mutants were crystallised, and structures obtained at 
2.8 Å for the F122T mutant, and 2.6 Å for the Y118S mutant. In both these cases, the designed 
mutations were sufficient to successfully disrupt crystal packing and the crystals were observed 
to be in a different modification. Notably, the active site was exposed with density for a GSH 
molecule observed in the G site. In addition, the previously disordered loop over the G site was 
seen to be ordered. These structures represented a major advance in the project. They allowed 
the structure of a complete active site to be determined for the first time, giving a complete 
model for in silico docking experiments to be carried out. An exposed active site made it possible 
to use crystals in this packing arrangement for soaking experiments to determine ligand binding 
sites. As the single site mutations were sufficient to disrupt crystal packing no attempt has yet 
been made to crystallise the double mutant, as it was preferable to use protein as consistent as 
possible with the wild type.  
The presence of a GSH molecule confirms that the absence of small molecules in the previous 
wild type crystal form was as a result of crystal packing rather than lack of affinity for compounds 
used in the co-crystallography experiments.  The GSH molecule had remained in the samples 
from protein purification and expression rather than being separately introduced. Even if the 
flavonoid molecules added to wild type protein had not bound, we would have expected to see 
a GSH molecule bound to the active site had it been accessible.  
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Thermal shift binding assays were carried out using the F122T and Y118S mutants to determine 
whether the flavonoid ligands were still seen to bind. In each case, no binding was observed. 
While this meant it would not be possible to use the mutants directly for soaking experiments, 
it did suggest that these residues were likely to be involved in flavonoid binding, identifying a 
probable binding location for these compounds in the H site.  
To allow for future soaking experiments, in addition to obtaining a more biologically relevant 
structure, attempts were made to crystallise wild type AmGSTF1 in the same space group. By 
using seeds created from F122T crystals in the tetragonal modification, in random Microseed 
Matrix Screening in combination with wild type protein, it was possible to obtain crystals of wild 
type protein in the packing arrangement of the mutant. Using this method it was possible to 
grow crystals of wild type AmGSTF1 which diffracted to 2.25 Å, in the same space group and 
crystal packing arrangement as had been observed for the F122T crystals. This structure was 
seen to be virtually identical to that of the of the F122T mutant, confirming the biological 
relevance of this structure as a model for the wild type protein.  
 115 
 
7 In Silico Studies of AmGSTF1 
 
As no co-crystal structure of AmGSTF1 in complex with a flavonoid inhibitor was obtained, in 
silico docking studies were carried out to further investigate the mode of action of these 
compounds. For the majority of investigations the program GOLD was used.134  
7.1 Introduction to GOLD 
 
GOLD uses a genetic algorithm to create and score multiple ligand poses which converge to give 
one pose per “run”. The user defines a number of runs, for example the default is 10, which 
would give 10 individual poses. Termination conditions are also set, which determine when the 
runs will stop. “Early termination” will result in runs stopping when a certain number of poses 
are within a certain RMSD, for example for this work, 3 solutions within 1.5 Å was used as a 
termination criteria. “Early termination” results in runs being stopped as soon as these 
conditions are met, regardless of the number of runs that were initially instructed.  
GOLD has a number of built in fitness functions which are used to score poses; GoldScore, 
ChemScore, ASP and ChemPLP.135 ChemPLP is the default function in GOLD and the fitness 
function used in this work, it will be examined in more detail here.  
ChemPLP is an empirical fitness function optimised for pose prediction (Equation 7-1).  
fitnessPLP =  −൫w௉௅௉  .  f௉௅௉  + W௟௜௚ି௖௟௔௦௛ .  f௟௜௚ି௖௟௔௦௛ + w௟௜௚ି௧௢௥௦.  f௟௜௚ି௧௢௥௦ + f௖௛௘௠ି௖௢௩  
+  w௣௥௢௧  . f௖௛௘௠ି௣௥௢௧ +  w௖௢௡௦ . f௖௢௡௦൯ 
fitnessCHEMPLP =  fitnessPLP − (f௖௛௘௠ି௛ + f௖௛௘௠ି௖௛௢ +  f௖௛௘௠ି௠௘௧) 
Equation 7-1: ChemPLP fitness function. This uses PLP adjusted with select bonding terms. PLP models 
steric complementarity, lig-clash is a heavy atom clash term, lig-tors is a ligand torsion potential. 
Chem-cov, a function for covalent docking,  chem-prot which considers flexible side chains and 
waters, and cons which handles constraints are included as necessary.   
PLP models the attraction and repulsion of protein and ligand heavy-atoms by designating atoms 
as: donor, acceptor, donor/acceptor, non-polar and metal. The interactions between these are 
then characterised (Table 7-1).136  
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Table 7-1: PLP interaction types 
 Protein Atom Type 
Ligand Atom Type donor acceptor don./acc. nonpolar metal 
Donor repulsive H-bond H-bond buried repulsive 
Acceptor H-bond repulsive H-bond buried metal 
don/acc H-bond H-bond H-bond buried metal 
nonpolar buried buried buried nonpolar buried 
 
GOLD is a flexible docking program, and during the course of a run both the conformation of the 
protein and ligand will be altered. While ligands will rotate around any internal rotatable bonds, 
stereochemistry will not be altered, and as a result it is necessary to input any stereoisomers 
separately. At a basic level, residues in the protein capable of forming hydrogen bonds, Ser, Thr, 
Tyr and Lys, undergo hydrogen bond optimisation. It is further possible to increase flexibility by 
defining the side chains of up to 10 residues in the active site as “flexible”. These can either be 
allowed to take on the structure of a rotamer from a library, either built in137 or input, or can be 
given complete freedom to rotate around acyclic bonds.  
In addition to increasing the flexibility of the protein, it is also possible to introduce a number of 
constraints into the docking. These can range from determining the distance between a protein 
and ligand, or forcing the presence of hydrogen bonds between protein and ligand in poses. 
These constraints are best used when a large amount of information is available about the mode 
of ligand docking, and as a result were not used for this work. 
7.2 Docking using Chimeric GSTs 
 
As a complete crystal structure had not originally been solved, with the initial wild type structure 
having two disordered loops, two options were available. Either to use an incomplete structure, 
or to create a chimeric structure using the incomplete structure for AmGSTF1 in conjunction 
with another structurally similar protein. As one of the hypothesised locations for the binding 
sites was located in the active site, defined by one of the disordered loops, it was decided to 
create a chimeric model to allow for most accurate docking.  
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7.2.1 Designing a chimeric AmGSTF1 
 
While only one structure of AmGSTF1 existed prior to this work, there are a large number of 
crystal structures for other GSTs which can be found on the PDB. The sequence similarities of 
these GSTs were compared to AmGSTF1 to identify which would provide the most likely 
positioning of the loops. Only phi class GSTs were considered, as whilst GSTs show high structural 
similarity between classes the differences that do exist occur predominantly in these loop 
regions. Structures of phi class plant GSTs exist for Arabidopsis thaliana50,138, Populus trichocarpa 
(poplar)139 and Zea mays (maize).56,124 A sequence alignment can be seen in Appendix D. 
Of these the structures from maize were found to be the most similar, with a sequence similarity 
of 63.4%. A number of regions are highly conserved, and the structure shows an rmsd of only 
1.27 Å for 182 equivalent Cα atoms from the partial AmGSTF1 structure. As a result they were 
used to create a chimeric structure.  
Ideally it would have been possible to mutate the amino acids from the maize GST, to those 
present in the AmGSTF1 sequence, in silico. However, due to an amino acid insertion in one of 
the loops this was not possible. As a result ModWeb,106,140 an online server that calculates likely 
structures of proteins based on the best available PDB model, was used to determine the most 
likely structure. Structures were created based on two maize structures: 1AXD and 1AW9. 1AXD 
is a structure for a Glutathione bound GST, while 1AW9 is for an apo-GST (Figure 7-1). The main 
difference between the structures exists in the loop over the G-site which is observed to undergo 
a large conformational change on GSH binding. As it was unknown whether the ligands would 
bind to the structure in the presence or absence of GSH, separate structures were produced 
based on each of the two conformations, for use in docking.  
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Figure 7-1: Superposition of AmGSTF1 (cyan) and ZmGSTF1 PDB code 1AXD (marine) and 1AW9 
(green). Figure produced in Pymol. 
In order to identify the most accurate possible structure for AmGSTF1, the loop regions created 
using ModWeb106 were removed and inserted into the original AmGSTF1 structure. A round of 
geometry minimisation was then carried out in Phenix.141 This idealises the geometry of a model 
according to standard geometry restraints, ensuring the bond geometry was standard in the 
areas where the loop regions of chimeric GSTs were joined. The chimeric GSTs produced were 
then used for docking in GOLD (Error! Reference source not found.).  
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7.2.2 Docking in the active site 
 
Docking was initially carried out using both the 1AXD and 1AW9 chimeric models, to identify if 
either gave a more likely docking pose for an inhibitor in the active site. As insufficient density 
had been seen to model Tyr118, a residue in the H site in the original structure, this was inserted 
manually, and given flexibility within the docking to adopt any rotamer from the built in library. 
This library contains the most commonly observed side-chain conformations for naturally 
occurring amino acids.137 This gave a complete structure of the G and H-site with all necessary 
relevant residues to be used in docking experiments (Error! Reference source not found.). 
a b 
Figure 7-2: Chimeric structures of AmGSTF1 based on (a): PDB 1AW9 (green) and (b): PDB 1AXD 
(marine). Figure produced in Pymol. 
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Initial screening was carried out using two different flavonoid molecules (Error! Reference 
source not found.). Whilst it had been shown to bind less strongly, an inhibitor with a short alkyl 
chain at the C5 position was used (Error! Reference source not found.), as docking programmes 
are known to deal better with compounds with limited flexibility. In addition the inhibitor 
containing the full C10 chain was used (Error! Reference source not found.), to see if a satisfactory 
pose could be determined for this hydrophobic chain.  
Tyr175 
Tyr178 
Phe122 
Tyr118 
Phe36 
Ser12 
Figure 7-3: Structure of AmGSTF1 based on 1AXD, showing active site and location of key residues. 
Figure produced in Pymol. 
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For both proteins, the binding site was defined as a 10 Å radius around the catalytic Ser12 
residue. As no information was known about binding pose, all waters were removed from the 
docking, and with the exception of the flexible Tyr118 residue all other settings were kept at 
their defaults, to avoid encouraging false interactions. ChemPLP was used as the scoring 
function, this is the newest GOLD scoring function, it is the fastest and has been seen to give the  
most accurate poses in most cases.136 
Interestingly, the two different chimeric protein models produced very different binding poses, 
and these will be discussed here.  
1AW9 (apo) based chimeric model 
Using both compounds 1 and 2, the majority of poses observed had them located outside the G 
or H sites. For the short chain inhibitor, one pose was obtained with the inhibitor situated in the 
G-site, binding to the loop in the extended form which is observed in the absence of GSH (Figure 
7-5). It is possible that the contacts formed by the inhibitor in this pose would act to stabilise 
the protein in this conformation, preventing GSH binding and therefore activity. However, as 
there is no known case of anything binding to the G-site with the exception of GSH or a GSH 
mimic, in which case a conformational change of this loop is seen, this seems unlikely. The lack 
of consistency observed between poses also suggests that this pose is unlikely to be adopted by 
the inhibitor in vivo.  
  1   2 
Figure 7-4: Inhibitors used for docking studies 
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Figure 7-5: Docking pose for flavonoid inhibitor in G-site of 1AW9 chimeric structure. The structure is 
shown in green and the inihibitor in grey in stick representation. Residues most involved in binding 
are highlighted as sticks, in addition to Ser12. Figure produced in Pymol. 
1AXD (ligand bound) based chimeric model 
For compound 1, a relatively consistent binding pose was identified in the H-site of the protein, 
with the inhibitor forming a range of interactions with the α4 helix of the protein (Error! 
Reference source not found.). The majority of poses for both stereoisomers are consistent, with 
the inhibitor forming π-π interactions with Phe122 and Tyr118. While these poses are consistent 
with the observation that the A ring must be aromatic,85 it is seen to form a π-stacking 
interaction with Phe122, this pose is inconsistent with several of the other observations from 
the SAR data. The B-ring is not observed to form any π interactions, which would be expected 
as it needs to be aromatic, and the hydroxyl at the C7 position does not form a hydrogen bond. 
As a result it is relatively unlikely that the binding pose predicted represents an accurate pose 
for the flavonoid inhibitor within the active site.  
 
 
 
 
 
Ser12 
Phe36 
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For compound 2, the poses are seen to be more varied, with an rmsd of up to 13.1 Å observed 
for the poses, as opposed to only 5.2 Å for the short chain inhibitor. While some of the poses 
observed for the core of the structure are similar to those observed for the short chain structure, 
with this part of the structure forming interactions with the α4 helix, the majority adopt different 
orientations where the majority of interactions are caused exclusively by the long chain. This 
would be inconsistent with the core of the molecule having a strong inhibitory effect on its own. 
In addition, these poses are clearly unsatisfactory, with a large number of short contacts 
observed between the protein and ligand in each case. As a result, further investigations using 
this model were carried out using exclusively compound 1, as this had provided better poses. 
Once a suitable prospective pose had been identified for the core of the molecule, it was hoped 
it would then be possible to identify possible areas of hydrophobicity where the long alkyl chain 
might bind.  
Having demonstrated the importance of the aromaticity of both the C-ring and B-ring in SAR 
studies, a second round of docking was carried out allowing all aromatic residues in the defined 
binding site freedom to adopt any rotamer within the built in library. It was likely that on ligand 
binding these residues might rotate to form optimal contacts, and allowing for this movement 
might give a more accurate portrayal of a possible binding pose.  
Ser12 
Tyr118 
Phe122 
Figure 7-6: Pose for short chain ligand in H-site of chimeric 1AXD structure obtained for docking 
with rigid active site with flexible Tyr118 and Phe122 residues. Figure produced in Pymol. 
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For the two different isomers two different binding poses were observed. For the R isomer in 
the predominant pose the compound binds outside of the G or H site, adopting a position where 
it stacks with the Phe36 lying between it and the C-terminal tail of the protein (Figure 7-7). This 
pose seems unlikely; while it has a similar fitness score to those observed with fixed residue 
docking, it is hard to imagine how the molecule would have an effect from this location.  
 
Figure 7-7: Docking pose obtained for R-isomer using Chimeric 1AXD structure with flexible aromatic 
active site residues. Figure produced in Pymol. 
 
For the S-isomer a more probable binding location was observed, with the compound again 
placed in the H-site, but in a different orientation than had been observed for the rigid docking 
(Figure 7-8). The C-ring forms a π-stacking interaction with Phe122 and the acid group forms a 
hydrogen bond with Tyr175. The B-ring is close to forming π-interactions with either Phe177 or 
Tyr178, which would explain the increased activity seen with aromaticity in this ring. It is possible 
one of these residues would, in reality, adopt a slightly different conformation on ligand binding, 
allowing a strong π-π interaction to form.  
Phe36 
Ser12 
Phe122 
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Figure 7-8: Docking pose obtained for S-isomer using Chimeric 1AXD structure with flexible aromatic 
active site residues. Figure produced in Pymol. 
Overall, this pose for the S-isomer represents a likely pose observed for docking in the active 
site, indicating that the flavonoid ligands may bind to this area in the H-site.  
 
7.2.3 Docking in the dimer interface 
 
In addition to the active sites which are involved in conjugative activity, GSTs possess an 
additional binding site: the L-site. In AtGSTF2, Quercetin, a flavonoid, has been identified as 
binding in this site,50 and as a result this was considered as a possible binding site for our 
flavonoid inhibitors (Error! Reference source not found.). The L-site is most often involved in 
transport of molecules and as it was suspected AmGSTF1 might be causing MHR via a signalling 
effect34 it was possible these inhibitors could be preventing binding of other small molecules to 
this site and thus any signalling effect. 
Phe122 
Ser12 
Tyr175 
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A docking site was defined based on the binding site of quercetin in AtGSTF2. An area of 10 Å 
around Glu89, which was located adjacent to the quercetin when AmGSTF1 was superimposed 
with AtGSTF2, was used.  
The fitness scores observed for poses in the L-site were significantly lower than those observed 
for the H-site (around 35-40 rather than 45-50). For each of the 10 poses of the inhibitor, the 
program placed the inhibitor on the surface of the protein as opposed to in a similar location to 
the quercetin in AtGSTF2 (Figure 7-10). The fact that no satisfactory pose was identified for the 
inhibitor in the dimer interface suggests that this is unlikely to be its binding location. 
Figure 7-9: Structure of AtGSTF2 (PDB: 5ADV) showing location of L-site with 
quercetin bound. Each monomer is shown as a different colour, and the 
quercetin molecule is in grey in a stick representation. Figure produced in 
Pymol. 
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Figure 7-10: Pose obtained for docking in the L-site. The ligand is seen on the exterior of the protein as 
opposed to finding a stable pose within the L-site. The two monomers of AtGSTF2 are shown in 
different shades of blue, and the quercetin molecule is shown in grey in stick representation. Figure 
produced in Pymol. 
 
7.3 Docking using a mutant AmGSTF1 structure 
 
Having obtained a structure of the F122T mutant, this was used for in silico modelling in place 
of the chimeric models. As the mutation was located in the active site, the Thr122 in the 
structure was mutated back to a Phe122, and this residue given flexibility in docking runs. 
7.3.1 Comparison between chimeric and F122T structures 
 
A number of significant differences were identified between the chimeric model and the F122T 
structure. As the F122T structure had GSH bound, it adopted a structure most similar to the 
chimeric structure based on PDB 1AXD, the ligand bound ZmGSTF1 structure. While the 
structures were similar, a number of differences resulted in an rmsd of 1.97 Å across 213 
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equivalent Cα atoms between the structures (Figure 7-11). The overall structure of the loop over 
the G-site was well predicted, with the fold very accurately matching that observed in the F122T 
structure, however, the placement varied significantly. The loop in the chimeric structure is seen 
to lie 3.5 Å from the position of the loop in the F122T structure, opening up the binding site. A 
difference is also observed in the positioning of the α4 helix and associated loop. The difference 
in the α4 helix observed between the different crystal forms has again resulted in the chimeric 
structure having a more open active site, with a small difference of 1.6 Å observed at the Phe122 
position, but with this extending to a maximum of 4.8 Å at the Met126 position. These two 
changes result in the active site, where docking is taking place, adopting a significantly different 
shape in the chimeric GST as opposed to the F122T complete structure.  
 
Figure 7-11: Superposition of Chimeric structure based on 1AXD (grey) and F122T mutant (slate). 
Figure produced in Pymol. 
 
 
 
  
In Silico Studies of AmGSTF1 
 
129 
 
7.3.2 Docking results using F122T structure 
 
Docking was initially carried out using a predominantly rigid setup, where only Tyr118 and the 
reinserted Phe122 were given flexibility. Tyr118 was included as poor density had been seen for 
it in the structure. As before, the flavonoid with the short alkyl chain was used for investigations. 
For the S-isomer, a very consistent pose was observed (Figure 7-12), with the docking 
terminating early as the top 3 poses were within 1.5 Å of each other. 
 
Figure 7-12: Docking pose observed for  S-isomer using F122T structure with flexible Tyr118 and 
Phe122 residues. Key residues involved in binding are shown in stick representation, and a hydrogen 
bond formed between the C7-OH and Ser12 is shown as a yellow dashed line. GSH is shown in green 
and the flavonoid inhibitor in cyan, both in stick representation. Figure produced in Pymol. 
 
For the R-isomer, while the run did not terminate early, the molecule was also found to adopt a 
relatively consistent position. The majority of solutions were found to lie within an rmsd of 4.4 Å, 
with the exception of two poses where the ring system is seen to flip (Figure 7-13). The level of 
consistency observed for both isomers is indicative of a better pose than was observed using the 
chimeric models, and the fitness scores observed are also significantly higher (around 75 as 
opposed to 50 for the chimeric models). 
Ser12 
Phe122 
Tyr118 
Tyr178 
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Figure 7-13: The two poses obtained for the central ring system for the R-isomer using the F122T 
structure with flexible Tyr118 and Phe122  residues. Residues involved in binding are shown in stick 
representation, and hydrogen bonds are shown as yellow dashed lines. GSH is shown in green and the 
flavonoid inhibitor in cyan, both in stick representation. Figure produced in Pymol. 
 
The poses observed were also consistent with the SAR data. The C ring is observed to be involved 
in edge-face π interactions with Phe122, which is consistent with the need for this ring to be 
aromatic. In addition, using this new structure, the B-ring is seen to form π-interactions with 
Tyr178, consistent with the reduction of activity observed if this ring was not aromatic. 
 
7.3.2.1 Flexible active site 
 
Having achieved a consistent and probable pose, a second docking was carried out where the 
active site was given more flexibility. A selection of residues observed to form interactions with 
the inhibitor were given total flexibility in the docking to determine if changes might occur in 
the active site on compound binding.  
With flexible residues, the ligand is seen to adopt an almost identical pose in the active site. As 
was expected, due to the consistency of previous poses no major changes in residue location 
were observed. However several small changes in conformation were observed. Most noticeably 
Tyr118 
Tyr118 
Phe122 
Phe122 
Tyr178 
Tyr178 
Ser12 
Ser12 
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the Phe122 residue is seen to adopt a different conformation where it forms stronger π-stacking 
interactions with the C-ring. In addition the Tyr178 residue is seen to move nearer to the B-ring, 
allowing for more efficient interactions to occur. The effect of these increased interactions can 
also be observed in the fitness score, which is significantly higher than that observed for the 
rigid docking, increasing to a maximum of 95 for the top pose.  
Three predominant interactions are observed which are consistent between the R and S isomer. 
Firstly, and most significantly, a π-π interaction is observed between the C ring and the Phe122 
residue. Aromaticity of this ring has been seen to be essential to compound binding, supporting 
the observation from docking that this would form π-interactions. Significantly, the F122T 
mutant is seen not to bind to the flavonoid compounds, further supporting this positioning for 
the flavonoid ring. Secondly, the oxygen of the C7 hydroxyl group is seen to form a hydrogen 
bond with the catalytic Ser12 residue, acting as a hydrogen bond acceptor. This is again 
consistent with the SAR, which demonstrates no significant loss in activity with alkylation of this 
group. The fact that addition of electron donating groups to this hydroxyl group result in a loss 
of activity can be explained due to sterics. While there is space in the region of this C7-OH group 
for additional groups, these would likely result in steric effects, explaining this activity decrease. 
Finally, the B-ring is seen to form a π stacking interaction with Tyr178. The fact that these 
interactions are consistent across all poses, as well as being consistent with the SAR studies give 
confidence in the docking (Figure 7-14). 
Only one significant difference is observed between the poses for the two isomers. For the S-
isomer, in the top ranked pose, a hydrogen bond network is seen to form with the α-alkoxy 
carboxylate group. Hydrogen bonds form between the hydroxyl group of the carboxylic acid and 
both Tyr175 and the amine group of Asn14, with this group acting as both a hydrogen bond 
acceptor and donator. A less extensive network is observed for the R-isomer, with the group 
forming a hydrogen bond with only the Tyr175 residue.  
In Silico Studies of AmGSTF1 
 
132 
 
 
Figure 7-14: Poses achieved for docking into F122T structure with flexible active site residues (a): R-
isomer (b): S-isomer. Protein is shown in slate with residues involved in binding shown in stick 
representation. The flavonoid inhibitor is shown in cyan, and the GSH molecule in green. Hydrogen 
bonds are shown as yellow dashed lines. Figure produced in Pymol. 
 
Using inhibitor 2 with the long alkyl chain was once again unsuccessful. The large amount of 
flexibility in the inhibitor resulted in no consistent pose being observed. Of the poses that were 
observed none was identified as being significantly more plausible than the others. Using 
inhibitor 1 the pose observed has a hydrophobic region near its binding location where it is 
expected this hydrophobic alkyl chain would bind.   
By way of confirmation this docking was also carried out using Glide,142 another of the leading 
programs for in silico modelling. This resulted in a very similar pose being observed, giving 
further confidence in the top pose generated by GOLD. In addition, a 5 ns molecular dynamics 
simulation was carried out using the Desmond software package,143 which demonstrated that 
the pose was energetically favourable, with the ligand remaining in the active site for the 
duration of the simulation.  
This pose, with the flavonoid inhibitors forming a complex in the active site points towards a 
possible mode of action. In this pose this inhibitor would block the active site, preventing 
Tyr178 
Tyr178 
Tyr175 
Tyr175 
Ser12 
Ser12 
a b 
Phe122 
Phe122 
Asn14 
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substrate binding. It would also stabilise the GSH molecule bound in the active site of the 
protein. As a large structural change is seen to occur on GSH binding,56 it is possible that in this 
GSH bound form  AmGSTF1 would be unable to play its causative role in MHR. Notably this is 
seen to be the case in HsGSTP1, with the GSH bound form unable to play its role in MDR.83 
7.4 Conclusions 
 
Initial in silico screening was carried out using chimeric AmGSTF1 models created from the 
partial AmGSTF1 structure, in addition to a model based on ZmGSTF1. Using this model it was 
possible to identify that the active site, and the H-site in particular, was most likely to be the site 
of flavonoid inhibitor binding. It was also possible to rule out the L-site as a probable location 
for inhibitor binding. However, using this model it was not possible to identify a pose consistent 
with all the SAR observed.  
Having obtained a structure for the F122T mutant this structure, with the Phe122 residue 
reinserted, was used for all subsequent docking experiments. From these experiments it was 
possible to determine a probable site of flavonoid inhibitor binding. A pose was observed in the 
H-site which was consistent with the SAR observed from thermal shift assays and activity assays. 
In addition, as the pose prominently features π-stacking interactions with the Phe122 residue, 
it is further supported by the observation that the flavonoid compounds do not bind to the 
F122T mutant.  
Docking experiments using compounds containing the long alkyl chain were found to be 
inconclusive. The docking programs do not respond well to the high degree of flexibility in this 
area, resulting in high levels of variation between poses. However, the poses observed for the 
core of the compound are situated in the vicinity of a highly hydrophobic region, and this may 
provide a likely binding site for this long alkyl chain.  
Based on the pose identified as most probable from the docking experiments it is possible to 
propose a possible mode of action for the inhibitors. Evidence suggests that flavonoid inhibitors 
bind to the H-site, which would both block other compounds from binding, thus preventing the 
catalytic activity of the enzyme. In addition they would also act to stabilise the GSH bound form 
of the protein, which is also thought to be an important feature of MDR inhibitors for 
HsGSTP1.117  
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8 Conclusions and Further Work 
 
8.1 Apo structure of AmGSTF1 
 
Building on previous work which had determined an apo crystal structure of AmGSTF1, this work 
extended the resolution to near atomic detail to 1.5 Å. The structure was seen to be typical of a 
phi class GST showing a high level of similarity to other phi class plant GST structures. While, as 
had been observed in the previous lower resolution structure, the crystal packing form resulted 
in two disordered loops, the higher resolution enabled density to be observed for an additional 
3 residues in these loop regions. Additionally, the crystal packing in this modification was found 
to prevent small molecule binding in the active site. Extensive crystallisation experiments were 
undertaken to identify a new crystal form using new crystallographic conditions and co-
crystallography, however no crystals were obtained of sufficient quality in any other packing 
form. Analysis of the interactions observed in the crystal using PISA113 predicts that this non-
biological interface is almost as strong as that seen in the biological dimer. The strength of this 
interaction provides a possible explanation for why it is observed so consistently.  
As it was not possible to disrupt crystal packing using different crystallisation conditions a series 
of mutants were rationally designed. Crystals for two of these mutants were obtained, in both 
cases these were in a different crystal modification and space group to the wild type protein. 
The structures of the F122T and Y118S mutants were solved to a resolution of 2.8 Å and 2.6 Å 
respectively. For both mutants the loop over the active site could be seen and the active site 
was occupied by a GSH molecule. For the F122T structure the second loop region, between the 
α4 and α5 helices, was also seen to be ordered, although for the Y118S structure the mutation 
resulted in an associated region of disorder.  
In order to obtain a wild type structure in the crystal packing form of the mutants, random matrix 
microseeding with seeds of the F122T mutant and wild type protein was carried out. This 
protocol produced crystals of wild type protein in the tetragonal modification, allowing for the 
first time the complete structure of wild type AmGSTF1 with ordered loops and a GSH molecule 
in the G-site, to be determined to 2.3 Å. This structure confirms the validity of the F122T mutant 
as a model for the wild type protein. Importantly, this new crystal form allowed for soaking 
experiments to be carried out to determine small molecule binding sites. 
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This method of cross-seeding wild type proteins with mutants is highly applicable for use in other 
protein systems. It allows for the possibility of mutating amino acids within the active site, which 
may be essential for binding or protein function, to gain a desirable crystal form. This desirable 
crystal form can then be used to seed wild type protein, giving a structure that is more 
biologically relevant and can be used for co-crystallography experiments.  
As the structure has some residues in the H-site with insufficient density to model side chains, 
future work should focus on optimising crystal conditions to obtain a structure at higher 
resolution than the current 2.3 Å. This structure could also be a starting point for in silico ligand 
discovery, enabling novel inhibitors to be identified. 
 
8.2 CNBF Inhibitors 
 
CNBF had previously been identified to form an adduct with the Cys120 residue of AmGSTF1 
using mass spectrometry. In this work, a crystal structure has been obtained at 2.0 Å. This is in 
the hexagonal crystal modification and has two disordered loops, including one in the active site 
area.  This structure shows density at Cys120 for a covalently bound CNBF molecule albeit at 
lower occupancy. However, no other major differences were observed from the apo structure 
and it was not possible to determine the mechanism by which this covalent adduct was causing 
inhibition.  
Binding assays using CNBF-modified and unmodified protein determined that CNBF did not 
prevent small molecule binding in the protein active site. However, using thermal shift assays it 
was not possible to ascertain if the covalent modification affected the binding constants for 
these molecules. Future work should use isothermal titration calorimetry to determine if CNBF 
covalent modification affects the binding constant of small molecules in the active site, in 
particular a NBF-GS conjugate.  
By soaking wild type crystals obtained from cross-seeding with F122T protein, it was possible to 
obtain a co-crystal structure for AmGSTF1 in complex with a NBF-GS conjugate with the structure 
solved to 2.3 Å. The conjugate was seen to bind in the active site, occupying a very similar 
position to inhibitors for HsGSTP1. Identification of this binding site in the active site suggests 
that CNBF may be working to inhibit the protein by two means possibly acting in combination; 
through covalent modification of the protein and by blocking the active site. This is supported 
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by work from biophysical studies demonstrating that CNBF modification at Cys120 does not 
prevent NBF-GS binding suggesting that in vivo the protein is likely to both be alkylated at Cys120 
and have NBF-GS bound in the active site. Further work should focus on trying to obtain a crystal 
structure of AmGSTF1 with both a Cys120-NBF adduct and NBF-GS bound in the active site. 
Seeds of the F122T mutant should be used alongside CNBF-modified protein to promote the 
crystal packing form that allows for small molecule binding in the active site. 
8.3 Flavonoid Inhibitors 
 
Thermal shift assays were used to characterise the binding of ligands to AmGSTF1. This data 
acted in a complementary manner to the CDNB inhibition data that had previously been 
collected. It also validates the data from these inhibition assays, as the two orthogonal assays 
are in agreement. Using this data it was possible to carry out detailed SAR analysis, identifying 
which aspects of the flavonoid structure were essential for binding and activity.  
In order to determine the likely binding site for flavonoid inhibitors the structure of the F122T 
mutant was used for in silico docking experiments. It was possible to propose a likely binding 
pose for flavonoid ligands in the H site of AmGSTF1. The pose agrees with the observations from 
SAR. In addition, the pose suggests that the flavonoid inhibitors form a π-interaction with 
Phe122. The F122T mutants, with this residue substituted for an aliphatic amino acid which 
could not form π interactions, did not bind flavonoid inhibitors. By contrast in thermal shift 
assays the F122T mutants were observed to bind NBF-GS. The structure of wild type protein in 
complex with NBF-GS demonstrates that Phe122 is not essential for NBF-GS binding, further 
supporting the argument that this residue plays a vital role in the binding site for flavonoid 
inhibitors. 
Initial attempts at obtaining a co-crystal structure of AmGSTF1 in combination with a flavonoid 
ligand by soaking were unsuccessful as the crystals were highly intolerant of DMSO, and all 
flavonoids were available only as DMSO stocks. Future work should focus on obtaining a co-
crystal structure using other methods. Soaking using solid compounds, the method used for the 
NBF-GS co-crystal structure, is a possibility. However due to limited solubility of the compounds 
this is unlikely to be successful. Due to this very limited solubility co-crystallisation is more likely 
to be successful than soaking. Crystallisation trials of protein with ligands in DMSO would 
identify conditions where crystals could grow in the presence of DMSO, allowing this solvent to 
be used to aid the solubility of the compounds. As in silico modelling was not able to provide a 
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conclusive binding position for the long alkyl chain contained within the compound, 
co-crystallography experiments would be particularly important with regards to determining 
where this may be binding. In turn this would help explain the role this functional group plays in 
increasing activity of the inhibitors. 
In addition to co-crystallisation efforts, future work could focus on further validating the pose 
obtained from in silico modelling using orthogonal methods. Single site mutants could be 
created for those residues identified in docking experiments as playing a major role in binding. 
Binding assays using flavonoid inhibitors could then be carried out to determine the importance 
of the various residues in compound binding. While these tests could be done using thermal 
shift assays, any changes in Tm between mutant proteins would make comparison of binding 
difficult. Preliminary work using microscale thermophoresis with AmGSTF1 and flavonoid 
inhibitors showed promising results and this may prove a useful method to obtain comparable 
binding constants for mutant and wild type proteins.  
 
8.4 Role of AmGSTF1 
 
While the work presented in this thesis has allowed for a better understanding of the mode of 
action of inhibitors for AmGSTF1, in particular their binding site within the protein, it is still only 
possible to speculate on how these molecules function to inhibit Multiple Herbicide Resistance. 
This work suggests that inhibition can occur either via blocking the H-site (in the case of flavonoid 
inhibitors) or via covalent modification in combination with blocking the H-site (in the case of 
CNBF). It has been shown that both classes of inhibitors are not inherently phytotoxic to black 
grass but are able to act as synergists alongside herbicides to restore herbicidal activity. That the 
inhibitors give a response both in vitro against AmGSTF1 and in vivo as synergists supports the 
hypothesis that it is their action against AmGSTF1 which causes this response.  
However, the role of AmGSTF1 in causing Multiple Herbicide Resistance is still poorly 
understood. Future work should focus on unravelling the overall function AmGSTF1 is playing in 
MHR. Preliminary work carried out in this thesis suggests that herbicides do not bind to 
AmGSTF1 supporting previous work that suggested that AmGSTF1 does not cause MHR by direct 
detoxification of herbicides.34 As inhibitors have been identified as binding within the H-site this 
suggests possible roles for AmGSTF1 within MHR. It is possible that they are acting to inhibit 
activity of the protein towards an as yet unidentified molecule by blocking the H-site, supporting 
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the hypothesis that the protein might be acting in a signalling role. Alternatively AmGSTF1 may 
be involved in protein-protein interactions as identified for HsGSTP1 in MDR. Future work should 
focus on identifying whether any other proteins may be involved in the MHR pathway. In this 
case the inhibitors may be acting in a manner similar to those for MDR by preventing these 
protein-protein interactions from occurring. 
By further understanding the role AmGSTF1 is playing will in turn allow for better design of 
inhibitors targeting this mode of action. It will also allow for a greater understanding of the role 
played by both CNBF and the flavonoid inhibitors. Only when there is a deeper understanding 
of the role played by AmGSTF1 in Multiple Herbicide Resistance will it be possible to fully 
determine the mechanism by which these inhibitors function. 
  
 139 
 
References 
 
1. Quastel, J. H. 2,4-Dichlorophenoxyacetic Acid (2,4-D) as a Selective Herbicide. in 
Agricultural control chemicals 1, 244–249 (American Chemical Society, 1950). 
2. Davies, J. & Caseley, J. C. Herbicide safeners: a review. Pestic Sci 55, 1043–1058 (1999). 
3. Sherwani, S. I., Arif, I. A. & Khan, H. A. Modes of Action of Different Classes of Herbicides. 
Herbicides, Physiology of Action, and Safety (2015). doi:10.5772/61779 
4. Délye, C., Jasieniuk, M. & Le Corre, V. Deciphering the evolution of herbicide resistance in 
weeds. Trends Genet. 29, 649–658 (2013). 
5. Weed Science Society of America-Herbicide Site of Action (SOA) Classification List. (2018). 
6. Sandermann, H. Plant metabolism of xenobiotics. Trends in Biochem Sci 17, 82–84 (1992). 
7. Yuan, J. S., Tranel, P. J. & Stewart Jr, C. N. Non-target-site herbicide resistance: a family 
business. Trends Plant Sci. 12, 6–13 (2007). 
8. Schuler, M. A. & Werck-Reichhart, D. Functional Genomics of P450S. Annu Rev Plant Biol 
54, 629–667 (2003). 
9. Schuler, M. A. Plant Cytochrome P450 Monooxygenases. Crit Rev Plant Sci 15, 235–284 
(1996). 
10. L. Lamoureux, G., H. Shimabukuro, R. & Stuart Frear, D. Glutathione and glucoside 
conjugation in herbicide selectivity. in Herbicide Resistance in Weeds and Crops 227–261 
(1991). doi:10.1016/B978-0-7506-1101-5.50020-6 
11. Bowles, D., Isayenkova, J., Lim, E.-K. & Poppenberger, B. Glycosyltransferases: managers 
of small molecules. Curr. Opin. Plant. Biol 8, 254–263 (2005). 
12. Lamoureux, G. L. & Rusness, D. G. Tridiphane [2-(3,5-dichlorophenyl)-2-(2,2,2-
trichloroethyl)oxirane] an atrazine synergist: Enzymatic conversion to a potent glutathione 
S-transferase inhibitor. Pest. Biochem. Physiol. 26, 323–342 (1986). 
13. Martinoia, E., Grill, E., Tommasini, R., Kreuz, K. & Amrhein, N. ATP-dependent glutathione 
S-conjugate ‘export’ pump in the vacuolar membrane of plants. Nature 364, 247–249 
(1993). 
14. Heap, I. The International survey of herbicide resistant weeds. (2018). 
15. Powles, S. B. & Yu, Q. Evolution in Action: Plants Resistant to Herbicides. Annu. Rev. Plant. 
Biol. 61, 317–347 (2010). 
16. Vila-Aiub, M. M., Neve, P. & Powles, S. B. Fitness costs associated with evolved herbicide 
resistance alleles in plants. New Phytol. 184, 751–767 (2009). 
References 
 
140 
 
17. Pang, S. S., Duggleby, R. G., Schowen, R. L. & Guddat, L. W. The crystal structures of 
Klebsiella pneumoniae acetolactate synthase with enzyme-bound cofactor and with an 
unusual intermediate. J. Biol. Chem. 279, 2242–2253 (2004). 
18. McCourt, J. A., Pang, S. S., King-Scott, J., Guddat, L. W. & Duggleby, R. G. Herbicide-binding 
sites revealed in the structure of plant acetohydroxyacid synthase. Proc Natl Acad Sci U S 
A 103, 569–573 (2006). 
19. Gronwald, J. W. Lipid Biosynthesis Inhibitors. Weed Sci. 39, 435–449 (1991). 
20. Zhang, H. L., Tweel, B. & Tong, L. Molecular basis for the inhibition of the 
carboxyltransferase domain of acetyl-coenzyme-A carboxylase by haloxyfop and diclofop. 
Proc. Natl. Acad. Sci. U. S. A. 101, 5910–5915 (2004). 
21. Délye, C., Zhang, X.-Q., Michel, S., Matéjicek, A. & Powles, S. B. Molecular bases for 
sensitivity to acetyl-coenzyme A carboxylase inhibitors in black-grass. Plant Physiol. 137, 
794–806 (2005). 
22. Dill, G. M. Glyphosate-resistant crops: history, status and future. Pest Manag Sci 61, 219–
224 (2005). 
23. Sammons, R. D. & Gaines, T. A. Glyphosate resistance: state of knowledge. Pest Manag Sci 
70, 1367–1377 (2014). 
24. Healy-Fried, M. L., Funke, T., Priestman, M. A., Han, H. & Schönbrunn, E. Structural basis 
of glyphosate tolerance resulting from mutations of Pro101 in Escherichia coli 5-
enolpyruvylshikimate-3-phosphate synthase. J. Biol. Chem. 282, 32949–32955 (2007). 
25. Gaines, T. A. et al. Gene amplification confers glyphosate resistance in Amaranthus 
palmeri. Proc. Natl. Acad. Sci. U. S. A. 107, 1029–1034 (2010). 
26. Feng, P. C. C. et al. Investigations into glyphosate-resistant horseweed (Conyza 
canadensis): retention, uptake, translocation, and metabolism. Weed Sci. 52, 498–505 
(2004). 
27. Yu, Q., Han, H., Nguyen, L., Forster, J. W. & Powles, S. B. Paraquat resistance in a Lolium 
rigidum population is governed by one major nuclear gene. Theor. Appl. Genet. 118, 1601–
1608 (2009). 
28. Plaisance, K. L. & Gronwald, J. W. Enhanced catalytic constant for glutathione S-transferase 
(atrazine) activity in an atrazine-resistant Abutilon theophrasti biotype. Pest. Biochem. 
Physiol. 63, 34–49 (1999). 
29. Powles, S. B., Wilson, H. P. & Westwood, J. H. Herbicide cross resistance and multiple 
resistance in plants. Available at: https://hracglobal.com/files/Herbicide-Cross-
Resistance-and-Multiple-Resistance-in-Plants.pdf. (Accessed: 4th January 2019) 
References 
 
141 
 
30. Whaley, C. M., Wilson, H. P. & Westwood, J. H. A New Mutation in Plant ALS Confers 
Resistance to Five Classes of ALS-Inhibiting Herbicides. Weed Science 55, 83–90 (2007). 
31. Kemp, M. S. (University of B., Moss, S. R. & Thomas, T. H. Herbicide resistance in 
Alopecurus myosuroides. ACS. Symp. Ser. Am. Chem. Soc. (1990). 
32. Letouzé, A. & GASQUEZ, J. Enhanced activity of several herbicide-degrading enzymes: a 
suggested mechanism responsible for multiple resistance in blackgrass (Alopecurus 
myosuroides Huds.). Agronomie 23, 601–608 (2003). 
33. Cummins, I., Cole, D. J. & Edwards, R. A role for glutathione transferases functioning as 
glutathione peroxidases in resistance to multiple herbicides in black-grass. Plant J. 18, 285–
292 (1999). 
34. Cummins, I. et al. Key role for a glutathione transferase in multiple-herbicide resistance in 
grass weeds. Proc. Natl. Acad. Sci. U.S.A. 110, 5812–5817 (2013). 
35. Öztetik, E. A Tale of Plant Glutathione S-Transferases: Since 1970. Bot. Rev 74, 419–437 
(2008). 
36. Sappl, P. G. et al. The Arabidopsis glutathione transferase gene family displays complex 
stress regulation and co-silencing multiple genes results in altered metabolic sensitivity to 
oxidative stress: Genomic and reverse genetic analysis of plant GSTs. Plant J. 58, 53–68 
(2009). 
37. Basantani, M. & Srivastava, A. Plant glutathione transferases — a decade falls short. Can. 
J. Bot. 85, 443–456 (2007). 
38. Frova, C. The plant glutathione transferase gene family: Genomic structure, functions, 
expression and evolution. Physiol. Plant. 119, 469–479 (2003). 
39. Salinas, A. E. & Wong, M. G. Glutathione S-transferases--a review. Curr. Med. Chem. 6, 
279–309 (1999). 
40. Bartling, D., Radzio, R., Steiner, U. & Weiler, E. W. A glutathione S-transferase with 
glutathione-peroxidase activity from Arabidopsis thaliana. Eur. J. Biochem. 216, 579–586 
(1993). 
41. Eshdat, Y., Holland, D., Faltin, Z. & Ben-Hayyim, G. Plant glutathione peroxidases. Physiol. 
Plant. 100, 234–240 (1997). 
42. Cummins, I., Moss, S., Cole, D. J. & Edwards, R. Glutathione transferases in herbicide-
resistant and herbicide-susceptible black-grass (Alopecurus myosuroides). Pestic. Sci. 51, 
244–250 (1997). 
43. Thom, R., Dixon, D. P., Edwards, R., Cole, D. J. & Lapthorn, A. J. The structure of a zeta class 
glutathione S-transferase from Arabidopsis thaliana: characterisation of a GST with novel 
References 
 
142 
 
active-site architecture and a putative role in tyrosine catabolism1. J Mol Biol 308, 949–
962 (2001). 
44. Marrs, K. A., Alfenito, M. R., Lloyd, A. M. & Walbot, V. A glutathione S-transferase involved 
in vacuolar transfer encoded by the maize gene Bronze-2. Nature 375, 397–400 (1995). 
45. Chen, Z., Silva, H. & Klessig, D. F. Active oxygen species in the induction of plant systemic 
acquired resistance by salicylic acid. Science 262, 1883–1886 (1993). 
46. Kauss, H. & Jeblick, W. Pretreatment of Parsley Suspension Cultures with Salicylic Acid 
Enhances Spontaneous and Elicited Production of H2O2. Plant Physiol. 108, 1171–1178 
(1995). 
47. Dudler, R., Hertig, C., Rebmann, G., Bull, J. & Mauch, F. A pathogen-induced wheat gene 
encodes a protein homologous to glutathione-S-transferases. Mol. Plant Microbe Interact. 
4, 14–18 (1991). 
48. Litwack, G., Ketterer, B. & Arias, I. M. Ligandin: a Hepatic Protein which Binds Steroids, 
Bilirubin, Carcinogens and a Number of Exogenous Organic Anions. Nature 234, 466–467 
(1971). 
49. Jones, A. M. Auxin-Binding Proteins. Annu. Rev. Plant. Physiol. Plant Mol. Biol 45, 393–420 
(1994). 
50. Ahmad, L., Rylott, E. L., Bruce, N. C., Edwards, R. & Grogan, G. Structural evidence for 
Arabidopsis glutathione transferase AtGSTF2 functioning as a transporter of small organic 
ligands. FEBS Open Bio 7, 122–132 (2017). 
51. Fernández-Cañón, J. M. & Peñalva, M. A. Characterization of a fungal maleylacetoacetate 
isomerase gene and identification of its human homologue. J. Biol. Chem. 273, 329–337 
(1998). 
52. Johansson, A. S. & Mannervik, B. Human glutathione transferase A3-3, a highly efficient 
catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J. 
Biol. Chem. 276, 33061–33065 (2001). 
53. Kanaoka, Y. et al. Cloning and crystal structure of hematopoietic prostaglandin D synthase. 
Cell 90, 1085–1095 (1997). 
54. Paumi, C. M., Smitherman, P. K., Townsend, A. J. & Morrow, C. S. Glutathione S-
transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferator-
activated receptor gamma (PPAR gamma) ligand, 15-deoxy-delta 12,14prostaglandin J2 
(15-d-PGJ2). Biochemistry 43, 2345–2352 (2004). 
55. Jowsey, I. R., Smith, S. A. & Hayes, J. D. Expression of the murine glutathione S-transferase 
alpha3 (GSTA3) subunit is markedly induced during adipocyte differentiation: activation of 
References 
 
143 
 
the GSTA3 gene promoter by the pro-adipogenic eicosanoid 15-deoxy-Delta12,14-
prostaglandin J2. Biochem. Biophys. Res. Commun. 312, 1226–1235 (2003). 
56. Neuefeind, T., Huber, R., Dasenbrock, H., Prade, L. & Bieseler, B. Crystal structrure of 
herbicide-detoxifying maize glutathione S-transferase-I in complex with 
lactoylglutathione: evidence for an induced-fit mechanism. J. Mol. Biol. 274, 446–453 
(1997). 
57. Valenzuela-Chavira, I. et al. Insights into ligand binding to a glutathione S-transferase from 
mango: Structure, thermodynamics and kinetics. Biochimie 135, 35–45 (2017). 
58. Tossounian, M. A. et al. Disulfide bond formation protects Arabidopsis thaliana glutathione 
transferase tau 23 from oxidative damage. Biochim Biophys Acta Gen Subj 1862, 775–789 
(2018). 
59. Tars, K. et al. Structural basis of the suppressed catalytic activity of wild-type human 
glutathione transferase T1-1 compared to its W234R mutant. J Mol Biol 355, 96–105 
(2006). 
60. Do, H. et al. Structural understanding of the recycling of oxidized ascorbate by 
dehydroascorbate reductase (OsDHAR) from Oryza sativa L. japonica. Sci Rep 6, 19498–
19498 (2016). 
61. Bodra, N. et al. Arabidopsis thaliana dehydroascorbate reductase 2: Conformational 
flexibility during catalysis. Sci Rep 7, 42494–42494 (2017). 
62. Lallement, P. A. et al. Structural and enzymatic insights into Lambda glutathione 
transferases from Populus trichocarpa, monomeric enzymes constituting an early 
divergent class specific to terrestrial plants. Biochem J 462, 39–52 (2014). 
63. Dirr, H., Reinemer, P. & Huber, R. X-ray crystal structures of cytosolic glutathione S-
transferases. Eur. J. Biochem. 220, 645–661 (1994). 
64. Holmgren, A., Söderberg, B. O., Eklund, H. & Brändén, C. I. Three-dimensional structure of 
Escherichia coli thioredoxin-S2 to 2.8 A resolution. Proc. Natl. Acad. Sci. U.S.A. 72, 2305–
2309 (1975). 
65. Eklund, H. et al. Structure of oxidized bacteriophage T4 glutaredoxin (thioredoxin). 
Refinement of native and mutant proteins. J. Mol. Biol. 228, 596–618 (1992). 
66. Epp, O., Ladenstein, R. & Wendel, A. The Refined Structure of the Selenoenzyme 
Glutathione Peroxidase at 0.2-nm Resolution. Eur. J. Biochem. 133, 51–69 (1983). 
67. Erhardt, J. & Dirr, H. Native Dimer Stabilizes the Subunit Tertiary Structure of Porcine Class 
pi Glutathione S-transferase. Eur. J. Biochem. 230, 614–620 (1995). 
References 
 
144 
 
68. Caccuri, A. M. et al. Catalytic Mechanism and Role of Hydroxyl Residues in the Active Site 
of Theta Class Glutathione S-Transferases Investigation of Ser-9 and Tyr-113 in a 
Glutathione-S-Transferase from the Australian Sheep Blowfly, Lucila cuprina. J. Biol. Chem. 
272, 29681–29686 (1997). 
69. Dixon, D. P., Davis, B. G. & Edwards, R. Functional divergence in the glutathione transferase 
superfamily in plants. Identification of two classes with putative functions in redox 
homeostasis in Arabidopsis thaliana. J. Biol. Chem. 277, 30859–30869 (2002). 
70. Armstrong, R. N. Glutathione S-Transferases: Structure and Mechanism of an Archetypical 
Detoxication Enzyme. in Advances in Enzymology and Related Areas of Molecular Biology 
(ed. Meister, A.) 1–44 (John Wiley & Sons, Inc., 1994). 
71. Dixon, D. P., Lapthorn, A. & Edwards, R. Plant glutathione transferases. Genome Biol. 3, 
reviews3004.1 (2002). 
72. McTigue, M. A., Williams, D. R. & Tainer, J. A. Crystal Structures of a Schistosomal Drug and 
Vaccine Target: Glutathione S-Transferase from Schistosoma japonica and its Complex 
with the Leading Antischistomal Drug Praziquantel. J. Mol. Biol. 246, 21–27 (1995). 
73. Graminski, G. F., Zhang, P., Sesay, M. A., Ammon, H. L. & Armstrong, R. N. Formation of the 
1-(S-glutathionyl)-2,4,6-trinitrocyclohexadienate anion at the active site of glutathione S-
transferase: evidence for enzymic stabilization of sigma-complex intermediates in 
nucleophilic aromatic substitution reactions. Biochemistry 28, 6252–6258 (1989). 
74. Wilce, M. C. J. & Parker, M. W. Structure and function of glutathione S-transferases. 
Biochim. Biophys. Acta. 1205, 1–18 (1994). 
75. Labrou, N. E., Mello, L. V. & Clonis, Y. D. Functional and structural roles of the glutathione-
binding residues in maize (Zea mays) glutathione S-transferase I. Biochem. J. 358, 101–110 
(2001). 
76. Moss, S. Rothamsted Research Report. (2013). 
77. Hicks, H. L. et al. The factors driving evolved herbicide resistance at a national scale. Nat. 
Ecol. Evol. 2, 529 (2018). 
78. Geissel, H. Problem Weeds in Cereals. (2004). Available at: 
http://www.crsbooks.net/agscience/weeds.html. (Accessed: 4th January 2019) 
79. Anderson, M. P. & Gronwald, J. W. Atrazine Resistance in a Velvetleaf (Abutilon 
theophrasti) Biotype Due to Enhanced Glutathione S-Transferase Activity. Plant Physiol. 
96, 104–109 (1991). 
80. Mahajan, S. & Atkins, W. M. The chemistry and biology of inhibitors and pro-drugs targeted 
to glutathione S-transferases. Cell. Mol. Life Sci. 62, 1221–1233 (2005). 
References 
 
145 
 
81. Tew, K. D. et al. The Role of Glutathione S-transferase P in signaling pathways and S-
glutathionylation in Cancer. Free Radic Biol Med 51, 299–313 (2011). 
82. Ricci, G. et al. Structural Flexibility Modulates the Activity of Human Glutathione 
Transferase P1-1 Role of Helix 2 Flexibility in the Catalytic Mechanism. J. Biol. Chem. 271, 
16187–16192 (1996). 
83. De Luca, A., Federici, L., De Canio, M., Stella, L. & Caccuri, A. M. New Insights into the 
Mechanism of JNK1 Inhibition by Glutathione Transferase P1-1. Biochemistry 51, 7304–
7312 (2012). 
84. Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug 
resistance. Oncogene 22, 7369–7375 (2003). 
85. Straker, H. E. Chemical methods towards the investigation of multiple herbicide resistance 
in black grass (Alopecurus myosuroides). (Durham University, 2014). 
86. Schwarz, M. Exploring the molecular basis of multiple herbicide resistance in black grass 
(Alopecurus myosuroides). (Durham University, 2017). 
87. Freitag-Pohl, S. Unpublished results. 
88. Protein identification and analysis tools on the expasy server. in The Proteomics Protocols 
Handbook (ed. Walker, J. M.) 571–607 (Humana Press, 2005). 
89. Dixon, D. P., Hawkins, T., Hussey, P. J. & Edwards, R. Enzyme activities and subcellular 
localization of members of the Arabidopsis glutathione transferase superfamily. J Exp Bot 
60, 1207–1218 (2009). 
90. Grøftehauge, M. K., Hajizadeh, N. R., Swann, M. J. & Pohl, E. Protein–ligand interactions 
investigated by thermal shift assays (TSA) and dual polarization interferometry (DPI). Acta. 
Crystallogr. D Struct. Biol. 71, 36–44 (2015). 
91. Habig, W. H., Pabst, M. J. & Jakoby, W. B. Glutathione S-transferases. The first enzymatic 
step in mercapturic acid formation. J. Biol. Chem. 249, 7130–7139 (1974). 
92. Armstrong, R. N. Glutathione S-transferases: reaction mechanism, structure, and function. 
Chem. Res. Toxicol. 4, 131–140 (1991). 
93. Mosca, R. & Schneider, T. R. RAPIDO: a web server for the alignment of protein structures 
in the presence of conformational changes. Nucleic Acids Res 36, W42–W46 (2008). 
94. Mosca, R., Brannetti, B. & Schneider, T. R. Alignment of protein structures in the presence 
of domain motions. BMC Bioinformatics 9, 352 (2008). 
95. Kabsch, W. XDS. Acta. Crystallogr. D Struct. Biol. 66, 125–132 (2010). 
96. Evans, P. R. An introduction to data reduction: space-group determination, scaling and 
intensity statistics. Acta. Crystallogr. D Struct. Biol. 67, 282–292 (2011). 
References 
 
146 
 
97. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta. 
Crystallogr. D Struct. Biol. 69, 1204–1214 (2013). 
98. McCoy, A. J. et al. Phaser crystallographic software. J Appl Cryst 40, 658–674 (2007). 
99. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta. Crystallogr. 
D Struct. Biol. 67, 235–242 (2011). 
100. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. 
Acta. Crystallogr. D Struct. Biol. 66, 486–501 (2010). 
101. Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and 
guidelines for its use. Acta. Crystallogr. D Struct. Biol.jligan 60, 2184–2195 (2004). 
102. Lebedev, A. A. et al. JLigand: a graphical tool for the CCP4 template-restraint library. Acta. 
Crystallogr. D Struct. Biol. 68, 431–440 (2012). 
103. Gorrec, F. The MORPHEUS protein crystallization screen. J Appl Cryst 42, 1035–1042 
(2009). 
104. Cowtan, K. The Buccaneer software for automated model building. 1. Tracing protein 
chains. Acta. Crystallogr. D Struct. Biol. 62, 1002–1011 (2006). 
105. Long, F. et al. AceDRG: a stereochemical description generator for ligands. Acta Crystallogr 
D Struct Biol 73, 112–122 (2017). 
106. Fiser, A. & Šali, A. Modeller: Generation and Refinement of Homology-Based Protein 
Structure Models. in Methods in Enzymology 374, 461–491 (Academic Press, 2003). 
107. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W. & Taylor, R. D. Improved protein-
ligand docking using GOLD. Proteins 52, 609–623 (2003). 
108. Niesen, F. H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to 
detect ligand interactions that promote protein stability. Nat Protoc 2, 2212–2221 (2007). 
109. Matulis, D., Kranz, J. K., Salemme, F. R. & Todd, M. J. Thermodynamic Stability of Carbonic 
Anhydrase:  Measurements of Binding Affinity and Stoichiometry Using ThermoFluor. 
Biochemistry 44, 5258–5266 (2005). 
110. Bullock, A. N. et al. Structural Basis of Inhibitor Specificity of the Human Protooncogene 
Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase. J. Med. Chem. 
48, 7604–7614 (2005). 
111. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein 
stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A 103, 
15835–15840 (2006). 
112. Palusiak, M. & Grabowski, S. J. Methoxy group as an acceptor of proton in hydrogen bonds. 
J. Mol. Struct. 642, 97–104 (2002). 
References 
 
147 
 
113. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. 
Mol. Biol. 372, 774–797 (2007). 
114. Fabrini, R. et al. Monomer-dimer equilibrium in glutathione transferases: a critical re-
examination. Biochemistry 48, 10473–10482 (2009). 
115. Nair, D. P. et al. The Thiol-Michael Addition Click Reaction: A Powerful and Widely Used 
Tool in Materials Chemistry. Chem. Mater. 26, 724–744 (2014). 
116. Fluorescence Anisotropy. in Principles of Fluorescence Spectroscopy (ed. Lakowicz, J. R.) 
353–382 (Springer US, 2006). doi:10.1007/978-0-387-46312-4_10 
117. Okamura, T. et al. Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal 
Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase 
(JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor 
Cells. J. Biol. Chem. 290, 30866–30878 (2015). 
118. Thom, R. et al. Structure of a Tau Class Glutathione S-Transferase from Wheat Active in 
Herbicide Detoxification,. Biochemistry 41, 7008–7020 (2002). 
119. Cummins, I. et al. Cloning, characterization and regulation of a family of phi class 
glutathione transferases from wheat. Plant Mol Biol 52, 591–603 (2003). 
120. Prade, L., Huber, R. & Bieseler, B. Structures of herbicides in complex with their detoxifying 
enzyme glutathione S-transferase - explanations for the selectivity of the enzyme in plants. 
Structure 6, 1445–1452 (1998). 
121. Oakley, A. J. et al. The crystal structures of glutathione S-transferases isozymes 1–3 and 1–
4 from Anopheles dirus species B. Protein Sci 10, 2176–2185 (2001). 
122. Cole, D. J. Detoxification and activation of agrochemicals in plants. Pestic. Sci. 42, 209–222 
(1994). 
123. Oakley, A. J. et al. The three-dimensional structure of the human Pi class glutathione 
transferase P1-1 in complex with the inhibitor ethacrynic acid and its glutathione 
conjugate. Biochemistry 36, 576–585 (1997). 
124. Neuefeind, T. et al. Cloning, sequencing, crystallization and X-ray structure of glutathione 
S-transferase-III from Zea mays var. mutin: a leading enzyme in detoxification of maize 
herbicides. J. Mol. Biol. 274, 577–587 (1997). 
125. Honegger, A., Spinelli, S., Cambillau, C. & Plückthun, A. A mutation designed to alter crystal 
packing permits structural analysis of a tight-binding fluorescein-scFv complex. Protein Sci. 
14, 2537–2549 (2005). 
126. Kelly, S. M., Jess, T. J. & Price, N. C. How to study proteins by circular dichroism. Biochim. 
Biophys. Acta 1751, 119–139 (2005). 
References 
 
148 
 
127. Greenfield, N. J. Using circular dichroism spectra to estimate protein secondary structure. 
Nat Protoc 1, 2876–2890 (2006). 
128. Lin, S., Lo, Y., Tam, M. & Liaw, Y. PDB 1VF3, To be published. 
129. Abuhammad, A. et al. “To Cross-Seed or Not To Cross-Seed”: A Pilot Study Using Metallo-
β-lactamases. Cryst. Growth Des. 17, 913–924 (2017). 
130. Ireton, G. C. & Stoddard, B. L. Microseed matrix screening to improve crystals of yeast 
cytosine deaminase. Acta. Crystallogr. D Struct. Biol. 60, 601–605 (2004). 
131. D’Arcy, A., Bergfors, T., Cowan-Jacob, S. W. & Marsh, M. Microseed matrix screening for 
optimization in protein crystallization: what have we learned? Acta Cryst F 70, 1117–1126 
(2014). 
132. D’Arcy, A., Villard, F. & Marsh, M. An automated microseed matrix-screening method for 
protein crystallization. Acta. Crystallogr. D Struct. Biol. 63, 550–554 (2007). 
133. Federici, L. et al. Structural basis for the binding of the anticancer compound 6-(7-nitro-
2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. Cancer Res 69, 
8025–8034 (2009). 
134. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a 
genetic algorithm for flexible docking. J. Mol. Biol. 267, 727–748 (1997). 
135. The GOLD User Guide (5.6.3 GOLD Release) - The Cambridge Crystallographic Data Centre 
(CCDC). Available at: https://www.ccdc.cam.ac.uk/support-and-
resources/ccdcresources/44a5b30d4b6c41cc98b7f01962542ff4.pdf. (Accessed: 28th 
October 2018) 
136. Korb, O., Stützle, T. & Exner, T. E. Empirical Scoring Functions for Advanced Protein−Ligand 
Docking with PLANTS. J. Chem. Inf. Model. 49, 84–96 (2009). 
137. Lovell, S. C., Word, J. M., Richardson, J. S. & Richardson, D. C. The penultimate rotamer 
library. Proteins 40, 389–408 (2000). 
138. Reinemer, P. et al. Three-dimensional structure of glutathione S-transferase from 
Arabidopsis thaliana at 2.2 A resolution: structural characterization of herbicide-
conjugating plant glutathione S-transferases and a novel active site architecture. J Mol Biol 
255, 289–309 (1996). 
139. Pégeot, H. et al. Structural plasticity among glutathione transferase Phi members: natural 
combination of catalytic residues confers dual biochemical activities. FEBS J 284, 2442–
2463 (2017). 
140. Pieper, U. et al. ModBase, a database of annotated comparative protein structure models 
and associated resources. Nucl. Acids Res. 42, D336–D346 (2014). 
References 
 
149 
 
141. DiMaio, F. et al. Improved low-resolution crystallographic refinement with Phenix and 
Rosetta. Nat Meth 10, 1102–1104 (2013). 
142. Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. 
Method and assessment of docking accuracy. J. Med. Chem. 47, 1739–1749 (2004). 
143. Bowers, K. et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity 
Clusters. in ACM/IEEE SC 2006 Conference (SC’06) 43–43 (IEEE, 2006). 
doi:10.1109/SC.2006.54 
144. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new 
ENDscript server. Nucl. Acids Res. 42, W320–W324 (2014). 
 150 
 
Appendix A: Biophysical Data 
 
B1: Complete data from thermal shift assays and CDNB inihibtion assays. Data from CDNB assays 
performed by Maria Schwarz (MS compounds) or Hannah Straker (COM and SYG compounds). N.D. 
shows where data was not determined. 
 
Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
COMMERICALLY AVAILABLE FLAVONOIDS 
COM1 
 
0.4 1.7 5.3 N.D. 42 N.D. 
COM2 
 
0.1 0.1 0.2 N.D. 70 96 
COM3 
 
0.4 1.4 4.8 N.D. N.D. N.D. 
COM4 
 
0.5 -0.1 -0.7 N.D. N.D. N.D. 
COM5 
 
0.4 0.0 -0.2 N.D. N.D. 61 
COM6 
 
 
0.3 0 -0.2 N.D. N.D. 14 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
COM7 
 
0.2 0.5 0.5 N.D. N.D. 69 
COM8 
 
0.4 0.2 0.1 N.D. 25 98 
SYNGENTA LIBRARY COMPOUNDS 
SYG1 
 
0.1 0 0.1 N.D. 6 N.D. 
SYG2 
 
0.3 0.4 0.6 N.D. 52 N.D. 
SYG3 
 
0.5 0.4 -0.4 N.D. 71 N.D. 
SYG4 
O
O
NO2
O  
0.6 0.5 0.9 N.D. 8 N.D. 
SYG5 
 
0.2 0.2 0.7 N.D. 6 N.D. 
SYG6 
 
0.1 0.3 0.5 N.D. 7 N.D. 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
SYG7 
 
0.2 0 0.7 N.D. 2 N.D. 
SYG8 
 
0.2 2.2 1.1 N.D. 100 N.D. 
SYG9 
 
-0.3 -0.2 0.2 N.D. 40 N.D. 
SYG10 
 
0 0.2 0.1 N.D. 12 N.D. 
SYG11 
 
0.1 0.1 0.4 N.D. 7 N.D. 
MARIA SCHWARZ COMPOUNDS 
MS-1-109 
 
0.1 0.2 0.2 N.D. 17 N.D. 
MS-1-12-1 
 
0.2 0.1 0.4 N.D. 0 55 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-12-2 
 
0.2 0.2 0 N.D. 8 59 
MS-1-123 
 
0.2 0 0.2 N.D. 25 98 
MS-1-129 
 
0.2 0.4 0.6 N.D. 25 N.D. 
MS-1-134 
 
0.2 0.5 1.2 71 99 N.D. 
MS-1-134 
E1 
E1 
0.2 0.2 0.5 46 N.D. N.D. 
MS-1-134 
E2 
E2 
0.2 0.5 1.2 68 N.D. N.D. 
MS-1-139 
 
0.1 0.3 1.1 6 39 N.D. 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-16 
 
0 0.2 0.1 N.D. N.D. 16 
MS-1-18 
 
0.1 0.2 0.2 N.D. 0 37 
MS-1-19 
 
0.2 0.1 0.3 N.D. 12 67 
MS-1-20 
 
0.2 0.2 0.1 N.D. N.D. 12 
MS-1-46 
 
0.3 0.3 0.4 N.D. 32 5 
MS-1-51 
 
 
 
0.2 0.3 0.3 N.D. 20 70 
MS-1-53-10 
 
0.3 0.1 0 N.D. 12 80 
MS-1-53-2 
OMeO
OMe O
F
 
 
0.2 0.3 0.3 N.D. 23 78 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-53-4 
 
0.2 0.2 0.7 N.D. 15 100 
MS-1-53-6 
 
0.1 0.1 -0.1 N.D. 12 87 
MS-1-6 
 
0.1 0.2 0 N.D. N.D. 13 
MS-1-66A 
 
0.3 0.2 -0.2 N.D. 24 79 
MS-1-66-B 
 
0.3 0 0.2 N.D. 11 100 
MS-1-66C 
 
0.3 0.2 0.3 N.D. 12 33 
MS-1-66-D 
 
0.3 0.3 0.3 N.D. 20 58 
MS-1-71 
 
 
0.2 0.3 0.2 N.D. 10 50 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-1-71 
 
0.2 0.3 0.1 N.D. 10 50 
MS-1-79 
 
-0.1 0 0.1 N.D. N.D. N.D. 
MS-1-79 
 
0.2 0.0 0.0 N.D. 22 49 
MS-1-80 
 
0.2 0.5 0.1 N.D. 19 56 
MS-1-82 
O
O
MeO
OMe
O
N
H
 
0.2 0.1 0.3 N.D. 34 64 
MS-3-12 
 
0.3 0.2 0.5 N.D. 5 N.D. 
MS-3-128 
 
-0.1 -0.2 -0.3 N.D. 8 53 
MS-3-13 
 
0.2 0.2 1.1 N.D. 14 N.D. 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-3-132A 
 
-0.1 -0.1 0 N.D. 6 59 
MS-3-140 
 
-0.1 -0.2 -0.2 N.D. 11 64 
MS-3-21 
 
0.2 0.4 2.3 4 69 N.D. 
MS-3-22 
 
0.3 0.7 2.9 40 86 N.D. 
MS-3-24 
 
0.4 0.7 0.9 58 97 N.D. 
MS-3-24 
 
0.2 0.7 1.43 75 90 N.D. 
MS-3-41 
 
-0.1 0 0 N.D. 9 36 
MS-3-42 
 
0.1 0.2 0.3 N.D. 14 35 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-3-43 
 
0.2 0.1 0.3 N.D. 11 60 
MS-3-50 
 
0.2 0.2 0.9 40 94 N.D. 
MS-4-30-1 
 
-0.4 -0.5 -0.5 N.D. 23 83 
MS-4-30-2 
 
0.4 0.4 0.1 N.D. 23 61 
MS-4-4 
 
-0.2 -0.3 -0.4 N.D. 13 53 
MS-4-48 
 
0.8 1.8 2.8 56 95 N.D. 
MS-4-50 
 
0.3 0.4 0.9 N.D. 26 89 
MS-4-8-1 
 
0 0 -0.1 N.D. 19 64 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-4-8-2 
 
0 0 -0.2 N.D. 9 58 
MS-4-9 
 
-0.1 -0.1 -0.3 N.D. 8 64 
MS-5-30 
 
0.7 1.6 4.3 52 95 N.D. 
MS-5-31 
 
0.6 0.5 0.7 N.D. 30 92 
MS-5-34 
 
1.2 1.3 2.1 N.D. 13 93 
MS-5-35 
 
0.7 0.8 1.0 N.D. 14 98 
MS-5-6 
 
 
 
0.7 1.6 3.8 67 98 N.D. 
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Compound 
Code 
Structure 
Thermal Shift 
Assay ΔT/ °C 
CDNB Inhibition 
/ % 
1 
μM 
10 
μM 
100 
μM 
1 
μM 
10 
μM 
100 
μM 
MS-5-7 
 
1.3 1.7 4.2 72 100 N.D. 
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Appendix B: Crystallographic Tables 
 
B1: Crystallographic data tables for crystal structures of wild type AmGSTF1 (structures discussed in 
chapter 4) 
 AmGSTF1 WT 
apo 
AmGSTF1 WT  
covalent CNBF 
Data Collection 
Space Group P 63 2 2 P 63 2 2 
Unit cell 
dimensions [Å], [˚] 
a=b=103.69, 
c=78.77 
==90, =120 
a=b=104.088, c=78.82 
==90, =120 
Resolution (Å)a 51-1.53 (1.56-
1.53) 
59.34 -2.00 (2.05-2.00) 
Beamline DLS i04-1 DLS i04-1 
Rmergea 0.03434 
(0.7881) 
0.091 (0.734) 
rMeasa 0.036887 
(0.88657) 
0.098 (0.802) 
rPim (pooled 
Friedels)a 
0.010 (0.27) 0.041 (0.338) 
I / Ia 27.326 (1.992) 13.6 (2.5) 
Completeness (%)a 100.0 (99.46) 95.7 (97.5) 
Redundancy 12.568 (10.348)  
Refinement 
No. reflections 
(all/free) 
38090/1777 16633/868 
Rwork / Rfree 0.193/0.217 0.19/0.237 
No. of non H atoms    
Protein 
Water 
Ligand 
 
1540 
112 
- 
 
1495 
59 
12 
B-factors 
Protein 
Water 
Ligand 
 
32.1 
39.2 
- 
 
35.7 
39.2 
63.1 
R.m.s. deviations 
Bond lengths (Å) 
Bond angles (°) 
 
0.0187 
1.936 
 
0.0161 
1.698 
 
aThe values in parentheses correspond to the outermost resolution shell 
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B2: Crystallographic data tables for crystal structures of mutant AmGSTF1, and structures obtained by 
cross-seeding with mutant AmGSTF1 (structures discussed in chapter 5) 
 
 F122T (GSH 
bound) 
Y118S (GSH 
bound) 
AmGSTF1 WT 
(GSH bound) 
AmGSTF1 WT 
(NBF-GS bound) 
Data Collection 
Space Group I 41 2 2 I 41 2 2 I 41 2 2 I 41 2 2 
Unit cell dimensions 
[Å], [˚] 
a=b=112.590, 
c=104.300 
===90 
a=b=112.611, 
c=103.646 
===90 
a=b=112.877, 
c=101.246 
===90 
a=b=112.896, 
c=101.669 
===90 
Resolution (Å)a 43.62-2.78 
(2.93-2.78) 
79.63-2.60 
(2.72-2.60) 
79.82-2.25 
(2.32-2.25) 
35.70-2.30 
(2.38-2.30) 
Beamline DLS i24 DLS i04-1 DLS i04-1 DLS i04-1 
Rmergea 0.040 (0.456) 0.093 (1.017) 0.065 (0.821) 0.069 (0.971) 
rMeasa 0.057 (0.645) 0.096 (1.059) 0.066 (0.032) 0.070 (0.989) 
rPim a 0.040 (0.456) 0.019 (0.209) 0.013 (0.007) 0.019 (0.186) 
I / Ia 10.7 (1.3) 22.7 (3.7) 29.0 (3.9) 26.5 (3.7) 
Completeness (%)a 99.8 (100) 100 (99.5) 100.0 (99.9) 100 (98.6) 
Multiplicity 1.8 (1.6) 26.1 (22.1) 25.8 (21.4) 26.4 (22.4) 
Refinement 
No. reflections 
(all/free) 
8718/478 10565/ 549 15823/ 765 14901/ 715 
Rwork / Rfree 0.18/0.24 0.20/ 0.28b 0.23/ 0.28 0.21/ 0.25 
No. of non H atoms    
Protein 
Water 
Ligand 
 
1683 
6 
20 
 
1637 
18 
20 
 
1678 
24 
20 
 
1696 
8 
32 
B-factors 
Protein 
Water 
Ligand 
 
86.1 
76.2 
91.0 
 
41.9 
66.7 
69.5 
 
57.5 
52.5 
67.2 
 
69.6 
58.7 
72.8 
R.m.s. deviations 
Bond lengths (Å) 
Bond angles (°) 
 
0.0104 
1.587 
 
0.0174 
1.973 
 
0.0191 
2.108 
 
0.0179 
1.961 
 
aThe values in parentheses correspond to the outermost resolution shell 
bRefined using 5 cycles of automatic TLS paramaters 
  
 163 
 
Appendix C: Mass Spectrometry Data 
 
C1: Strep Tagged AmGSTF1 
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C2: Untagged AmGSTF1 
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C3: AmGSTF1 Y118S Mutant 
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C4: AmGSTF1 F122T Mutant 
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C5: AmGSTF1 Y118S F122T Mutant 
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Appendix D: Sequence Alignment 
 
Figure D1: Alignment of sequences of relevant GSTs. Sequences aligned using Clustal Omega.  Figure 
created using ESPript.144  
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Table D1: Sequence similarity to AmGSTF1. Calculated using NCBI BLAST. 
 
Protein Sequence Similarity to AmGSTF1/ % 
ZmGSTF1 63 
ZmGSTF3 47 
AtGSTF2 41 
AtGSTF8 42 
PtGSTF1 38 
PtGSTF2 38 
PtGSTF5 46 
PtGSTF7 52 
PtGSTF8 44 
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Appendix E: Protein and DNA 
Sequences 
 
AmGSTF1 Wild Type (strep tagged) Protein Sequence  
MASWSHPQFEKGLINHMAPVKVFGPAMSTNVARVTLCLEEVGAEYEVVNIDFNTMEHKSPEHLARNPFG
QIPAFQDGDLLLWESRAISKYVLRKYKTDEVDLLRESNLEEAAMVDVWTEVDAHTYNPALSPIVYQCLFNP
MMRGLPTDEKVVAESLEKLKKVLEVYEARLSKHSYLAGDFVSFADLNHFPYTFYFMATPHAALFDSYPHVKA
WWDRLMARPAVKKIAATMVPPKA 
(Strep tag is shown in red) 
AmGSTF1 Wild Type (strep tagged) Nucleotide Sequence  
ATGGCTAGCTGGAGCCACCCGCAGTTCGAGAAAGGCTTAATTAACCATATGGCGCCGGTGAAAGTTTT
TGGCCCGGCCATGAGCACCAACGTTGCACGTGTGACCCTGTGCCTGGAAGAAGTTGGTGCAGAATATG
AAGTTGTGAATATTGATTTCAACACCATGGAACATAAAAGCCCGGAACACCTGGCGCGCAATCCGTTTG
GCCAGATCCCGGCCTTCCAGGATGGTGATCTGCTGCTGTGGGAAAGTCGTGCAATTAGCAAATATGTTC
TGCGCAAATATAAAACCGATGAAGTTGATCTGCTGCGTGAAAGCAACCTGGAAGAAGCAGCGATGGT
GGATGTTTGGACCGAAGTTGATGCCCATACCTATAATCCGGCACTGAGCCCGATCGTGTATCAGTGTCT
GTTTAACCCGATGATGCGCGGCCTGCCGACCGATGAAAAAGTTGTTGCAGAAAGCCTGGAAAAACTGA
AAAAAGTGCTGGAAGTTTATGAAGCGCGTCTGAGCAAACACAGCTATCTGGCCGGTGATTTCGTTAGC
TTTGCAGATCTGAATCATTTCCCGTATACCTTTTATTTCATGGCAACCCCGCACGCGGCCCTGTTTGATA
GCTATCCGCATGTGAAAGCATGGTGGGATCGCCTGATGGCACGTCCGGCAGTGAAGAAAATCGCCGC
GACCATGGTGCCGCCGAAAGCC 
(Strep tag is shown in red) 
AmGSTF1 Wild Type (untagged) Protein Sequence  
MAPVKVFGPAMSTNVARVTLCLEEVGAEYEVVNIDFNTMEHKSPEHLARNPFGQIPAFQDGDLLLWESRA
ISKYVLRKYKTDEVDLLRESNLEEAAMVDVWTEVDAHTYNPALSPIVYQCLFNPMMRGLPTDEKVVAESLEK
LKKVLEVYEARLSKHSYLAGDFVSFADLNHFPYTFYFMATPHAALFDSYPHVKAWWDRLMARPAVKKIAAT
MVPPKA 
AmGSTF1 Wild Type (untagged) Nucleotide Sequence  
ATGGCGCCGGTGAAAGTTTTTGGCCCGGCCATGAGCACCAACGTTGCACGTGTGACCCTGTGCCTGGA
AGAAGTTGGTGCAGAATATGAAGTTGTGAATATTGATTTCAACACCATGGAACATAAAAGCCCGGAAC
ACCTGGCGCGCAATCCGTTTGGCCAGATCCCGGCCTTCCAGGATGGTGATCTGCTGCTGTGGGAAAGT
CGTGCAATTAGCAAATATGTTCTGCGCAAATATAAAACCGATGAAGTTGATCTGCTGCGTGAAAGCAAC
CTGGAAGAAGCAGCGATGGTGGATGTTTGGACCGAAGTTGATGCCCATACCTATAATCCGGCACTGAG
CCCGATCGTGTATCAGTGTCTGTTTAACCCGATGATGCGCGGCCTGCCGACCGATGAAAAAGTTGTTGC
AGAAAGCCTGGAAAAACTGAAAAAAGTGCTGGAAGTTTATGAAGCGCGTCTGAGCAAACACAGCTATC
 171 
 
TGGCCGGTGATTTCGTTAGCTTTGCAGATCTGAATCATTTCCCGTATACCTTTTATTTCATGGCAACCCCG
CACGCGGCCCTGTTTGATAGCTATCCGCATGTGAAAGCATGGTGGGATCGCCTGATGGCACGTCCGGC
AGTGAAGAAAATCGCCGCGACCATGGTGCCGCCGAAAGCC 
AmGSTF1 Y118S Mutant Protein Sequence 
MAPVKVFGPAMSTNVARVTLCLEEVGAEYEVVNIDFNTMEHKSPEHLARNPFGQIPAFQDGDLLLWESRA
ISKYVLRKYKTDEVDLLRESNLEEAAMVDVWTEVDAHTYNPALSPIVSQCLFNPMMRGLPTDEKVVAESLEK
LKKVLEVYEARLSKHSYLAGDFVSFADLNHFPYTFYFMATPHAALFDSYPHVKAWWDRLMARPAVKKIAAT
MVPPKA 
AmGSTF1 Y118S Mutant Nucleotide Sequence 
ATGGCGCCGGTGAAAGTTTTTGGCCCGGCCATGAGCACCAACGTTGCACGTGTGACCCTGTGCCTGGA
AGAAGTTGGTGCAGAATATGAAGTTGTGAATATTGATTTCAACACCATGGAACATAAAAGCCCGGAAC
ACCTGGCGCGCAATCCGTTTGGCCAGATCCCGGCCTTCCAGGATGGTGATCTGCTGCTGTGGGAAAGT
CGTGCAATTAGCAAATATGTTCTGCGCAAATATAAAACCGATGAAGTTGATCTGCTGCGTGAAAGCAAC
CTGGAAGAAGCAGCGATGGTGGATGTTTGGACCGAAGTTGATGCCCATACCTATAATCCGGCACTGAG
CCCGATCGTGTATCAGTGTCTGTTTAACCCGATGATGCGCGGCCTGCCGACCGATGAAAAAGTTGTTGC
AGAAAGCCTGGAAAAACTGAAAAAAGTGCTGGAAGTTTATGAAGCGCGTCTGAGCAAACACAGCTATC
TGGCCGGTGATTTCGTTAGCTTTGCAGATCTGAATCATTTCCCGTATACCTTTTATTTCATGGCAACCCCG
CACGCGGCCCTGTTTGATAGCTATCCGCATGTGAAAGCATGGTGGGATCGCCTGATGGCACGTCCGGC
AGTGAAGAAAATCGCCGCGACCATGGTGCCGCCGAAAGCCTAA 
AmGSTF1 F122T Mutant Protein Sequence 
MAPVKVFGPAMSTNVARVTLCLEEVGAEYEVVNIDFNTMEHKSPEHLARNPFGQIPAFQDGDLLLWESRA
ISKYVLRKYKTDEVDLLRESNLEEAAMVDVWTEVDAHTYNPALSPIVYQCLTNPMMRGLPTDEKVVAESLEK
LKKVLEVYEARLSKHSYLAGDFVSFADLNHFPYTFYFMATPHAALFDSYPHVKAWWDRLMARPAVKKIAAT
MVPPKA 
AmGSTF1 F122T Mutant Nucleotide Sequence 
ATGGCGCCGGTGAAAGTTTTTGGCCCGGCCATGAGCACCAACGTTGCACGTGTGACCCTGTGCCTGGA
AGAAGTTGGTGCAGAATATGAAGTTGTGAATATTGATTTCAACACCATGGAACATAAAAGCCCGGAAC
ACCTGGCGCGCAATCCGTTTGGCCAGATCCCGGCCTTCCAGGATGGTGATCTGCTGCTGTGGGAAAGT
CGTGCAATTAGCAAATATGTTCTGCGCAAATATAAAACCGATGAAGTTGATCTGCTGCGTGAAAGCAAC
CTGGAAGAAGCAGCGATGGTGGATGTTTGGACCGAAGTTGATGCCCATACCTATAATCCGGCACTGAG
CCCGATCGTGTATCAGTGTCTGTTTAACCCGATGATGCGCGGCCTGCCGACCGATGAAAAAGTTGTTGC
AGAAAGCCTGGAAAAACTGAAAAAAGTGCTGGAAGTTTATGAAGCGCGTCTGAGCAAACACAGCTATC
TGGCCGGTGATTTCGTTAGCTTTGCAGATCTGAATCATTTCCCGTATACCTTTTATTTCATGGCAACCCCG
CACGCGGCCCTGTTTGATAGCTATCCGCATGTGAAAGCATGGTGGGATCGCCTGATGGCACGTCCGGC
AGTGAAGAAAATCGCCGCGACCATGGTGCCGCCGAAAGCCTAA 
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AmGSTF1 Y118S F122T Mutant Protein Sequence 
MAPVKVFGPAMSTNVARVTLCLEEVGAEYEVVNIDFNTMEHKSPEHLARNPFGQIPAFQDGDLLLWESRA
ISKYVLRKYKTDEVDLLRESNLEEAAMVDVWTEVDAHTYNPALSPIVSQCLTNPMMRGLPTDEKVVAESLEK
LKKVLEVYEARLSKHSYLAGDFVSFADLNHFPYTFYFMATPHAALFDSYPHVKAWWDRLMARPAVKKIAAT
MVPPKA 
 
AmGSTF1 Y118S F122T Mutant Nucleotide Sequence 
ATGGCGCCGGTGAAAGTTTTTGGCCCGGCCATGAGCACCAACGTTGCACGTGTGACCCTGTGCCTGGA
AGAAGTTGGTGCAGAATATGAAGTTGTGAATATTGATTTCAACACCATGGAACATAAAAGCCCGGAAC
ACCTGGCGCGCAATCCGTTTGGCCAGATCCCGGCCTTCCAGGATGGTGATCTGCTGCTGTGGGAAAGT
CGTGCAATTAGCAAATATGTTCTGCGCAAATATAAAACCGATGAAGTTGATCTGCTGCGTGAAAGCAAC
CTGGAAGAAGCAGCGATGGTGGATGTTTGGACCGAAGTTGATGCCCATACCTATAATCCGGCACTGAG
CCCGATCGTGTATCAGTGTCTGTTTAACCCGATGATGCGCGGCCTGCCGACCGATGAAAAAGTTGTTGC
AGAAAGCCTGGAAAAACTGAAAAAAGTGCTGGAAGTTTATGAAGCGCGTCTGAGCAAACACAGCTATC
TGGCCGGTGATTTCGTTAGCTTTGCAGATCTGAATCATTTCCCGTATACCTTTTATTTCATGGCAACCCCG
CACGCGGCCCTGTTTGATAGCTATCCGCATGTGAAAGCATGGTGGGATCGCCTGATGGCACGTCCGGC
AGTGAAGAAAATCGCCGCGACCATGGTGCCGCCGAAAGCCTAA 
AtGSTF8 (Strep tagged) Protein Sequence 
MASWSHPQFEKGLINHMASIKVHGVPMSTATMRVLATLYEKDLQFELIPVDMRAGAHKQEAHLALNPFG
QIPALEDGDLTLFESRAITQYLAEEYSEKGEKLISQDCKKVKATTNVWLQVEGQQFDPNASKLAFERVFKGM
FGMTTDPAAVQELEGKLQKVLDVYEARLAKSEFLAGDSFTLADLHHLPAIHYLLGTDSKVLFDSRPKVSEWIK
KISARPAWAKVIDLQKQ 
(Strep tag is shown in red) 
AtGSTF8 (Strep tagged) Nucleotide Sequence 
ATGGCTAGCTGGAGCCACCCGCAGTTCGAGAAAGGCTTAATTAACCATATGGCCAGTATCAAGGTTCA
CGGAGTCCCCATGTCCACCGCCACAATGCGCGTCCTCGCTACTCTTTACGAGAAAGATCTCCAGTTCGA
GCTCATCCCCGTCGATATGAGAGCCGGTGCCCACAAGCAAGAGGCCCACCTTGCCCTCAACCCCTTCGG
TCAAATTCCTGCTCTCGAGGACGGTGATTTGACGCTTTTCGAGTCAAGAGCCATCACACAGTACCTAGC
AGAGGAATACAGTGAGAAAGGTGAAAAGCTTATCTCCCAAGACTGCAAGAAAGTCAAGGCAACCACT
AACGTATGGCTTCAAGTTGAAGGTCAACAGTTTGACCCTAACGCCTCTAAGCTTGCCTTCGAGCGTGTC
TTTAAAGGCATGTTCGGCATGACCACTGACCCTGCCGCTGTCCAAGAGCTCGAAGGTAAGCTCCAGAA
AGTCTTGGATGTCTACGAGGCTAGGCTCGCCAAATCTGAGTTCTTGGCTGGTGATTCCTTCACTCTTGCT
GATCTTCACCACCTCCCAGCCATCCATTACTTGTTGGGTACTGACTCCAAGGTGCTCTTTGACTCTCGCCC
TAAGGTTAGCGAGTGGATTAAGAAGATCTCTGCCAGGCCTGCTTGGGCTAAGGTTATTGACCTCCAGA
AGCAG 
(Strep tag is shown in red)  
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Appendix F: Herbicide Binding 
 
H1: Herbicide Compounds Tested 
 
 
H2: Thermal Shift Data for Herbicide binding to AmGSTF1 
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Appendix G: Apo Structures of 
AmGSTF1 
 
G1: Details of datasets collected of apo AmGSTF1 from co-crystallography experiments using 
Flavonoid Inhibitors. 
 
Dataset 
Number 
Resolution/ 
Å 
Ligand used for 
co-crystallography 
Completeness/ 
% 
R Rfree 
1 1.52 COM1 99.9 0.23 0.25 
2 1.55 MS-4-50 100 0.20 0.22 
3 1.58 MS-4-48 100.0 0.25 0.27 
4 1.59 MS-4-30-1 100.0 0.27 0.30 
5 1.61 MS-4-50 100.0 0.27 0.29 
6 1.7 COM1 100 0.24 0.28 
7 1.75 MS-4-48 99.9 0.27 0.31 
8 1.75 MS-4-30-1 93.7 0.26 0.28 
9 2.4 MS-5-31 99.6 0.21 0.27 
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